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Abstract 
Studying single cell protein expression is becoming increasingly important; however it is limited by 
the availability of highly sensitive technology. In adult cardiac progenitor cells (CPCs), expression of 
all the key cardiac transcription factors can be found, and both in vivo and in vitro studies have 
shown they can form cells of the cardiac lineage. However, effective mobilisation of these cells in 
situ for heart regeneration remains elusive. Close examination of CPCs for the important interactions 
and modifications may reveal the control mechanisms holding them in their arrested state, and 
therefore could lead to more effective cell therapies for heart failure. 
Total internal reflection microscopy is a super-resolution technique, allowing the visualisation of 
individual protein molecules through fluorescent labelling.  It uses and immunoassay to pull down 
the protein of interest, detecting the protein with a secondary fluorescently labelled antibody. Whilst 
the assay sensitivity relies heavily on the antibody kinetics, it avoids the need to genetically modify 
proteins with fluorescence. Thus the assay can be adapted to look at any protein, in any cell, and can 
be multiplexed to examine many proteins simultaneously. 
In this thesis, an assay for the detection of the cardiac transcription factor, Gata-4, is developed. 
Gata-4 is pivotal for cardiac development; it is a part of an extensive gene regulatory network, 
interacting with many other key transcription factors to confer precise heart morphogenesis. It is 
expressed in cardiac progenitor cells, and the aim here was to quantify protein expression from single 
CPCs. 
Another facet examined here was the potential use of alternative protein capture agents. DNA 
oligonucleotides, encoding the consensus binding sequence for Gata-4 was investigated for its 
suitability in an assay for single cell protein expression. Whilst this yielded promising results it was 
constrained by the lack of a suitable negative control. 
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Chapter 1 
??? Introduction 
? ????????????????????????????????
Proteomic analysis of cell populations has elucidated a huge amount of information. However, 
fluctuations in protein expression are known to occur across cell populations. This heterogeneity 
can be instructive, but is masked by bulk analysis. In the fields of cancer and stem cell research, this 
heterogeneity is very important. In the case of cancer, it can lead to drug resistance, and in stem cell 
niches it is the source of self-renewal as well as multipotency (Easwaran et al. 2014; Enver et al. 2009). 
Thus, being able to analyse protein expression of individual cells within a population will be 
instructive. In the case of stem cells, elucidating the mechanisms of control would permit 
manipulation of the differentiation pathways, which is essential for producing specified cells of high 
purity for therapies. 
Protein analysis at the single cell level is fundamentally difficult. Unlike mRNA it cannot be 
amplified, in addition, the copy number can vary by orders of magnitude, from a few hundred to 
tens of thousands. Whilst the housekeeping genes are very abundant, consisting of 25% of the total 
cellular protein, other important proteins such as transcription factors and signalling proteins tend 
to have low expression levels and have temporal activity (van Hoof et al. 2012). Thus, extremely 
sensitive techniques are required to analyse proteins from a single cell. 
Protein expression does not correspond to mRNA expression (Taniguchi et al. 2010a; Schwanhäusser 
et al. 2011; Lu et al. 2009), and whilst single cell mRNA studies are gaining ground, it overlooks the 
plethora of regulatory mechanisms that control protein activity. These include post translational 
modifications (protein acetylation, phosphorylation, sumoylation and ubiquitination), cellular 
localisation, protein-protein interactions, inhibition by micro RNA and epigenetic regulation. A 
good example of regulation separated from simple transcription-translation is that of Gata-4. Gata-
4 activity is regulated by phosphorylation by the mitogen activated kinases. However, 
phosphorylation by GSK3β marks the protein for nuclear export and subsequently is degraded. This 
demonstrates how it is not simply about protein expression levels. Examining protein modifications 
and interactions can be insightful to the pathways at play, particularly in stem cell differentiation. 
Our group is investigating endogenous cardiac progenitor cells as source of new cardiac tissue. These 
cells have been demonstrated by many groups to generate cells of the cardiac lineage. They exist in 
 20 
small numbers in the heart, expressing cardiac transcription factors but not structural genes. 
Understanding the cues which keep these cells in an arrested state will be important in harnessing 
these cells as a therapy for cardiac repair. 
Traditional approaches to protein analysis, such as mass spectrometry and gel electrophoresis, are 
not amenable to single cell protein analysis. These techniques require large samples, encompassing 
whole populations of cells, and are not very quantitative. Whilst progress has been made with cell 
mass cytometry and epifluorescent microscopy there is still an unmet need in single cell proteomics.  
Our group has developed a single cell proteomic platform using an immunoassay coupled to total 
internal reflection microscopy (TIRFM), a highly sensitive technique that can detect single 
molecules. Together with microfluidic cell handling this platform is capable of single cell protein 
detection. Currently the system works with p53 protein detection (Salehi-reyhani et al. 2011; Burgin 
et al. 2014) and the group is working towards detecting other proteins as well as protein 
modifications and protein-protein interactions. This thesis aims to develop the assay for detection 
of protein in cardiac progenitor cells, which exist in small numbers in the heart, focusing on the 
transcription factor Gata-4.  
1.1.1   Advances in proteomic technologies 
There is a whole range of proteomic technologies that have been used to study proteins on the 
population level. Whilst some of these have been adapted to single cell studies, the progress has 
been slow and many advances still need to be made. The technologies developed with high 
sensitivity and capability for single cell analysis are illustrated in Figure 1.1. With the rise of 
microfluidics, the handling of small volumes has become easier. However, at the single cell level, 
sample loss through lysis, separation or detection stages, will severely impact results (Wang & 
Bodovitz 2010a). This obstacle is clearly seen by the lack of studies that have achieved single cell 
proteomics (Figure 1.1).  Thus, the integration of sample manipulation is paramount to the success 
of single cell proteomics. 
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Figure 1.1 Schematic showing the capabilities of the most sensitive proteomic technologies. The plot 
illustrates the number of different proteins that can be detected in a single sample (y axis) and the 
operating volume (x axis), with the latter often impacting the overall sensitivity. Technologies 
highlighted in green have achieved detection from individual cells. A dashed border indicates only 
peptide or small molecule detection and not protein detection. Other technologies are working 
toward improving sensitivity, with some achieving attomolar and zeptomolar sensitivity but this 
work is mainly conducted with, small populations of cells, cell lysate or secreted proteins (blue).The 
acronyms for the technologies are as follows: Fluorescent scanning (Fl Sc), Mass spectrometry with 
capillary electrophoresis (MS CE), mass spectrometry (MS), total internal reflection microscopy 
(TIRF), single cell mass cytometry (SCMC). References for the studies using these technologies are 
listed in the text, with further details listed in the appendix (table A). 
 
Antibodies have been instrumental in protein studies, whether via the traditional immunoassay or 
by flow cytometry. Some of the bottle necks to using antibodies include their affinity, labelling and 
immobilisation strategies and will be discussed further in Chapter 6.  
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Figure 1.2. Illustration of different antibody immobilisation and detection techniques. A) Schematic 
of immune PCR chemistry. This technique is very similar to the traditional ELISA except with DNA PCR 
amplification to develop the signal. Here a tertiary antibody conjugated to DNA via biotin-streptavidin is 
used to detect the antibody-antigen binding. The presence of the DNA molecules permits PCR and the 
resulting products therefore correlate to the presence of antigen. Taken from Sanna et al. 1995. B) 
illustrates of the technique termed DNA barcoding used by Shin et al. 2011, Shi et al. 2012, Ma et al. 2011 
for single cell analysis. Here single stranded DNA (ssDNA) is immobilised on glass and hybridised to its 
complement which is conjugated to an antibody. Antigen detection is conducted with fluorescently 
conjugated antibodies. It allows for multiplexing of antibodies as well as functional antibody 
immobilisation.  
Developments in immunoassay detection chemistry led to increased sensitivity in the early 90’s. 
These included processes such as immunoPCR, rolling circle amplification and immuno-detection 
amplified by T7 RNA (Sano et al. 1992; Zhou et al. 1993; Mweene et al. 1996; Sanna et al. 1995; Zhang 
et al. 2001). These chemistries harnessed the power of amplification by PCR and linked it directly to 
antibody-antigen detection, permitting a lower limit of detection of 580 antigen molecules (Sano et 
al. 1992). At the time, all these developments demonstrated remarkable increases in sensitivity in 
comparison to the standard ELISA but were still limited by detection technologies.  
Mass spectrometry is the most powerful proteomic technology, possessing the advantage of whole 
proteome analysis which can detect interactions as well as modifications and with no labelling 
requirements. Despite this, it is difficult to analyse small volumes and thus not well suited to single 
cells studies. This technology is currently limited to the analysis of peptides and small molecules 
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from single cells (Lapainis et al. 2009; Rubakhin et al. 2000; Jo et al. 2007; Wang & Bodovitz 2010b). 
Steadily, advances are being made into single cell protein detection. To date, the highest resolution 
was obtained from single pancreatic islets, containing up to 4000 cells (Waanders et al. 2009a). By 
coupling  mass spectrometry with separation by liquid chromatography, Waanders et al. (2009) were 
able to resolve 6,873 proteins.  However, the ability to detect low abundant proteins is still very 
limited (Galler et al. 2014). 
Whilst a diverse range of modifications has been trialed with mass spectrometry (see appendix table 
A) with the aim of achieving single cell sensitivity the limitations remain the same. These include 
the high sample loss during manipulation, the ability to detect low abundant proteins without 
labelling and the huge amounts of data processing which is computatively intensive, taking days in 
some instances. 
Fluorescent activated cell sorting (FACS), is one of the most developed and utilised form of single 
cell proteomics. This powerful technology couples high throughput, sorting at 10,000 cells per 
second (Galler et al. 2014; Bendall et al. 2012), with single cell resolution. Whilst not hugely 
quantitative, it can sort cells based on fluorescence into high and low protein expression, and has 
the ability to simultaneously deal with multiple colours, permitting detection of up to 15 different 
proteins within a single cell (Galler et al. 2014; Wu & Singh 2012a; Bandura et al. 2009). Conversely, 
cells either require fixing and staining with antibodies or genetic modification to fluorescently tag 
the protein of interest. Both instances can pervert the cells natural homeostasis.  
One big drawback is that the technique requires manual manipulation of large cell populations, and 
is therefore not suitable for rare cell populations. Microfluidic handling helps to circumvent this and 
there have been many developments in this area (Galler et al. 2014; Wu & Singh 2012b). Despite these 
drawbacks, some nice studies tallying mRNA and protein expression used FACS, highlighting the 
stochasticity and disparity between mRNA and protein (Newman et al. 2006)  
Single cell mass cytometry is quickly closing the gap between whole proteome analysis and single 
cell studies. This technique combines the single cell handling by flow cytometry and protein analysis 
by mass spectrometry. Essentially, cells are labelled with up to 30 different antibodies conjugated to 
metal element tags via metal chelating polymers (Lou et al. 2007a).  These tags are then detected by 
induced coupled plasma time-of-light mass spectrometry (ICP MS; Wu & Singh 2012; Bandura et al. 
2009). The availability of different metal-polymer tags overcomes the limited number of 
fluorophores and their confounding overlap in emission wavelengths (Wu & Singh 2012b; Bandura 
et al. 2009). In addition, the sensitivity of mass spectrometry in this setup is capable of distinguishing 
between protein expression levels that differ by orders of magnitude and is working toward absolute 
quantification (Lou et al. 2007b; Bandura et al. 2009). 
 24 
Although being a high throughput technology, processing 1000 cells per second (Bendall et al. 2012), 
it still requires large sample quantities (Bandura et al. 2009), and is thus not suitable for rare cells. 
In theory, this technique can detect as low as 100 ions; however, this has yet to be achieved in practise 
(Bendall et al. 2012). Advances in antibody conjugation will shortly circumvent this: by adding 
conjugation with more and heavier metals, thereby decreasing the limit of detection (Bendall et al. 
2012). 
Single cell studies are readily conducted by epifluorescence. Using time lapse fluorescence, Cohen 
et al. (2008) demonstrated differential expression and localisation of up to 1000 proteins from live 
individual cancer cells. Although the method demonstrated high throughput capacity, it required 
the use of a fluorescently tagged protein library. As a consequence, the method cannot be conducted 
on clinical samples without genetic modification. Further still, this characterised differential 
expression rather than absolute quantification. In addition, the use of reporter library limits analysis 
to a few proteins per cell.  
With simple tweaks such as coupling with flow (Huang et al. 2007a; Todd et al. 2007) or simply using 
intensity measurement (Taniguchi et al. 2010b), epifluorescence could be used to quantify protein 
in single cells or at low concentrations in blood plasma. It was through this method that the first 
direct comparisons between mRNA and protein counts in a single cell were made, showing that at 
any given time the two do not correlate (Taniguchi et al. 2010b).  The main limitation of 
epifluorescence is that it illuminates everything in the field of view. Thus without constraining 
counting to genetic fluorescent tags or having the benefit of a step wise increase in protein 
concentration (Cai et al. 2006), this technique demands a great deal of sample processing. Requiring 
complex microfluidics to capture, wash, lyse and separate the proteins before imaging. 
Whilst it might be very complex to harness epifluorescence for single cell studies, it is feasible. The 
Heath group (California Institute of Technology, USA), uses a fluorescent scanner, as is commonly 
used for DNA microarrays. They conducted on-chip single cell lysis and were able to detect 10 
different proteins from one cell (Shin et al. 2010; Shi et al. 2011). Furthermore, they use DNA 
barcoding as their antibody immobilisation technique, which permits multiplexing and facilitates 
functional immobilised antibody (Figure 1.2). Although this technique only compared relative 
expression levels and not absolute quantification, it shows the steady progression in the field.   
Surface plasmon resonance has been used for many years in determining antibody-antigen reactions 
but until very recently it has not had single molecule resolution (Zijlstra et al. 2012; Mayer et al. 2010). 
As yet, this has not been applied to single cell studies but with its label-free advantage, it presents 
exciting possibilities to the proteomics field. 
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Total internal reflection fluorescent microscopy (TIRFM) has the benefit over Epifluorescence in 
that it excludes bulk fluorescent illumination by only illuminating materials at the glass-liquid 
interface. It can thus help circumventing the complexities of sample separation and washing in small 
volumes. Further still, it is perfectly adapted to single molecules studies: with its super resolution it 
can image single fluorescent molecules. In live cell studies, it is a powerful tool for studying cell 
surface proteins and can be applied to both protein tracking and interactions (Leake et al. 2006; 
Ohara-Imaizumi et al. 2004; Sako et al. 2000; Douglass & Vale 2005). Unfortunately, its shallow 
depth of field means it is not well suited to intracellular studies. Consequently, intracellular proteins 
must be released and brought close to the glass-liquid interface in order to be detectable by TIRFM. 
This means that the cells must either secrete the proteins, such as free protein found in blood 
samples (Lee et al. 2009), or be lysed (Salehi-reyhani et al. 2011). 
Another useful application of TIRFM is in the study of protein-protein interactions. Jain et al. (2011) 
demonstrated this in a study using cell lysate, and were able to detect interactions from a minimum 
of 10 cells. Although this study does not show single cell sensitivity, with the current advances in 
technology we believe this is an attainable goal. 
Single cell proteomics is an ever evolving field that is technically very demanding. There is as yet no 
gold standard in the field for single cell protein analysis. Given the different modalities of proteins, 
there is unlikely to be one solution, but rather a collection of techniques that complement each 
other. In this thesis, TIRF is used to explore the possibility of conducting protein analysis in cardiac 
progenitor cells. We work towards achieving single sensitivity by reducing the reaction volumes by 
using microfluidic technology coupled with high affinity antibodies 
1.1.2   Single molecule counting with Total Internal Reflection 
Microscopy 
Our group has developed a single molecule counting algorithm, with which we can quantify protein 
molecules bound to the surface and visualised using TIRFM. Total internal reflection microscopy 
works by directing a laser at a glass-liquid interface at an angle such that the laser beam is totally 
reflected. At the angle of reflection a small evanescent wave is emitted with a maximum height 
between 100-300 nm. This shallow depth of excitation means that any fluorescent molecules in the 
bulk volume are excluded and only molecules near the surface boundary are being imaged, as 
illustrated in Figure 1.3. A pull down antibody was used to capture the protein of interest, and a 
second fluorescently conjugated antibody was used to label the protein.  
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Figure 1.3. Illustration of total internal reflection microscopy. The laser beam (line in green) is directed 
at a glass interface at such an angle that the beam is totally reflected. At the point of reflection an 
evanescent wave of light is emitted, that decays exponentially (semi-circle of green). This excites any 
fluorescent molecules within this 100-300 nm region. The fluorescent molecules contained within the 
bulk volume remain dark. Antibody is printed onto the glass surface (in black) and used to pull down the 
protein of interest so that it is within the evanescent wave. A second fluorescently conjugated antibody 
(grey) is used to detect the bound proteins, with the fluorescent molecules only becoming excited within 
the evanescent wave.  
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The adult mammalian heart possesses scant ability to regenerate itself. It can respond to work 
overload via muscular hypertrophy and it heals tissue damage (e.g. myocardial infarction) by scar 
tissue formation. This is often an inadequate replacement for the lost beating tissue, with the 
increased strain eventually leads to heart failure. Although it is reported that the human heart has a 
1% annual turnover (Bergmann et al. 2009), replenishing the cardiac tissue with new cardiomyocytes 
does not offset injury under normal (unassisted) conditions. 
To counter this inadequacy to regenerate, a range of stem cells have entered clinical trials for cardiac 
repair, with limited efficacy. The first to be trialed were skeletal myoblasts. Although they were seen 
to improve function in in vivo experiments and in clinical trials, there were serious doubts to their 
safety. Whilst being autologous, these cells were unable to make electrical connections with 
cardiomyocytes and were reported to cause arrhythmias in transplanted patients (Dimmeler et al. 
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2005; Menasché 2004; Ptaszek et al. 2012). Haematopoietic stem cells were the next cells to be trialled 
in infarct patients. Various haematopoietic cell types have been tested, with bone marrow 
mononuclear cells being the most common. Whilst a mild improvement was seen in cardiac function 
in some studies, a recent meta-analysis strongly indicates that this has no effect on improving cardiac 
function or reducing further cardiac events (Jong et al. 2014). The reported improvements are more 
likely due to paracrine effects; increasing angiogenesis and supporting existing cells  and not 
formation of new cardiomyocytes (Zimmet et al. 2012; Mirotsou et al. 2011; Ptaszek et al. 2012). Results 
from Jong’s meta-analysis suggest that mesenchymal stem cells are more likely to be beneficial and 
that these would have better scope as off the shelf treatment. Being an immune privileged cell 
implies that cells from younger, healthy donors could be used, thereby offering a potentially more 
efficacious treatment, than using the patient’s own cells, which are likely less responsive (Jong et al. 
2014).   
Most recently there are two trials using cardiac progenitor cells, harnessing stem cells endogenous 
to the heart for cardiac repair. Cardiac progenitor cells (CPCs) are a diverse population of cells, which 
are identified by a selection of different markers including c-kit+, Sca-1+, Isl-1+, PDGFRα as well as 
the side population phenotype (Beltrami et al. 2003; Oh et al. 2003; Moretti et al. 2006; Pfister et al. 
2005; Oyama et al. 2007; Chong et al. 2013). As a whole, these populations of cells are defined by 
their ability to differentiate into cells of the cardiac lineage, such as cardiomyocytes, endothelial and 
smooth muscle cells. 
As yet, the role that these CPCs play in the adult heart is unclear. Evidence through lineage tracing 
suggests that they act in cardiac homeostasis, with Sca-1+ cells being shown to replenish the pool of 
cardiomyocytes, though at a low frequency, in the adult murine heart (Uchida et al. 2013). Both the 
Sca-1+ CD31- and ckit+/lin- pools of CPCs have been shown to increase in the early stages after 
infarction and home to the insulted area, suggesting they play a role in the response to pathology 
(Wang et al. 2006; Ellison et al. 2013). In particular, stimulation by prostaglandin E1 in myocardial 
infarction revealed that Sca-1+ could contribute to the formation of new cardiomyocytes in the border 
zone (Hsueh et al. 2014).   
Further to this, a Sca-1+ knockout study showed that these cells play a role in mediating the response 
to stress, with KO mice displaying age related cardiac dilation and dysfunction induced by chronic 
overload (Rosenblatt-Velin et al. 2011). 
Whilst both ckit+ and Sca-1+ cells appear to transdifferentiate in vivo, different  studies have reported 
varying degrees of efficacy in response to myocardial damage (Wang et al. 2006; Ellison et al. 2013). 
Some report that administration of c-kit+/lin- cells have a marked capacity for regeneration and 
improvement of cardiac function (Beltrami et al. 2003; Ellison et al. 2013). However, Molkentin et al. 
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(2014) recently reported a very minimal contribution of the ckit+ cells to the formation of new 
cardiomy0cytes. In addition, a study by Bailey et al. (2012) showed that the ability of CPCs to repair 
the heart diminished upon loss of Sca-1+.  
Supporting the use of  Sca-1+/CD31- cells in cell therapy, Wang et al. (2006)  showed that they 
attenuated the decline in cardiac function and observed modest regeneration of cardiomyocytes. 
However, moderation of the adverse remodelling processes is proposed to be mediated mostly by 
paracrine effects as seen by an increase in angiogenesis (Wang et al. 2006). 
Work in our group has focused on cardiac progenitors defined by Sca 1+ expression and the side 
population phenotype. In our lab, these cells have been shown to be clonagenic and express a variety 
of cardiac transcription factors that are important during heart development; these include Gata4, 
Mef2c, TBX5 and NKX2.5 (Figure 1.4).  However, these cells do not express the cardiac structural 
genes. Work by others have shown that these cells differentiate in vitro to form cardiomyocytes, 
endothelial cells and smooth muscle cells (Oh et al. 2003; Wang et al. 2006; Matsuura et al. 2004; 
Pfister et al. 2005).  
The expression of Sca-1+ also exists outside the heart in other stem cell niches and in some somatic 
cells, most notably in the haematopoietic stem cell population (Bradfute et al. 2005; Ito et al. 2003). 
Many studies have tried to elucidate the role of Sca-1+ in these populations and indicate that it plays 
a role in stem cell lineage determination and self-renewal, although the latter is disputed by Bradfute 
et al. (Ito et al. 2003; Bradfute et al. 2005). 
More recent studies on the function of Sca-1+ in the heart indicate that this population of cells helps 
to maintain the pool of cardiac progenitors and  acts as a regulator of cardiomyocytes renewal in the 
heart (Rosenblatt-Velin et al. 2011). Sca-1+ cells tend to reside in stroma along with mesenchymal 
cells, endothelial cells and pericytes, though staining indicates some reside in close contact with 
cardiomyocytes, akin to that seen of satellite cells and skeletal muscle (Uchida et al. 2013).  
As yet, a human homologue to Sca-1+ has not been identified and initial attempts to isolate human 
cardiac progenitors used the ckit+ marker (Bearzi et al. 2007). However, cross reactivity with the Sca-
1+ antibody indicates an orthologue likely exists (Goumans et al. 2007). In fact the murine Sca-1+ 
antibody was used to purify a population of human adult cardiac progenitors (Goumans et al. 2007; 
den Haan et al. 2012). These cells were shown to differentiate in vitro, expressing cardiac structural 
genes, forming functional gap junctions that enable electrical coupling and responded to L-channel 
calcium inhibitors and β adrenergic stimulation (Goumans et al. 2007). These differentiated 
cardiomyocytes appear more mature than those obtained from foetal ventricular cardiomyocytes 
(Goumans et al. 2007). This strongly supports the development of these cells as a clinical application, 
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or at least provides a good model for pharmacological, physiological or developmental studies 
(Goumans et al. 2007). 
Cardiac progenitor cells are rare in the adult heart, representing only 0.03% of the heart’s cell 
population (Oh et al. 2003). Even though their response to insult is inadequate, their role in tissue 
homeostasis and their capacity to ameliorate the pathological response in in vivo studies, 
demonstrates their great potential in the clinic. In the current CPC clinical trials, the cells are 
harnessed by growing them outside the patient after isolating the cells from a heart biopsy, before 
injecting the cells back into the heart. As to the efficacy of this, only time will tell.  
1.2.1   Cell population heterogeneity 
The importance of transcription factor expression in these cells is that it indicates that they are 
committed to the cardiac lineage, although they appear to be in arrested state. As mentioned earlier, 
in vivo and in vitro experiments show that these cells differentiate into cells of the cardiac lineage, 
but the exact mechanisms controlling this are unknown. 
1.2.2  What is the key to unlocking the cardiogenic potential of 
cardiac progenitor cells?  
As yet there is not a definitive method for differentiation of murine CPCs to cardiomyocytes. Whilst 
there exists a variety of different approaches, attaining high purity cardiomyocytes is a challenging 
task. Common reagents employed for differentiation include dexamethasone, 5-azacytadine, 
oxytocin, co-culture with neonatal cardiomyocytes or the combination of different growth factors 
(Yang et al. 2011; Chong et al. 2013; Oh et al. 2003; Goumans et al. 2007; Beltrami et al. 2003; Miyamoto 
et al. 2010; Matsuura et al. 2004). Part of the problem with these approaches is their efficiency since 
the reagents 5-azacytadine and oxytocin both convert CPCs to cardiomyocytes at a low rate (Oyama 
et al. 2007; Matsuura et al. 2004). The maturity of the cells is limited, particularly with 5-azacytadine, 
where sarcomeres remain unorganised, and do not form striations (Beltrami et al. 2003; Matsuura et 
al. 2004). Further still, these cells do not seem restricted to the cardiac lineage with Sca-1+ cells 
expressing osteogenic and adiopocyte markers (Matsuura et al. 2004). Whilst oxytocin seems to 
produce a more thorough result with spontaneously beating cultures, the efficiency of this is only 
1% (Matsuura et al. 2004). 
Culture with neonatal cardiomyocytes is more efficient, with Miyamoto et al. (2010) reporting 
complete conversion of ckit+ cells to cardiomyocytes with good structural organisation. However, 
the risk of cross contamination makes this an unlikely candidate for clinical applications.  
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Differentiation using co-culture is most likely due to the growth factors expressed by the exogenous 
cardiomyocytes. A combination of different factors has been used to develop differentiation 
protocols. In the mouse, Rosenblatt-Velin et al. (2005) showed that FGF-2 is an important factor. 
However, in different species different factors are in operation. For instance, Goumans et al. 
employed TGF-β with 5-azacytidine to achieve 94.7% cardiomyocytes from human CPCs. In 
comparison,  5-azacytidine alone produced less than 15% cardiomyocytes (Goumans et al. 2007).  
Despite the quest for efficient differentiation procedures, the correct ratio of cell types for therapy 
is not defined. Considering the benefit of paracrine effects that the clinical trials have shown, it is 
likely a combination of cell types are needed, augmenting the vascularisation with endothelial cells 
as well as increasing contractile tissue with new cardiomyocytes.   
Further to this, harnessing potential of adult CPCs is much more difficult than that of neonates 
(Rosenblatt-velin et al. 2005). Expression of the key cardiac transcription factors alone is not 
sufficient to induce differentiation  (Olson & Schneider 2003), and thus it is important to understand 
the control mechanisms in place. 
 
Figure 1.4. Heatmap showing the heterogeneous expression of the key cardiac transcription factors 
in cardiac progenitor cells. Twenty different clones were compared by microarray analysis and showed 
different transcription factor expression patterns, and z-scores were calculated from δCT values. The 
asterix (*) indicates the clones which were used in this thesis. Figure obtained from Noseda et al. 2015. 
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The Sca-1+ CPC clones isolated in our lab express a mosaic of the cardiac transcription factors (Figure 
1.4). It is speculated that having an incomplete set of the key cardiac transcription factors might be 
holding them in the arrested state. Filling the key gaps might push the cells towards the 
cardiomyocytes cell fate. Of course, there is more at play during differentiation than just the 
expression of cardiac transcription factors alone. 
Much has been elucidated on the differentiation of stem cells to cardiomyocytes, demonstrating an 
importance of transcription factor interactions in addition to chromatin modifications.  
1.2.3  Stochasticity in stem cell differentiation 
Waddington was the first to describe an epigenetic landscape for stem cell differentiation, proposing 
that pluripotent cells start at the top of the hill. As they roll down, they deviate along different 
differentiation pathways becoming ever more restricted by their lineage choice, as shown in Figure 
1.5 with the valleys representing the ever increasing lineage restriction. 
 
Figure 1.5. Waddington epigenetic landscape, illustrating how a pluripotent stem cell starts at the top 
of the valley, and as it progresses downhill, it may take various paths (or valleys) which increasingly 
restrict the cell fate along a certain lineage. Taken from Ladewig et al. 2013 
There have been some developments in this story, particularly with regard to the transdifferentiation 
and pluripotent reprogramming of somatic cells. Originally, reversing cell commitment was 
considered impossible, but the breakthrough in induced pluripotent stem cells showed that the 
somatic cell state is reversible with the right stimuli (Takahashi et al. 2007; Okita et al. 2007). In 
accordance with this, the landscape theory has progressed, indicating that this transdifferentiation 
does not have to occur along the same forward pathway, nor does the commitment pathway follow 
the steepest gradient (Wang et al. 2011). A good example of the latter is the differentiation of HL60 
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promyelocytic progenitors to neutrophils where differentiation can be triggered by two different 
chemicals, DMSO or all-trans retinoic acid. Whilst achieving the same outcome, the two chemicals 
activate different pathways (Macarthur et al. 2009)  
Another more recent development in the theory is that of attractor states. These are not necessarily 
the fully differentiated cell, but can be any stable phenotype. For example, whilst the 
undifferentiated stem cells are considered rather unstable and transient, the subsequent progenitor 
cells attain a more stable state and may rest in an “attractor” state before further lineage specification 
(Wang et al. 2011; Enver et al. 2009). This is most notably seen in studies of haematopoietic 
progenitors where the lineage decision between erythroid and myeloid cell fates is governed by the 
expression of the transcription factors PU.1 and Gata1. These transcription factors can skew the 
commitment decision either way, but their simultaneous low expression produces a stable state, 
through which only the expression above a threshold will kick further lineage specification 
(Chickarmane et al. 2009; Huang et al. 2007b). This concept is illustrated in Figure 1.6  
 
Figure 1.6. Illustrates the concept of attractor states, which are wells in the epigenetic landscape in 
which cells can fall into along the differentiation pathway. These attractor states are fairly stable, and may 
represent a progenitor cell. Cells can still form a variety of cell types (a and b valleys), within a certain 
lineage, but require expression above the threshold of the determinant transcription factors. Taken from 
Enver et al. 2009 
This is an interesting concept with regard to CPCs, which seem stable yet are able to differentiate 
into the three cell types of the cardiac lineage in addition to reports of osteogenic and adipocyte 
marker expression. Whilst CPCs are more complicated than the bistable switch seen in 
haematopotcytes expression of PU.1 and Gata1, the expression levels of key transcription factors may 
play a part. 
Deterministic versus stochastic gene expression: which is most effective in determining stem cell 
differentiation? The likely answer is both. Differentiation pathways are governed by a network of 
transcription factors. In addition, noise is inherent to all organisms, and arises from many different 
 33 
sources from chromatin conformation to the number and availability of transcription factories, as 
well as the number and location of transcription factor binding sites (Raj & van Oudenaarden 2008). 
In unicellular organisms this phenomenon is beneficial, by having a subset of the population that 
can immediately respond to changes in the environment (Enver et al. 2009; Newman et al. 2006). 
This is not only cost efficient, meaning that only some cells are in a sensing mode at the same time, 
but also ensures survival of the population (Raj & van Oudenaarden 2008). 
Although noise may be minimised there are some examples where it has been shown to play a key 
role in development. For instance, it was demonstrated in the development of the murine ol’factory 
sensing system where a diverse range of sensory receptors are required but which are manifested by 
simple stochasticity of gene expression (Vassar et al. 1993) 
How much do stem cells try to minimise noise? Whilst expression of genes determines the lineage 
decision, the levels of expression appear to be inherently stochastic. This was shown by Chang et al. 
(2008) who demonstrated that Sca-1+ haematopoietic stem cells could regenerate a heterogeneous 
population of Sca-1+ expression from a single clone. Sca-1+ low and high expressing have different 
lineage preferences; however, the population attractor state is that where there is a distribution of 
protein expression, from low to high. 
It would be interesting to study different levels of protein expression within the cardiac progenitor 
cell population. The CPC cells are a population selected on the basis of Sca-1+, CD31- expression, with 
the side population phenotype. Despite this refined selection procedure, there is still a great amount 
of variability in the transcription factor expression and within that, most likely a heterogeneous 
expression of each protein.  
1.2.4   Deterministic mechanisms for differentiation of 
cardiomyocytes from cardiac progenitor cells 
The heart is the first organ to develop in the body, the mechanisms behind which are evolutionarily 
conserved across species (Olson 2006). Heart formation starts with the specification of cardiac 
mesoderm, from the lateral plate mesoderm and defined by the expression of Mesp1 (Saga et al. 1996; 
Saga et al. 1999; Saga et al. 2000). These cells migrate to form the cardiac crescent, and subsequently 
form the linear heart tube through lateral folding of the embryo. This tube then undergoes looping 
and septation to form the four chambered heart. To begin with, the tube consists of two layers of 
cells, the internal endocardial cells and the exterior myocardial cells which form the myocardium. 
Migration of the neural crest forms the final layer of epicardium, through which arises the coronary 
vasculature and cardiac fibroblasts, and migration of second heart field forms the right ventricle and 
outflow tracts. 
 34 
Cardiomyocytes form only 1/3 of the total population of cells in the heart. The remaining 65-70% of 
cells are non-myocytes and consist of fibroblasts, endothelial cells, pericytes, smooth muscle cells 
and macrophages (Nag 1980). Unmistakably, heart formation is an intricate process and governing 
this is a complex network of transcription factors and chromatin remodelling factors. The core 
cardiac transcription factors include Nkx2.5, Gata-4, 5 and 6; the TBX family, Hand 1 and 2, Isl-1, and 
the MEF family. These are supported by the addition of serum response factor (SRF) and myocardin. 
This complex gene regulator network works through transcription factor interactions and in 
regulating each other’s expression (Figure 1.7). In concert, these control expression of cardiac 
structural proteins, gap junctions, calcium signalling proteins, as well as cell proliferation, 
hypertrophy, chamber septation and patterning. 
Nx2.5 is one of the first transcription factors to mark the onset of cardiomyocyte differentiation 
(Komuro & Izumo 1993). It is an evolutionary conserved gene; the first orthologue was identified in 
drosophila and called tinman, as without this factor the heart did not develop (Bodmer 1993). Whilst 
Nkx2.5 is essential in drosophila, in mice the null phenotype leads to abnormal heart morphogenesis, 
with lethality by E9.5  (Lyons et al. 1995). This suggests a more redundant role for transcription 
factors in the mammalian heart (Olson 2006; Olson & Schneider 2003) 
Gata-4 is another important regulator of cardiac development. Whilst it does not appear to 
determine cardiomyocyte lineage specification, it plays an important role in migration and 
formation of the linear heart tube (Molkentin et al. 1997; Kuo et al. 1997). Its significance is 
highlighted by Gata-4 knockout studies which showed embryonic lethality between E8.5-10.5 , with 
mice lacking heart tube formation and irregular distribution of procardiomyocytes  (Molkentin et 
al. 1997; Kuo et al. 1997). However, tetraploid complementation clearly demonstrated that Gata-4-/- 
cells are able to differentiate into cardiomyocytes (Kuo et al. 1997). From the onset of its expression 
at E7.0 (Heikinheimo et al. 1994), Gata-4 is active during all stages of heart development, continues 
to maintain the adult heart after birth (Charron & Nemer 1999) and is pivotal to hypertrophic 
response in adult heart failure (Oka et al. 2006; Suzuki 2011; Morimoto et al. 2001; Molkentin et al. 
1998; Liang, De Windt, et al. 2001; Liu et al. 2008). It is a potent transactivator, promoting expression 
of many cardiac structural genes including ANF, BNP, cTnI, α-MHC, β-myosin heavy chain and 
platelet-derived growth factor receptor β  (Charron & Nemer 1999; Oka et al. 2007).  
Whilst the transcription factors Nkx2.5 and Gata-4 are globally expressed in the heart, and are potent 
transactivators of the cardiac muscle program, they are not sufficient to induce cardiomyogenesis 
on their own (Charron & Nemer 1999). However, interactions between transcription factors have 
been shown to potentiate cardiac gene expression. For instance, an early study by Durocher et al. 
(1997) showed that both Nkx2.5 and Gata-4 can interact and synergise to promote ANF and BNP 
expression. In more recent studies, reprograming fibroblasts to cardiomyocytes showed that Gata-4 
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was indispensable, supporting Gata-4 as a key player in the formation of cardiomyocytes (Ieda et al. 
2010; Nam et al. 2013; Song et al. 2012).  
Gata4 is known to interact with a number of different transcription factors, which include SRF, Mef2, 
Tbx5, NFAT and FOG-2 (Dai et al. 2002; Garg et al. 2003; Lu et al. 1999). Some of these transcription 
factors have restricted expression within the developing heart, being deployed in certain chambers 
but not others. For instance HAND2 is restricted to the right ventricle whereas HAND1 is expressed 
in the left (Mcfadden et al. 2000; Dai et al. 2002). Gata-4 is known to directly regulate HAND2 
expression (Mcfadden et al. 2000), interacting with the protein to synergistically promote cardiac 
gene expression (Dai et al. 2002). Another example of chamber restricted expression is that of Tbx5. 
Whilst it is expressed throughout the cardiac crescent, its expression becomes graded upon tube 
formation and is subsequently further restricted to the left ventricle and atria upon looping and 
septation (Bruneau et al. 1999).   
Interactions not only mediate protein expression but, in a top down approach, also confer 
responsiveness to key signalling pathways. Specifically, the interaction of Gata-4 with NFAT permits 
responsiveness to calcium signalling, a pivotal player in pathological cardiac hypertrophy 
(Molkentin et al. 1998; Molkentin 2004; Oka et al. 2005; Morimoto et al. 2001; Kakita et al. 2001). 
Calcium signalling responds to growth stimuli, and feeds into the gene transcription by the 
dephosphorylation of NFAT by calcium/calmodulin dependent protein phophatase, calcineurin 
(Oka et al. 2005). This permits translocation to the nucleus where it can intereact with other 
transcription factors, such as Gata-4, and promote gene expression (Molkentin et al. 1998; Taigen et 
al. 2000) 
In addition to the synergistic interactions, Gata-4 can also be negatively regulated by the interaction 
with the zinc finger protein FOG-2 (Lu et al. 1999). FOG-2 is important for heart morphogenesis and 
vascular development but can only bind DNA through its interaction with Gata-4 (Crispino et al. 
2001). Whilst in vitro studies show that it predominantly inhibits Gata-4 transcriptional activity (Lu 
et al. 1999; Svensson et al. 1999), this is cell-type and gene dependent and may activate transcription 
in some instances.  
Gata-4 itself is expressed in a variety of other tissues including the visceral endoderm, as well as the 
definitive mesendodermal derived tissues such as the developing liver, lungs, gonads and gut 
(Molkentin 2000). It is the unique combinatorial expression of these transcription factors that 
confers tissue specificity, as seen in the heart (Dai et al. 2002).  
Schlesinger et al. (2011) demonstrated this high degree of combinatorial regulation in a 
comprehensive transcriptome study of four of the cardiac transcription factors; Gata-4, Nkx2.5, SRF 
and Mef2a. They analysed the DNA binding sites using ChIP-chip and used siRNA to examine the 
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functional consequence of transcription factor knockdown. From this they identified that these four 
transcription factors simultaneously control 91 genes, 3 of them control 121 genes, and 143 genes by 
just Gata4 and Nkx2.5 (Schlesinger et al. 2011). Inhibition with siRNA only produced a mild 
disruption in the expression of the target genes; thereby demonstrating the redundancy that can 
occur during development. This study also showed the importance of acetylation, with histone 3 
acetylation markedly increasing Gata-4 and SRF target gene expression. 
 
Figure 1.7. A schematic overview of the gene regulatory network governing cardiac development. 
This diagram is restricted to the interplay that occurs in the first heart field, which forms the left ventricle 
and atria. Whilst many of the genes regulate each other’s gene expression, they also interact to promote 
expression of the structural genes. In this way the transcription factors act in a feed forward loop. For 
example, whilst Gata-4 promotes expression of Nkx2.5, Mef2c and HAND2 it also physically interacts with 
these proteins to promote heart development. Arrows designate gene activation and bars inhibition. 
Adapted from Herrmann et al. 2012 
Undeniably, there are many other considerations besides transcription factor interactions. These 
include protein modifications such as phosphorylation, acetylation and sumoylation; as well as the 
chromatin conformation which is controlled by remodelling agents and more recently on the scene 
is the interplay of microRNAs. 
Phosphorylation of Gata-4 plays a large role in regulating its activity. Notably, there are two distinct 
mitogen activated kinase cascades that activate Gata-4; the p38 and the MEK1-ERK12 signalling 
pathways. These have been shown to relay the response of hypertrophic stimuli, such as 
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phenylephrine and endothelin-1, increasing the Gata-4 transcriptional activity of B-type naturietic 
peptide and A-type naturietic peptide (Kerkelä et al. 2002; Liang, Wiese, et al. 2001). Conversely, 
phosphorylation by GSK3β negatively regulates Gata-4 activity by targeting the transcription factor 
for nuclear export (Morisco et al. 2001) 
miRNA have been described as fine-tuners of gene expression, down regulating low expression 
proteins and honing protein expression in specific cell types (Liu & Olson 2010). A single type of 
miRNA can target many different transcripts, most often working by inhibiting mRNA translation 
(Liu & Olson 2010). miRNA1 and 133 have been shown to be important in cardiac development and 
maintenance, with dicer knockout causing embryonic lethality (Liu & Olson 2010).  This emphasises 
the importance of monitoring protein levels directly, and not only mRNA levels, as it is protein 
production that is most commonly disrupted by miRNAs. 
Another important player in controlling gene expression is that of chromatin modifications. In the 
closed state, chromatin exists in tightly coiled formation around histones. Opening of the chromatin 
by relaxing these coiled structures is known to enhance gene expression in that region by permitting 
access of the transcription factors to the gene promoter binding sites. There are a large number of 
regulators of chromatin conformation. These include the histone acetylases and histone 
deacetylases, methylation, and ATPase based factors such as SWI/SNF-like complex. 
In the liver, Gata-4 is known as the ‘pioneer’ factor being able to access promoter regions in 
compacted chromatin (Cirillo et al. 2002). However, this does not necessarily occur in heart 
development as there is mounting evidence for the role of chromatin remodelling agents. In 
particular Baf60c, a cardiac specific subunit of the SWI/SNF-like complex, was shown to facilitate 
attachment of Gata-4 to promoter sequences, although this was in non-cardiac mesoderm (Takeuchi 
& Bruneau 2009). 
Transduction of hESC with factors to direct cardiomyocyte formation showed that the minimum 
required was Tbx5 and Gata4, but the four factors, Tbx5, Gata4, Nkx2.5 and Baf60c were the most 
efficient (Dixon et al. 2011). The need for the chromatin remodelling agents is corroborated by earlier 
work on Baf60c, which showed its global expression in the heart of the developing embryo (Lickert 
et al. 2004). Silencing of this subunit resulted in lethality and severe cardiac malformations, 
reportedly due to the underdevelopment of the first and second heart field progenitors (Lickert et 
al. 2004). In vitro experiments showed that Baf60c fostered the interaction between cardiac 
transcription factors Nkx2.5, Tbx5 and Gata-4 with Brg1, the BAF complex ATPase (Lickert et al. 
2004; Puri & Mercola 2012). 
Other instances indicating chromatin modification are that of the interaction between HAND2 and 
Gata-4, which simultaneously recruited p300, a protein with histone acetyltransferase activity 
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(HATs; Dai et al., 2002). p300 also directly acetylates Gata-4 enhancing its DNA binding and 
transcriptional activity and subsequently demonstrated its importance in regulating cardiogenesis 
(Kawamura et al. 2005).  
 
Figure 1.8. Schematic illustrating some of the important protein-protein interactions which regulate 
the activity of the key cardiac transcription factor Gata-4. Calcium signalling responds to growth 
stimuli and feeds into the gene network in multiple ways. It acts via calmodulin (CaM) which activates 
calcineurin to dephosphorylate the transcription factor NFAT. This permits its translocation to the 
nucleus where it can interact with Gata-4. Calcium signalling also controls HDAC activity, where 
phosphorylation mediates its nuclear export allowing MEF2c to interact with other transcription factors. 
The mitogen activated kinases, p38 and ERK1/2, are also involved in promoting cardiac gene expression 
by phosphorylating Gata-4. However, Gata-4 activity is countered by phosphorylation with GSK3β which 
promotes its nuclear export and subsequent degradation. These interactions and protein modifications 
demonstrate the complexity of protein regulation. Adapted from (Akazawa & Komuro 2003) 
Opposing the action of HATs are the histone deacetylases (HDACs), which act to deacetylate the 
amino tails of histones. This restores their positive charge and promotes the compact conformation 
of the chromatin (Haberland et al. 2009; Grunstein 1997). HDACs are highly implicated in mediating 
pathological hypertrophy in response to heart failure. Studies have shown that the class II HDACs 
repress the transcription factor Mef2c through direct binding, thereby inhibiting its transcriptional 
activity and interaction with other transcription factors  such as Gata-4 (Zhang et al. 2002; Olson et 
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al. 2006; Chan et al. 2003). In cardiogenesis specifically, inhibition of HDAC 4 with thrichostatin in 
P19 embryonic carcinoma stem cells (Karamboulas et al. 2006) up regulated expression of the 
transcription factors Nkx2.5, Gata-4 and Mef2c as well as the structural protein cardiac α-actin. Thus, 
this demonstrates the significance of HDACs in cardiogenesis. 
The gene regulatory network controlling cardiac development is complex (Figure 1.7). The examples 
here focus on the pivotal role of the transcription factor Gata-4; highlighting the vast regulatory 
networks in which it is involved and which is far more complicated than gene expression alone 
(Figure 1.8). Gata-4 transcriptional activity is controlled by interactions with other transcription 
factors and regulatory proteins, some of which confer post translation modifications. These 
modifications include acetylation, phosphorylation and sumoylation and act not only to control its 
activity but the cellular location and susceptibility to degradation, all of which impact the 
transcriptional activity. Another facet of transcription factor control is access to the enhancer 
regions, which is controlled by chromatin conformation and modulated by proteins families such as 
HATs, HDACs and SWI/SWIF like complex. Thus, it is clear that protein analysis is necessary, and 
that studying protein interactions and modifications will be instructive as to the pathways 
controlling differentiation of cardiomyocytes.  
? ??????????????????????????????????????????????????????????????????
?????????????????
There is compelling biomedical need to regenerated cardiac tissue. Clinical trials with bone marrow 
stem cells had limited efficacy in improving cardiac output in patients who had suffered a myocardial 
infarction. Current trials are using endogenous cardiac progenitor cells, expanding the cells ex vivo 
from a biopsy before re-administration. Although they have been shown to form cardiomyocytes in 
in vivo studies, these cells are poorly characterised. The great challenge is to activate the cardiac 
progenitor cells in situ for cardiac repair (Vieira & Riley 2013; Bollini et al. 2011).  
Already, it is known that forced expression with the key cardiac transcription factors can direct 
fibroblasts to the cardiac cell fate. Elucidating the key steps that control differentiation would be 
preferable to the use of retroviral transformation (Vieira & Riley 2013). The CPCs express the key 
cardiac transcription factors whilst maintaining a stable progenitor phenotype. Rigorous 
examination the status quo of these cells is needed in order to understand the cues holding these 
cells in their arrested state. By understanding the activity status of transcription factors or their 
protein interactions will facilitate unlocking their cardiogenic potential. 
Given that cardiac progenitor cells are so few in number in the heart, studying the protein expression 
of the fresh cells is almost impossible without clonal expansion. Further still, clonal expansion of 
these cells has shown that there is a heterogeneous expression of the core cardiac transcription 
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factors. Therefore being able to study these cells at the single cell level would be greatly beneficial, 
and is currently not met by other technologies.  
The aim of this thesis was to develop an assay that could detect protein from a single cardiac 
progenitor cell using total internal reflection microscopy, with a view to looking at protein 
interactions in the future. 
Gata-4 has a prominent role in cardiac development, being a key component of the gene regulatory 
network and is known to be expressed in the cardiac progenitor cells. There are many important 
other players in cardiac differentiation; however, their inclusion in such an assay as this is highly 
dependent on the availability of specific, high affinity antibodies. An initial search of the antibodies 
commercially available for the key cardiac transcription factors revealed that there was limited 
availability of monoclonal antibodies for the factors of interest. Since it is known that polyclonal 
antibodies have lower affinity for their target to monoclonals, it was decided to setup the assay using 
the cardiac transcription factor Gata-4, which had a large repertoire of monoclonal antibodies.  
The assay is based on the traditional antibody sandwich system, in which proteins are pulled down 
with printed capture agents and detection performed through fluorescently conjugated secondary 
antibody. Two approaches were used for the development of this assay; the first was using antibodies 
as is typical, and the second approach focused on developing a DNA based protein-capture agent.  
The chapters in this thesis describe the different stages of assay development, and detail further 
background information for each section. Chapter 2 lists all the materials and methods, whilst 
chapter 3 explains the single molecule counting algorithm developed by the group and used to 
process the TIRFM data.  
Chapter 4 details the initial stages of assay development, with validating suitable Gata-4 antibodies, 
using the standard techniques of Western blotting and immunohistochemistry.  For optimising such 
a sensitive technique, several parameters need to be considered and are discussed in Chapter 5. 
These include surface chemistry, immobilisation strategies, and types of conjugations as well as 
antibody concentration. This is followed by the calibration of the assay in Chapter 6 and discusses 
the issues of affinity and other parameters which affect the assay’s limit of detection. Chapter 7 shows 
the development of single cell experiments with cardiac progenitor clones, then details all the 
permutations and finally discusses possible improvements in addition to the limitations. Chapter 8 
focuses on the possible development of alternative protein-capture agents, and details the 
development of the DNA capture agents for Gata-4. Finally, Chapter 9 rounds up all the discussion 
points and summarises the main findings and limitations, improvements and future work. 
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Chapter 2 
??? Methods and materials 
? ??????
All cells used throughout this study are listed in the table below (Table 2.1). 
Name Source Tissue origins Purpose 
HEK 293 FT Invitrogen (R700-07) 
Human embryonic kidney cell 
line, immortalised. Contains the 
SV40 viral antigen 
Transfection for 
protein expression 
Hep G2 HPA (85011430) Human hepatocyte carcinoma Protein isolation 
MCF7 
Willison, 
Imperial 
College 
London 
Human breast adenocarcinoma Protein isolation 
HeLa 
Tate group, 
Imperial 
College, 
London 
Human cervix epitheloid 
carcinoma 
Transfection for 
protein expression 
Sca1+ clonal 
cardiac 
progenitors 
cells 
Schneider et 
al. Imperial 
College 
London 
Adult mouse heart, derived 
from a single cell 
Protein isolation, 
TIRFM single cell 
experiments 
Table 2.1. List of all cells used in this study. 
? ?????????????
All cells were grown at 37 oC, in 5% CO2, in DMEM containing 10% FBS (Table 2.3), except cardiac 
progenitor clones which were cultured in CGM (see Table 2.2 for details) on collagen I coated flasks. 
Flasks were coated in the tissue culture hood using collagen I solution (Table 2.4), adding 1 ml per 
10 cm2 dish and leaving for 30 minutes before aspirating. Coated flasks were left in the hood overnight 
to dry. Flasks were washed once in PBS (PAA, UK # H15-002) prior to use.  All cells were passaged at 
about 80% confluency with 0.25% trypsin-EDTA (Life technologies, UK, # 25200-056). 
?
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Clonal Growth Medium (CGM) Manufacturer (Catalogue Number) 
65 % DMEM / Ham”s F-12 Life technologies, UK (#11320074) 
35 % Iscove's Modified Dulbecco's Medium  
Life technologies, UK (#12440046) 
3.5 % Bovine growth serum  Merck Millipore, UK (# SH30541) 
100U/ml Antibiotics-Antimycotics  Life Technologies, UK (# 15240096)   
2 mM L-Glutamine Life Technologies, UK (# 25030024)   
0.1 mM β-Mercaptoethanol  Sigma aldrich, UK (# M7522) 
1.3 % B27 media supplement  Life technologies, UK (# 17504044)    
6.5 ng/ml Epidermal growth factor  Peprotech, UK (# AF-100-15)   
13 ng/ml fibroblast growth factor-basic Peptotech, UK (# 100-18B)   
0.0005 U/ml thrombin  Roche Applied Biosystems, UK (#10602400001) 
0.345 ng/ml human cardiotrophin-1 Cell Sciences, UK (# CRC700B)   
Table 2.2. Recipe for clonal growth media (CGM) used to culture cardiac progenitor cells, SP3 and SP16. 
DMEM culture medium  Manufacturer (Catalogue Number) 
Dulbecco's modified eagle medium Sigma Aldrich, UK (# D6429) 
10% Foetal bovine serum PAA, UK (# A15-151) 
Table 2.3. Culture media for all cells except cardiac progenitor cells. 
Collagen-coating solution  Manufacturer (Catalogue Number) 
50 μg/ml Type 1 rat tail collagen BD Biosciences, UK (# 354236) 
547 μl Glacial acetic acid  Thermo Fisher, UK (# A/0400/PB17) 
500 ml Distilled water Life Technologies, UK (# 15230162) 
Table 2.4.  Details of collagen coating solution used to coat culture flasks for growing cardiac progenitor 
cells.  
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? ?????????????????????????????????????????????????????
An N terminus Flag tagged Gata4 expression vector, was created using expression vectors pCDNA3.1 
containing the Flag sequence (from Dr. D Mann’s group) and pCMV6-XL4 containing the human 
Gata-4 expression sequence (Origene, USA # SC124037). The Gata-4 insert was created by PCR, with 
a TEV cleavage site using the primers detailed in Table 2.5. The primer sequences encoded 5’ 
restriction sites XhoI and XbaI on the forward and reverse strands, respectively. The pCDNA3.1 
vector encoding the flag tag and the PCR product were cut using the restriction enzymes, XhoI and 
XbaI, for which the conditions are listed in Table 2.6  
Primer Sequence 
Forward CTCGAGTTGAAAACCTGTATTTTCAGGGAGGA
GGAATGTATCAGAGCTTGGCCATG 
Reverse TCTAGATTACGCAGTGATTATGTCCCC 
Table 2.5. Primer sequences to amplify Gata4 insert. In bold are the restriction 5' sites encoded, XhoI for 
the forward seqeunce and XbaI in the reverse sequence. The TEV cleavage site encoded in the forward 
primer is italicised.  
Digestion 
1xNEB buffer 4 
0.1mg/ml BSA 
2 units XhoI 
2 units XbaI 
2ug of DNA 
Incubte at 37oC for 1.5 hours 
Heat inactivate at 65oC for 20 minutes 
Table 2.6. Reagents and conditions for digesting DNA vector and Gata4 insert. 
? ???????????????????????????
Protein was expressed in HEK 293T cells transfected with the plasmids using Fugene 6 transfection 
reagent (Promega), at a ratio of 3:1 reagent to DNA. Media was changed prior to transfection and 
cells grown for up to 48 hours before harvesting (see protein isolation protocol in section 2.5). 
The FLAG tag on the Gata-4 protein allows isolation using a FLAG specific antibody, and the TEV 
cleavage site allows for protein elution. To purify the protein, magnetic protein G coated beads were 
cross–linked with an anti-Flag antibody (F1804, Sigma Aldrich) according to the manufacturer’s 
instructions. Cell lysates were then incubated with the beads for 10 minutes at room temperature, 
followed by washing in PBS. Upon transferal to a new tube the beads were treated with Pro-TEV plus 
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(#V6101, Promega) to cleave the protein. The enzyme is then removed from the protein solution via 
it’s HQ tag, which binds to nickel when passed through a HisLink affinity column (#V8823, 
Promega). The resulting purified protein was aliquoted and stored at -80oC.  
? ?????????????????????????????????
To retain protein function, cell lysates were made with non-denaturing conditions. Whole cell 
lysates were made by washing cells three times in cold PBS, before incubating with non-denaturing 
lysis buffer contain 1% triton X-100, for 10 minutes with shaking (see below for buffer details). Cells 
were then collected by scraping and sonicated to release nuclear proteins. Sonication was done at 
4oC, with 5 repetitions of 5-10 seconds of sonication with a pause of 30 seconds in between to avoid 
overheating. The cell lysates were then spun at 14,000 rpm for 10 minutes at 4oC to pellet cell debris. 
The supernatant was collected and stored at -20oC or -80oC for long term storage.  
All protein samples were stored with 10% glycerol to preserve protein function upon freezing. 
Protease and phosphatase inhibitors (#78442, Pierce) were added to all buffers and contained 
aprotinin, sodium fluoride, sodium orthovanadate, β-glycerophosphate, bestatin, E64 and leupeptin.  
Non-denaturing lysis buffer 
50mM Tris HCl pH7.4-8.0 
150mM NaCl 
10% glycerol 
1% Triton X-100 
Table 2.7. Non-denaturing lysis buffer recipe 
? ??????????????????????????????????
Cells were placed on ice and washed three times with cold PBS, scraped and pelleted at 3000 rpm 
for 5 minutes in a swing bucket centrifuge. Cells were then resuspended in 6 volumes of Harvest 
buffer (10 mM HEPES pH7.9, 50 mM NaCl, 0.5 M Sucrose, 0.1 mM EDTA, 0.50% Triton x 100). 
After incubation for 5 minutes on ice, the nuclei was pelleted at 1000 rpm in a swing bucket 
centrifuge for 10 minutes. The cytosolic supernatant was carefully collected and subsequently cleared 
of cellular debris by centrifugation at 14,000 rpm for 15 minutes. The nuclei pellet was washed and 
resuspended in buffer A (10 mM HEPES pH7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA) and re-
pelleted at 1000 rpm for 5 minutes. The supernatant was discarded and 4 volumes of buffer C (10 mM 
HEPES pH7.9, 500 mM NaCL, 0.1 mM EDTA, 0.1 mM EGTA) added, and then vortexed at 4oC for 15 
minutes to release nuclear protein. The nuclear lysate was then repelleted at 14,000 rpm for 10 
minutes at 4oC and the nuclear extract collected. Protease and phosphatase inhibitors (#78442, 
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Pierce) were added to all buffers prior to use and contained aprotinin, sodium fluoride, sodium 
orthovanadate, β-glycerophosphate, bestatin, E64 and leupeptin.  
? ?????????????????
Prior to loading, protein samples were denatured by adding 4x sample buffer containing SDS and 
heated to 94oC for 10 minutes. Samples were loaded on to polyacrylamide gels at between 20-30μg 
per lane and run on 10% gels with a 4% stacking gel, in running buffer containing SDS, at 75-90V for 
up to 2 hours in mini vertical gel tanks (Hoefer, USA # SE250). Proteins were then transferred from 
the gels to nitrocellulose membranes in tris-glycine transfer buffer containing methanol at 90v, 4oC 
for 1.5 hours in Mighty Small Transfer Tank (Hoefer, USA # TE22). Nitrocellulose membranes were 
blocked in 5% skimmed milk powder (Sigma Aldrich, UK # 70166) in PBS-tween 20 (PBST). 
Membranes were then probed with primary antibody over night at 40C on a rotator. Membranes 
were washed three times in PBST, for 5 minutes each wash. Membranes were then incubated, whilst 
shaken, with the secondary antibody conjugated to horse radish peroxidise, followed by washing 
three times in PBST. Signal was developed using ECL western blotting detection reagents (GE 
Healthcare Life Sciences, UK #?RPN2109) and visualised either by x-ray film (Amersham Hyper Film 
ECL, GE Healthcare Life Sciences, UK # 28-9068-35) or with the G:BOX Chemi XX6 imaging system 
(Syngene, UK). 
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Target Host 
Species 
Type 
Application used in 
( ug/ml) 
Company (Product code) 
A
n
ti
-G
at
a4
 a
n
ti
b
o
d
ie
s 
Mouse 
Monoclonal 
(IgG2b) 
WB (1), IF(10) R&D systems, UK (# MAB2606) 
Mouse 
Monoclonal 
(IgG1) 
WB (0.5), IF(0.5) BD biosciences, UK (# 560327) 
Rabbit 
Monoclonal 
(IgG) 
WB (1/250) Abnova, Taiwan (# ab134057) 
Mouse 
Monoclonal 
(IgG2b) 
WB (1/250) Abnova, Taiwan (# ab86371) 
Mouse 
Monoclonal 
(IgG3) 
WB (0.4) Sigma Aldich, UK (# SAB3300090)  
Mouse 
Monoclonal  
(IgG2a) 
WB (0.5) 
Santa Cruz Biotech., USA             (# 
sc25310X) 
Gata - 5 Goat Polyclonal IF Santa Cruz Biotech, (# sc-7280) 
Gata - 6 Rabbit Polyclonal WB Thermo Fisher, UK (#PA1-104X) 
HSP90 Rabbit Polyclonal WB (1 in 1000) Cell signalling tech., USA (# 4874) 
Beta-Actin Mouse 
Monoclonal 
(IgG1) 
WB (1in 2000) Sigma Aldrich, UK (# A54441) 
Conjugated secondary antibodies 
Anti-
mouse 
Horse 
HRP,  
polyclonal 
WB (1in1000) Cell signalling tech., USA (# 7076) 
Anti-rabbit Goat 
HRP,  
polyclonal 
WB (1 in 1000) GE Healthcar, UK (# RPN4301) 
Anti-goat Donkey 
HREP, 
Polyclonal 
WB (0.4) 
Santacruz Biotech., USA                
(# sc-2020) 
Anti-
Mouse 
Goat 
FITC, 
polyclonal 
IF (1 in 1000) 
Santacruz Biotech., USA                
(# sc-2010) 
Isotype controls 
IgG1 Mouse Monoclonal IF(0.5) R&D systems, UK (# MAB002) 
IgG2B Mouse Monoclonal IF(10) R&D systems, UK (# MAB004) 
IgG Rabbit Polyclonal IF R&D systems, UK (#AB-105-C) 
IgG Goat Polyclonal IF R&D systems, UK (#AB-108-C) 
Table 2.8. List of all antibodies used in both Western blot (WB) and immunofluorescent cell staining (IF). 
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4x sample buffer Company (product number)  
0.5 M Tris (pH 6.8)  Sigma Aldrich, UK (# T1503) 
36% Glycerol  Sigma Aldrich, UK (# G5516) 
18% ml 20% SDS  Sigma Aldrich, UK (# L3771) 
0.04% Bromophenol Blue  Fisher Scientific, UK (# 10040040) 
4% Beta-Mercaptoethanol Sigma Aldrich, UK (# M3148) 
Table 2.9. List of ingredients for 4x Laemmli sample buffer, used to for running protein samples on 
acylamide gels. 
 
1x running buffer Company (product number)  
25mM Tris Base  Sigma Aldrich, UK (# T1503) 
192mM Glycine Sigma Aldrich, UK (# G8898) 
0.1% SDS Sigma Aldrich, UK (# L3771) 
Table 2.10. Recipe for running buffer used to run protein samples on acrylamide gels 
 
1x Transfer buffer Company (product number) 
25mM Tris Base  Sigma Aldrich, UK (# T1503) 
192mM Glycine Sigma Aldrich, UK (# G8898) 
20% Methanol VWR Int. Ltd., UK (L13255) 
Table 2.11. Recipe for transfer buffer used to transfer proteins from the acrylamide gel to a nitrocellulose 
membrane using electrophoresis. 
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10% resolving gel Company (product number) 
10% Acrylamide/Bis (19:1) AppliChem, UK (# UN3426) 
1.5 M Tris (pH 8.8)  Sigma Aldrich, UK (# T1503) 
10% SDS  Sigma Aldrich, UK (# L3771) 
10% APS Sigma Aldrich, UK (# A3678) 
0.1% TEMED Sigma Aldrich, UK (# T9281) 
Table 2.12. List of ingredients for making the acrylamide gels. This is made first and then the 4% stacking 
gel poured on top. 
4% stacking gel Company (product number) 
4% Acrylamide/Bis (19:1) AppliChem, UK (# UN3426) 
0.5 M Tris (pH 6.8)  Sigma Aldrich, UK (# T1503) 
10% SDS  Sigma Aldrich, UK (# L3771) 
10% APS Sigma Aldrich, UK (# A3678) 
0.1% TEMED Sigma Aldrich, UK (# T9281) 
Table 2.13. Recipe for 4% stacking gel which formed the top 2 cm of the polyacrylamide gels. 
? ? ???????????????????????????????????????????
Glass coverslips were placed in 24-well plates and coated in collagen I as with coating cell culture 
plates (see section 2.2). The night before fixation, cells were plated between 50-100,000 cells per well. 
The following day cells were washed three times in PBS and fixed with 4% formaldehyde, 20 minutes 
on ice followed by three PBS washes. Cells were permeabilised with a 1:1 mixture of methanol and 
acetone at -20oC for 10 minutes. Cells were blocked in PBS containing 4% FBS for 1 hour at room 
temperature. Cells were then incubated overnight with primary antibodies in blocking solution, 
shaking overnight at 4oC. Cells were then washed three times in PBS and then incubated in 
fluorescently conjugated secondary antibodies solution whilst shaking for 1 hour at room 
temperature (for antibody concentrations see Table 2.8). 
After the final three PBS wash steps, coverslips were mounted on microscope slides using 
FluoroshieldTM mounting medium containing DAPI (Sigma Aldrich, UK # F6057) and visualised 
using Zeiss Observer Z1 epifluorescence microscope.  
? ??????????????????
Reverse transcription PCR was run in order to check gene expression. Separate primers were used 
for mRNA detection in mouse and human cell lines. The murine primers were GapDH (Integrated 
DNA Technologies) for the control and Gata-4 (# RDP-345, R&D Systems) producing a band at 479 
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bp. The annealing temperature for the GapDH (452bp) and Gata-4 primers were 64 and 54.4oC 
respectively. For the human cell lines a Gata-4 primer with an amplicon of 68bp was used (#4331182, 
life technologies) with an annealing temperature of 60oC. For low the low weight amplicons (less 
than 100 bp), products were run on 10% acrylamide TBE gels with an Ultralow Range DNA Ladder, 
spanning 10-300bp (GeneRuler). otherwise products were run on 1% agarose gel containing gelred 
using a 1 kb DNA ladder (Gene ruler) and on a 4% TBE gel. 
RNA was extracted using the Qiagen shredder kit according to the manufacturer’s instructions. 
Human Universal and Murine Universal Reference RNA was used as the positive controls and 
Human Colon and Murine Kidney RNA was used as the negative controls (eBioscience, UK). PCR 
was performed using the Qiagen One-Step PCR kit and the conditions optimised for the primers. 
Stage Temp Time   
Reverse 
transcription 50 30 mins  
Initiation 95 15 min  
Melting 95 30 sec 
Re
pe
at
 3
0 
tim
es
 
Annealing 54.4-64 30 sec 
Extension 72 1 min 
Final 
Extension 72 10 min   
Table 2.14. Conditions for RT PCR, annealing temperatures different for Gata-4 and GAPDH primers 
respectively. 
 
10% TBE gel Company (product number 
1xTBE Fisher Scientific, UK (# FQ-B52) 
10% acrylamide (19:1) AppliChem, UK (# UN3426) 
Table 2.15. Recipe for gel used for DNA PAGE. 
? ?????????????????????????? ????????????????????????? ?????????????
Double stranded DNA oligonucleotides were designed for Gata-4 protein capture. The DNA binding 
regions were chosen based on consensus sequences found for Gata-4 in the Transfac® data base 
(Biobase GmbH). The ANF Gata4 binding site and the ANF mutant negative control were obtained 
from (Charron et al. 1999). DNA was bought as single strands and then hybridised by heating to 94oC 
and cooling over several hours. Details of the sequences are listed in Chapter 8. 
 ?
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? ???????????????????????????
Capture agents were printed with the OmniGrid Micro, microarray (Digilab, UK) using micro 
spotting pins (ArrayIt, USA # 946MP2). All capture agents were printed in 3x SSC, 1.5M Betane (Diehl 
et al. 2001) on clean glass coverslips, thickness no. 1.5 (VWR, UK #631-0147), unless otherwise stated. 
The SSC-betane buffer was the chosen as it improved spot homogeneity both in DNA and, in our 
experience, antibody printing (Diehl et al. 2001). Amine modified DNA capture agents were printed 
on GPTS modified glass coverslips.  All capture agents were printed at 50-60% humidity. 
GPTS modified glass coverslips were prepared by cleaning in methanol, followed by 0.5 M sodium 
hydroxide and then plasma cleaned. Glass coverslips were then incubated with GPTS solutions, 
containing 2.5% GPTS, 5% acetic acid and ethanol with pH2-3. Slides were incubated for 1 hour at 
room temperature before washing in distilled water and dried with nitrogen gas. Unmodified glass 
coverslips were cleaned in three changes of methanol with sonication of at least 30 minutes. 
? ?????????????????
In order to micropattern PDMS with micrometer scale features a template is made on a silicon wafer 
using photolithography. This is formed by placing a photomask onto light sensitive photoresist and 
the design is transferred by exposure to UV light. In order to coat the silicon wafer with photo resist, 
the wafer is spun with SU-8 50 (MicroChem), ramping the speed to 500rpm at an acceleration of 
100rpm/second and held for 5 to 10 seconds, the spin coater is then ramped to 2000 rpm at an 
acceleration of 300 rpm and held there for 30 seconds. This gives a coating with a thickness of 50 
μm. The photoresist is then soft baked to remove the solvents and densify the film by pre-baking at 
65oC for 6 minutes followed by soft baking at 95oC for 20 minutes. The photoresist is then exposed, 
with the photomask on top, to UV (350-400 nm) to a total of 400 mJ/cm2. The wafer is then baked 
once more to cross link the exposed regions, heating at 65oC for 1 minute followed by a post exposure 
bake at 95oC for 5 minutes. The SU-8 mask is then developed in SU-8 developer (MicroChem) for 6 
minutes, followed by washing in isopropyl alcohol and finally dried in nitrogen gas. 
? ?????????????????????????????????????
PDMS devices were made by casting PDMS at a 1:10 ratio with curing agent onto the silicon wafer 
masks. The PDMS was placed in a desiccator to de-gas and then allowed to set at room temperature, 
overnight on a flat surface. The devices were then cut out and ports drilled using 300 μm drill bits. 
The PDMS was then cleaned in ethanol with sonication followed by drying with nitrogen gas. 
Devices were then aligned to printed coverslips using a jig (made in house). The designs of the 
microfluidics are in the relevant results chapters.    
 ?
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? ???????????? ??????????
Microfluidic device were connected to an electronic pump set (Labsmith, USA) that can administer 
microfluidic volumes and was controlled by the accompanying computer software (Labsmith, USA). 
The devices were connected to samples with peek tubing, inner diameter 160 μm, outer diameter 
360 μm. Devices required desiccation with fluid before connecting to pumps.  
? ??????????????
An inverted microscope (Nikon Ti-E, Nikno, Japan) with a 60x oil-immersion objective (apo, 1.49 
NA, Nikon) was used for single molecule microscopy. The specifications of this microscope include 
widefield white light and epi-fluorescent imaging provided by halogen and mercury lamps. The 
turret housed the following objectives: achromat 10x 0.25 NA dry, plan fluor 20x 0.5 NA dry, plan 
fluor 40x 0.9 NA dry, as well as the 60x objective mentioned above. The motorised stage could 
translate in x,y directions and the objectives translated in the z axis. This enabled the perfect 
focusing sytem (PFS) which automatically adjusted the focal plane during imaging, thereby 
eliminating focal drift.  The microscope has two filter carousels; the upper contained the standard 
Nikon FITC, DAPI, and TRITC dichroic filters plus the TIRF illumination dichroic (Chroma, USA). 
The lower carousel contained a filter set for the pulsed laser source used for laser lysis, a single-edge 
dichroic (LPD01-532R-25; Laser 2000, UK) and long pass filter (LP03-532RS-25; Laser 2000, UK) with 
wavelength at 532 nm or 1064 nm, respectively. The single edge filter prevents reflected or scattered 
light from reaching the detector. 
The microscope is connected to a motorised TIRF unit (MTU) to convert the solid –state continuous 
wave laser beam with the wavelength of 473 nm (MBL-473-200; Laser 2000, UK) into TIRF. Two 
other lasers were attached through the back port; a pulsed Nd-YAG at 1064 nm for laser lysis and a 
Ytterbium fibre laser at 1070 nm for optical trapping of cells. Figure 2.1 illustrates the optical setup. 
For fluorescent detection an IXON DU-897E electron-multiplying charge-coupled device (EM-CCD; 
Andor Technologies, Ireland) is used.  Intrinsic noise primarily results from dark current and read 
noise which is minimised by thermoelectric cooling. Single molecule detection is achieved due to 
the background discrimination coupled with the high sensitivity of the EM-CCD.   
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Figure 2.1. Optical setup for TIRF microscopy, the optical trapping and the laser lysis. The lasers; 473nm 
continuous waver laser, Nd:YAG pulsed laser at 1064 nm and Ytterbium fibre laser at 1070 nm are coupled 
into the back port of the microscope. EM-CCD = electron multiplying charge-coupled device camera, 
PM= periscope mirrors, M = mirror, λ/2 = half-wave plate, PBS = polarising beam splitter, FM=flip mirror 
L1 & L2 = lenses in beam expander , MTU = Nikon motorised TIRF unit, FC = filter cube. Taken from 
Salehi-reyhani et al. 2011. 
? ??????????????????????????????????
Here a single beam of wavelength 1070 nm, power set at approximately 50 mW, from a Ytterbium 
fibre laser, is highly focused using the 60x 1.49 NA, oil-immersion objective to provide attractive and 
repulsive forces. Where the focused beam is most narrow, there is a very strong electric field 
gradient. Dielectric particles (like cells) are attracted along the gradient to the strongest point. The 
x,y translation of the motorised stage allows manipulation and movement of the cells through the 
microfluidic device. 
? ????????????
A high energy solid-state Nd:YAG pulsed laser (Surelite SL I-10; Continuum, USA) was used for cell 
lysis. This laser can deliver a single pulse, of 6 ns in duration, at a wavelength of 532/1064 nm. The 
pulse fire is operated by a manual joystick, delivering a pulse of maximum 1.43± 0.13 J. A 60× NA=1.49 
oil-immersion objective is used, focusing pulses to 10 μm above the cells.
???
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Chapter 3 
??? Single molecule counting algorithm 
The counting algorithm used in this work was developed by other members of the research group 
(Burgin et al 2014). The Matlab program I specifically used for my data sets was developed by Dr. 
Aidan Brown. The algorithm consists of three parts; i) background correction of the laser 
illumination profile, ii) setting a threshold, iii) counting of single molecules based on pixel size and 
intensity. 
? ???????????????????????????????? ?????????????????
For image detection we used a sensitive digital detector and an electron multiplying current coupled 
device (EMCCD, Andor 897). This technology is capable of detecting single photons and designed 
to detect weak signals above intrinsic noise. The intrinsic camera noise includes photon shot noise, 
dark current, read noise and the analogue to digital conversion, and clocked induced charge. Much 
of the intrinsic noise is overcome by the electron multiplying gain function which is able to multiply 
weak signals such that the intrinsic noise is negligible. The cooling feature in the device ensures that 
dark noise is kept to a minimum.   The EMCCD corrects for gain fluctuations, so that the peak of the 
distribution is the same for each frame. 
The next step in background correction is to flatten the field of view. The laser beam illuminates the 
field of view with uneven intensity due to fibre alignment (see Figure 3.1.B). Photon excitation from 
a fluorophore scales with laser intensity; therefore, in a single image fluorescent molecules in the 
centre of the field of view will have a greater intensity than those in the periphery. It is therefore 
important to eliminate this uneven intensity, otherwise weaker signals will not have the same 
weighting as stronger signals. 
The background correction is applied by taking a set of control images, in this case frames containing 
fluorophore only, and taking the average across the set. A broad guassian kernel filter is applied with 
a radius of 60 pixels. This gives the averaged distribution of laser intensity across the images. All 
frames are divided by this background image, resulting in an even intensity distribution across the 
image. Since the intensity of each frame can vary across the data set, for example between time 
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points or different frames, the background correction applied is scaled so that the intensity of the 
background image matches the intensity of each individual frame. Background intensity of each 
frame was measure in regions where there was no printed antibody and few real single molecules. 
The algorithm used these intensities to scale the correction image to match of the image being 
corrected.  
A second filter, a clustering mask, was applied to the data set to discriminate true signal from 
background noise. This is a disc filter with a radius of 1.5 pixels, it identifies local maxima in both 
the x and y direction. Fluorescence of a single molecule (fluorophore conjugated antibody) will 
display over more than one pixel, displaying intensity over a group of connected pixels.  Typically, 
background noise does not cluster and occurs on individual pixels that are not connected. This filter 
dilutes background noise and blurs real single molecules across a broader range of pixels.  
Figure 3.2 shows the effect of different filter sizes on single molecule count. By applying a filter of 
radius 0.5, no discrimination is made between background noise and true signal, and thus produces 
a high false positive count. By applying a larger filter, akin to the size of true single fluorescent 
molecule, reduces the signal by 3 fold. There is negligible difference between a filter size of radius 1 
or 1.5. Hence, discriminating single molecules based on size is a useful tool decrease the false positive 
count. 
* 
* 
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Figure 3.1. Outline of the background correction process. Starting with the raw images taken of 
background on glass with only fluorophore present (A) and of protein binding to printed antibody (B). C 
and D show the corresponding pixel intensities of the raw data (Z axis), where the x,y axes represent 
position across the field of view. C, essentially shows the Gaussian profile of the laser beam, resulting in 
uneven illumination across the field of view. D shows the intensity across the printed antibody spot after 
incubation with Gata4. It can be seen that pixels in the centre of the spot are more intense than at the 
periphery. E and F are the intensities after dividing through by the blurred background image. The 
Gaussian profile of the laser beam has become planar (E) and the pixel intensity across the antibody spot 
is normalised (F). 
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Figure 3.2. A comparison of different filter sizes to identify single molecules. Filters are applied to 
sample data; printed DNA incubated with Gata4 protein and secondary ant-Gata4 detection antibody. 
Filter radius 0.5 identifies single pixels and therefore all intense pixels will be counted, producing a high 
single molecule count. There is a significant difference between filter with radius 0.5 and that of radius 1 
and 1.5. There is no observable difference between filter with radius 1 or 1.5. Filter of 1.5 was applied to all 
further data sets. 
? ????????????????????????????????????????????????????
Setting the threshold above background requires measuring the intensities on a background region 
in each frame, a region of plain glass, where there are few single fluorescent molecules. There are 
two methods to determining the threshold; the first takes a histogram of the total intensities in each 
background region. The second method, which this algorithm used, finds the local maxima in each 
background regions. This essentially sums the single molecules found in this region. In both cases, 
the mean plus three times the standard deviation is taken to be the threshold ensuring a confidence 
interval of 99.7%; thereby reducing the false positive signal to 0.3%. Anything above this threshold 
is considered real single molecules and everything below is taken to be just background. 
 ?
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? ???? ? ?? ?? ?
?
??
?
??
??
?
??
?
?
??
??
?
?
?
?
?
? ?
??
? ?
? ?
?
?
? ?
??
? ?
?
?
? ?
??
? ?
? ?
?
?
? ? ? ?
? ? ? ?
? ? ? ? * 
*
  
57 
 
Counting single molecules 
The algorithm calculates the single molecule count based on the density of fluorescence in each 
frame. If the density of single molecules is low such that they are spatially separated then single 
molecules can be counted using a clustering mask which is able to pick out single molecules against 
background. However, this method is limited to approximately 700 molecules (figure 3.3), after 
which the molecule count deviates from the true molecule count and plateaus at 2000 molecules. 
This particular method is limited by the density of single molecules increases, as spatial resolution 
is lost as molecules begin to overlap. Instead, another method is used where the cumulative intensity 
of the single molecules is scaled to determine the number of molecules.  
To demonstrate the accuracy of the algorithm, a data set was simulated (Ovesný, P. et al. 2014) 
varying the number of input molecules from approximately 50 – 30,000. For each image generated, 
the true number of molecules is known which allows for the comparison of the two molecule 
counting methods: 1) using the clustering mask to identify single molecules, 2) scaling the image 
intensity. This data shows that the scaling method is highly accurate at calculating the number of 
molecules present across the entire range. In contrast, the single molecule identification method is 
only accurate up to approximately 700 molecules, plateauing at 200o molecules. As mentioned 
above, this is due to the lack of spatial resolution when molecules begin to overlap. The, the scaling 
method was used in this thesis to calculate the molecule count for all subsequent data sets. 
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Figure 3.3 uses simulated data to show the accuracy of the single molecule counting algorithm. The 
raw intensity of each simulated image was plotted versus the molecule count, with the true number 
of input molecules shown in black. The intensity scaling method (grey) and single molecule 
identification method (blue) are compared against the input reference for accuracy. The scaling 
method is highly accurate over the entire range of intensities and molecule counts, fitting very 
closely with that of the input molecules. The single molecule identification method is accurate up 
to approximately 700 molecules after which it deviates from the input curve.  
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Chapter 4 
4. Validation of Gata-4 antibodies 
Using TIRFM for detecting single protein molecules requires antibodies with both high specificity 
and affinity to its target protein. By using two antibodies to the target protein, in a conventional 
sandwich assay format, the specificity of the assay is increased. In this assay antibodies directed at 
different epitopes of Gata-4 were used. Information on the exact epitope target is often restricted, 
and often only specified as a large region of the target protein. It is important that the two antibodies 
used in the sandwich assay recognise different epitopes so that the two antibodies can bind the same 
antibody simultaneously. Although this may be less important if the protein forms dimers.  
 
Figure 4.1. Schematic of Gata-4 protein highlighting the regions containing the transactivation 
domains (TAD), N-terminal Zinc finger (NZf), C-terminal zinc finger (CZf) and the nuclear 
localisation signal (NLS). The epitopes recognised by the antibodies tested in this study are denoted by 
the black line (-), with its respective antibody above. Not all antibody binding regions are depicted as 
some of this information is restricted. Diagram adapted from Molkentin 2000.  
Typically, antibodies recognise a region of 15 amino acids; however these may not necessarily be 
continuous amino acids but rather those brought closer together by protein folding (Frank 2002). 
The Gata-4 transcription factor has many active domains and Figure 4.1 illustrates its two 
transactivation domains, the two zinc fingers that permit DNA binding and a nuclear localisation 
signal (Ip et al. 1997). The antibodies validated in this chapter were raised against short peptide 
sequences and are depicted in Figure 4.1, of which specific details are in Table 4.1.  
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The Western blot is a well establish protocol for protein detection, developed in the late 70’s  by 
three independent groups simultaneously (Burnette 1981; Towbin et al. 1979; Renart et al. 1979). It is 
a denaturing technique whereby proteins are sorted by size. Whilst the field of DNA and RNA 
analysis has progressed vastly since the invention of the Southern and Northern blots, the Western 
blot still remains the gold standard for analysis protein expression. Here, the Western blot is used 
to assess the specificity of the anti-Gata-4 antibodies for the Gata-4 protein. 
? ????????
?????? ?????????????
Methods of making cell lysate and western blotting are listed in Chapter 2, section 2.5-2.6. Cell 
lysates were loaded equally, with each lane containing 20 μg of protein and purified protein at 100 
ng. The concentration of each antibody used is listed in the Table 4.1 below. Primary antibodies were 
incubated with the immunoblots for 1 hour at room temperature before washing and incubating 
with the corresponding secondary detection antibody.  
?????? ????????????????????????????????
Cells were fixed using 4% formaldehyde and permeabilised using methanol. Cells were stained either 
with the anti-Gata-4 antibody MAB2606 or BD along with their respective isotype control antibodies, 
IgG2b and IgG1, at the same concentrations. All antibody concentrations are listed in Chapter 2, 
Table 4.1. 
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Shorthand 
name 
Target epitope (amino 
acid position) 
Host 
Species 
Type 
Company / 
Product code 
MAB2606 Met27-Phe211 Mouse 
Monoclonal / 
IgG2b 
R&D / MAB2606 
BD 354-367 Mouse 
Monoclonal / 
IgG1 
BD biosciences / 
560327 
Ab57 5-30  Rabbit 
Monoclonal / 
IgG 
Abnova / 
ab134057/ 
EPR4768 
Ab71 27-211 Mouse 
Monoclonal / 
IgG2b 
Abnova / ab86371 
Sig90 296-442 Mouse 
Monoclonal / 
IgG3 
Sigma Aldich / 
SAB3300090  
Sc-25310 328-439 Mouse 
Monoclonal / 
IgG2a 
Santa Cruz / 
sc25310X 
?
Table 4.1. Details of the Gata-4 antibodies tested in this study. Information on the immunogen 
sequence was used to identify which would be suitable for use in an antibody sandwich assay. The 
shorthand names are used in all other figures and text. 
? ????????
?????? ?? ???????????????????????????????????????????????????????
????????
Antibodies were validated against a positive and negative control lysate. For the positive control, 
either HeLa cells transfected with a Gata-4 expression vector (+) was used and compared to the 
untransfected counterpart (-). Expected molecular weight of Gata-4 is 45 kDa and whole blots are 
shown here to demonstrate the specificity of the antibody. In total six monoclonal antibodies were 
tested. 
Three antibodies of the six tested appeared to be specific for the Gata-4 protein. These were 
MAB2606, Sig90 and BD (Figure 4.2), all of which produced a band near the expected height of 45 
kDa and gave a clean blot with the negative control. The three remaining antibodies did not appear 
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specific to Gata-4 protein as they either produced bands that were too low in molecular weight 
(sig90), to high (ab71) or produced bands in both lanes (ab57).  This suggests that the antibodies 
ab71, sig90 and ab57 are not suitable.  
 
Figure 4.2. Immunoblot of monoclonal anti-Gata-4 antibodies validated against either HeLa Gata-4 
transfected lysate (+) and untransfected lysate (-). Three antibodies gave positive signal at the 
expected height for Gata-4 protein (45 kDa), these were Sc, BD and MAB2606. The remaining 
monoclonal antibodies either produced bands at the wrong height for Gata-4 (Sig90, ab71) or 
produced bands in both the positive and negative control lanes (ab57). All blots were tested for the 
loading control, β-actinin, which produced an expected band at 42 kDa for each lysate, and which 
was very slightly lower than the band expected for Gata-4 protein. 
  Figure 4.3. Reverse transcription PCR of the 
untransfected HeLa cell line (HeLa) for Gata-4 
expression, testing using primers that produce a 
product of 68bp and therefor run on acrylamide gel in 
order to resolve bands. This was compared to Human 
Reference (Hu Ref) RNA as positive control and 
Human Colon (Hu Col) as a negative control for Gata-
4 mRNA expression. GapDH was used as a loading control 
with an expected height of 452 bp.  
All blots were stained with the loading control Beta-actinin to ensure that both the positive and 
negative control lysates were loaded equally. The untransfected HeLa cell line demonstrated no 
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Gata-4 RNA expression by reverse transcription PCR (Figure 4.3), and was compared to a Universal 
Human reference sample containing all human tissues and which was positive for Gata-4. Human 
Colon RNA, identified using the Array Express database (EMBL-EBI; Kolesnikov et al. 2015), was used 
as the negative control.  
 
Figure 4.4. Western blot testing the two Gata-4 antibodies on cardiac progenitor cells. The two 
clones tested were clone 3 and 16, and nuclear (Nuc) and cytosolic (Cyto) fractions were tested for 
Gata-4 protein expression. As expected the Gata-4 was found to be localised to the nucleus and was 
only detected in Clone 3 and not Clone 16. Gata-4 purified protein was included as positive control 
(+ve). B-actin expression was used as the loading control, demonstrating even loading in all lysates 
and no expression in the purified protein. 
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Figure 4.5 Reverse transcription PCR 
showing Gata-4 expresion in the murine 
cardiac progenitor cells, SP3 and SP16 as 
compared to a positive and negative 
control, Mouse Universal Reference (Ms 
Ref) and Mouse Kidney (Ms Kid) RNA. Both 
the Mouse Universal Reference and the 
cardiac progenitor clone  SP3 proved 
positive for Gata-4 with a band near the 
expected height of 479bp. Mouse kidney 
and cardiac progenitor clone SP16 showed 
no detectable Gata-4 expression by routine 
RT-PCR in accordance with the disparate 
levels of Gata-4 mRNA by qPCR. (Noseda et 
al. 2015). GapDH was used as the loading control 
Two of the cardiac progenitor clones, Clone 3 and Clone 16 were tested for Gata4 expression (Figure 
4.4).   Cell lysates were separated into their cellular and nuclear fractions and tested against the two 
Gata-4 antibodies, BD and MAB2606. Gata-4 purified protein was used as a positive control. Both 
the BD and MAB2606 antibodies detected protein expression in the nuclear fraction of Clone 3, but 
not in Clone 16. The band detected is of the same height as the Gata-4 protein for the BD antibody. 
The band produced by the MAB2606 antibody is slightly lower than the purified protein. This could 
be an artefact of the gel, with slight uneven electrophoresis which often happens due to over-heating. 
Beta-actin was used as the loading control with an expected height of 42 kDa, Histone 1 protein (H1, 
approximately 30kDa) and HSP90 (90 kDa) used to show clear nuclear and cytosolic fractionation, 
respectively. The Gata-4 expression correlates with reverse transcription PCR data which shows 
Gata-4 mRNA expression in Clone 3 but not Clone 16 (Figure 4.6). 
 
4.2.2   Immunofluorescence of murine cells to detect native 
Gata-4 protein 
One way of assessing whether antibodies can detect native, non-denatured protein is to run a non-
denaturing polyacrylamide gel electrophoresis (PAGE) followed by immunoblotting, like in Western 
blotting. This was used in the early stages of antibody validation but was not successful due to 
technical issues.  
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Running basic proteins on native PAGE is challenging. Gata-4 is a relatively basic protein, with a pI 
of approximately 9.4 (predicted from online bioinformatics resource portal, ExPASy, Swiss Institute 
for Bioinformatics). This means when run in a buffer of pH 8.8 it is likely to have neutral charge and 
therefore not migrate. Several runs showed that the protein stacked at the top and didn’t run into 
the gel. This was either due to the basic nature of the protein or that it formed large protein 
complexes or aggregates too large to migrate into the gel.  
Thus, immunofluorescence was used to assess the native binding capacity of the antibodies. Indirect 
immunofluorescence was performed on the clonally derived cardiac progenitor cells from mouse 
(Schneider, Imperial College London, UK) which are known to express Gata-4 (see Figure 1.4 for 
clone details). The cell lines HEK and Hep G2 were not tested as they were not intended to be used 
for cell experiments in the TIRFM assay. Figure 4.6 shows the staining of the clonal cardiac 
progenitor cells with the anti-Gata-4 antibodies and the nuclear stain, DAPI. Cells show a distinct 
nuclear localisation of the Gata-4 protein, with the DAPI signal (blue) and the Gata-4 signal (green) 
overlapping in the merged image. Staining with the isotype controls gave minimal signal, affirming 
that the Gata-4 antibodies are detecting the target protein.   
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Figure 4.6. Immunofluorescent staining of clonally derived cardiac progenitor clones. Clones known 
to express Gata-4 protein were probed using two different anti-Gata-4 antibodies, both showing nuclear 
staining (red) which co-localised with DAPI staining (blue). The Anti-Gata-4 MAB2606 and BD  
antibodies were compared with their respective isotype controls, IgG2B and IgG1. 
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4.2.3 Immunofluorescence to test cross-reactivity between Gata 
factors 
To assess if the antibodies detected other Gata proteins, HeLa cells were transiently transfected with 
either Gata-4, Gata-5 or Gata-6 and counterstained with the two Gata-4 antibodies plus the 
respective control antibody, Gata-5 or Gata-6 (Figure 4.7). The results show that the Gata-4 
antibodies detect protein in the cells transfected with Gata-4 but not the cells transfected with Gata-
5 or Gata-6. In addition the IgG control antibodies were negative for all transfected cells.
 
Figure 4.7 Immunofluorescent staining of HeLa cells transiently transfected with either Gata-4, 5 or 
6. Cells were then counterstained with the Gata-4 antibodies and the respective control antibodies,  
Gata-5 or  Gata-6 antibody (single experiment, tested in duplicate). 
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? ???????????
?????? ?? ????????????????????
Of the six antibodies tested only a half proved to be specific for Gata-4 from Western blot analysis. 
Of the three, BD and MAB2606 were chosen to be tested on chip. Whilst this may seem like a hasty 
decision, initial Western experiments indicated that the Sc antibody was not specific for Gata-4, it 
was only after retesting the antibodies with HeLa lysate (initial experiments were with HEK 293T) 
that Sc was seen to be a possible candidate antibody. Unfortunately, due to time constraints this 
antibody was not robustly tested on-chip. 
?????? ??????????????????????????
There are 6 members of the Gata family, of which Gata-4, 5 and 6 bear the most similarity. Gata-4 
shares 45% and 33% identity with Gata-5 and Gata-6, respectively, with the highest degree of 
similarity occurring in the zinc fingers (basic local alignment search tool; NCBI).  These three Gata 
members often have overlapping expression, particularly in the heart (Charron & Nemer 1999; 
Charron et al. 1999; Zhao et al. 2008) and Gata-4 and 6 are both expressed in cardiac progenitor cells 
studied in our group (Chapter 1, Figure 1.4, Noseda et al. 2015).  
Considering the possibility of cross-reactivity of the Gata-4 antibodies with other Gata factors, 
antibody specificity was tested. The results here indicate that the antibodies are specific to their 
target, staining positive in the cells expressing Gata-4 but not in cells expressing Gata-5 or 6.  An 
important limitation is that the counterstaining with Gata-5 and Gata-6 was relatively low; however, 
it was relatively higher than negative control and the Gata-4 antibody staining of Gata-5 and 6 
transfected cells. In addition to this, specificity was also suggested by staining in the cardiac 
progenitor cells (discussed below) and the initial antibody validation with untransfected and 
transfected HeLa cells (Figure 4.2) 
?????? ????????????????????????????????????????????
Microarray expression data from our group (Chapter 1, Figure 1.4, Noseda et al. 2015) shows a myriad 
of transcription factor expression in the cardiac progenitor cells. Based on this data, a clone positive 
and negative for Gata-4 were chosen to test out this assay, these were Clone 3 and clone 16 
respectively. Gata-4 expression was verified using Western Blot analysis (Figure 4.4) with the two 
chosen Gata-4 antibodies and by PCR (Figure 4.5). This confirmed that Clone 3 expresses Gata-4 in 
the nucleus whilst Clone 16 was negative for Gata-4 expression. 
 ?
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?????? ?? ????????????????????????????????????????????????????
??????????????????
Assessment of antibody binding to native proteins was initially trialled by native PAGE. However, 
the protein remained in the stacking wells and did not migrate into the gel very far. This could be 
due to formation of large complexes which under denaturing conditions will dissociates. 
Alternatively it could be due to the basic nature of the protein, which running in a buffer of pH 8.8 
will neutralise the protein’s charge. Various other conditions were trialed but did not work, including 
testing with more alkaline buffer or an acidic buffer and reversing the charge.  
Immunofluorescence can be used to detect target proteins within cells. In this instance, it does not 
indicate the specificity of the antibody but does demonstrate if the antibody can recognise the native 
form of the protein. Although, cell fixation protocol can modify the proteins, it is good 
representation of native proteins. The antibodies BD and MAB2606 both demonstrated native 
detection, staining Gata-4 in the nucleus as would be expected for the transcription factor.  This is 
important with regards to single cell proteomics as antibodies will encounter the native protein 
form, and not the denatured form.  
 
? ????????
?? In total 8 antibodies were tested via Western blotting to assess their specificity to the Gata-
4 transcription factor 
?? Two monoclonal antibodies were identified as specific for Gata-4 protein detection; 
MAB2606 and BD 
?? These were tested on the cardiac progenitor clones and showed Gata-4 expression in Clone 
3 but not Clone 16
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Chapter 5 
??? Optimisation of antibody immobilisation and 
labelling 
? ?????????
The key to the success of any immunoassay is the antibody immobilisation and labelling strategies 
(Kusnezow et al., 2003; Wild, 2001). Inefficient immobilisation or over labelling can directly impinge 
the assays sensitivity and therefore will affect this assays ability to detect proteins from a single cell. 
The factors considered and optimised in this chapter are: antibody fluorescent labelling, 
immobilisation of the pull down antibody, the concentration of the detection antibody and surface 
passivation. Although, the assay is ultimately limited by the availability of antibodies with good 
affinity, these additional parameters can increase sensitivity by reducing background noise and 
increasing antibody functionality.  
?????? ????????????????????????????????????????????????????????
Optimising the concentration of detection antibody is a balance between maximising antigen-
antibody interaction and minimising non-specific antibody binding. The concentration must be high 
enough to saturate all antigen binding epitopes. This is because under-labelling the antigen can lead 
to undercounting. The caveat here is that non-specific binding is not saturable and increases with 
increasing antibody concentration, thereby diminishing the signal to noise ratio (Wild, 2001). 
Therefore, the ratio of signal to background noise will have a maximum, above which more antibody 
will only decrease the signal-to-background ratio (Wild, 2001). 
?????? ????????????????????????????????????????????????
Antibodies can be labelled directly or indirectly. The indirect method requires a second antibody 
directed against the species, or isotype, of the first antibody (e.g. mouse, rabbit, goat, igG1, IgG2, 
IgG2B). This method is quite often used in immunohistochemistry (as seen in Chapter 4, Figure 4.6) 
as it is less costly than directly labelling the antigen-specific antibody with fluorophore. It also allows 
amplification of the signal, since the many anti-species antibodies can bind the Fc region or heavy 
and light chains of their target antibody.  
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However, using the indirect labelling method in this system would require using three antibodies 
simultaneously. This introduces and extra element to non-specific binding, increasing the likelihood 
of cross-reactivity. It also relies heavily on the affinity of the tertiary antibody for the secondary, as 
low affinity antibody would result in unbinding and would not be suitable for this assay. An 
alternative to using full length antibodies is to use Fab fragments directly conjugated to 
fluorophores. The fragments used in this chapter were isotype specific and were compared to 
detection antibodies that were covalently labelled. 
5.1.2.a Choice of fluorescence:  organic fluorphores versus 
quantum dots 
Quantum dots are nanocrystals with photophysical properties that make them very suitable for 
multiplexing and long imaging acquisitions. In brief, they have broad excitation band but are highly 
tuneable, offering a range of different wavelength emissions distinct from the excitation wavelengths 
(Giepmans, Adams, Ellisman, & Tsien, 2006; Medintz, Uyeda, Goldman, & Mattoussi, 2005).  In 
addition they are resistant to photobleaching and biological degradation, making them very suitable 
to biological applications. On the other hand, the quantum dots are very large at 20-30 nm in 
diameter (Giepmans et al., 2006; Medintz et al., 2005), which swamps the smaller size of antibodies 
which have an average height only of 14.5 nm and width of 8.5nm (Lee et al., 2009). The large size of 
quantum dots would slow the diffusion rate of the antibody, thereby limiting the assay kinetics. In 
contrast, fluorescent proteins are often only a few hundred Dalton and are thus much smaller than 
antibodies which are typically 150 kDa. 
The structure of quantum dots renders them insoluble, and they require additional coatings to 
resolve this and enable conjugation to proteins (Medintz et al., 2005). The conjugation strategies 
involve either covalent linking to amine or thiol groups of proteins or by adsorption (Medintz et al., 
2005). There is little control exerted over how the antibodies are orientated and how many are 
attached per quantum dot (Medintz et al., 2005). This, along with the diffusion limitation and the 
liability of cross linking, makes this technology unsuitable for this application at present. 
5.1.2.b Covalent conjugation of fluorescent molecules to 
antibodies  
The three main strategies for direct labelling with organic fluorophores: via primary amines, the 
carbohydrate groups or the thiol groups (Figure 5.1). These all involve covalently bonding a 
fluorescent molecule to the antibody. The primary amines are most commonly used; although this 
method offers little control over where in the antibody it is labelled and by how much (Haugland, 
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1995).  This means that primary amines near or in the binding region can be targeted and thereby 
affect the antigen binding capacity.  
 
Figure 5.1. Illustration of the three different labelling mechanisms to fluorescently conjugate 
antibodies. These are covalent bonding via the primary amines in the antibody (A), labelling via the 
carbohydrate chains located in the Fc regions (B), or labelling via the thiol group which is released by breaking 
one of the disulphide bonds in the hinge region. Diagram adapted from Haugland 2001. 
Other labelling targets can be the disulphide bonds that help form the tertiary structure. These link 
the heavy and light chain, and also form hinge region which connects the two antibody halves. The 
sulphide bridge in the hinge region is quite accessible and can almost be selectively hydrolysed to 
expose a reactive thiol (Haugland, 1995, 2001). This can then be used for covalent bonding of a 
fluorescent molecule, often by using maleimide reactive groups. This offers control over where and 
how much the antibody is labelled, effectively resulting in a 1:1 ratio of fluorescence to antibody. The 
down side is that the tertiary structure can be effected and therefore impact binding efficacy. 
The final approach is to use the carbohydrate groups which are only found in the antibody Fc region 
(Haugland, 1995, 2001). This means that antibodies are labelled away from the binding region. 
However, the process of oxidising the carbohydrates to reveal reactive aldehydes is quite lengthy 
and requires high starting concentrations (above 1mg/ml) of antibody and often results in large 
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antibody loss (Haugland, 2001; Kusnezow et al., 2003). Thus, this strategy is unsuitable here because 
the commercial antibodies used are supplied at less than 1mg/ml and in very small quantities. 
Sometimes antibodies are linked to fluorophores by biotin-streptavidin binding. These molecules 
have very strong affinity for each other; therefore avoid the issue of unbinding. Fluorophores are 
covalently linked to streptavidin and the antibody to biotin. The biotin is covalently linked to the 
antibody in the same manner as discussed above, either with primary amines, thiols or to the 
carbohydrate chain of the antibody. Thus it presents the same problem as with directly labelling but 
provides an extra processing step, which will result in more antibody loss.  
5.1.2.c Artefacts of labelling   
Another caveat to antibody labelling is the stabilising buffers the antibodies are provided in. If these 
contain primary amines such as BSA or glycerol, both common stabilising agents, then labelling will 
be hindered as it labels these agents. This can result in high non-specific binding as well as inefficient 
antibody labelling, both affecting the assay sensitivity. These stabilising agents can be removed using 
a dialysis kit, but this often results in a loss of antibody. 
Labelling with amines often requires a greater than 10-20 times molar excess of fluorophores to 
antibody, resulting in each antibody having multiple fluorophores per antibody, with an optimum 
of between 3-8 fluorophores per mole of antibody (Haugland, 1995). There are many commercial kits 
available which are optimised for labelling small quantities of antibody (<20µg). Thus, this method 
seemed most accessible in the context of this assay. 
In this chapter, indirect labelling using Fab fragments was compared with the direct conjugation 
using covalent bonding to the primary amines. 
5.1.3 Antibody immobilisation strategies 
Many strategies have been developed for immobilising antibodies on a glass surface (Angenendt, 
Sobek, Lehrach, & Cahill, 2003; R. C. Bailey, Kwong, Radu, Witte, & Heath, 2007; Boozer, Ladd, Chen, 
& Jiang, 2006; Cho et al., 2007; Kusnezow & Hoheisel, 2003; Kusnezow, Syagailo, Goychuk, Hoheisel, 
& Wild, 2006; Seurynck-Servoss, White, Baird, Rodland, & Zangar, 2007; Vijayendran & Leckband, 
2001). However, retaining the functionality off antibodies immobilised on a surface remains the 
biggest challenge in protein array technology.   The questions remain as to whether to orientate the 
antibody or not, and whether to lift them off the surface and if so by how much (Kusnezow et al., 
2003).  
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5.1.3.a Orientated versus non-orientated antibodies 
It is thought that by orientating the antibodies the binding regions remain accessible and thereby 
increase the functionality of the immobilised protein. The biggest drawback here is the 
functionalization of the antibody which it often results in huge antibody loss. These orientation 
techniques include using immobilisation via biotin-streptavidin (Cho et al., 2007), through 
carbohydrate modification (Cretich, Damin, Pirri, & Chiari, 2006; Kusnezow & Hoheisel, 2003; 
Kusnezow et al., 2003; Seurynck-Servoss et al., 2007) or with Protein G (Bae, Oh, Lee, Lee, & Choi, 
2005; MacBeath, 2002). There is an added benefit in that both Biotin-streptavidin and Protein G both 
lift the antibody off the glass and may increase functionality by decreasing steric hindrance. 
Non-orientation methods include immobilisation through adsorption, covalent binding using the 
primary amines (Angenendt et al., 2003) or 3D hydrogels (Olle et al., 2005; Seurynck-Servoss et al., 
2007). Despite possibly having a more suitable environment for antibodies, the latter of these is not 
suitable for the TIRF application due to thickness of the structure and the reportedly high 
backgrounds (Kusnezow et al., 2003; Seurynck-Servoss et al., 2007). Adsorption has the advantage 
of maximising the amount of antibody possible to print down, though not all the antibody will be 
functional. Immobilisation via the amines allows extension of the antibodies away from the surface 
by surface modifications. For instance reacting an epoxide, such as GPTS, with the silicon glass 
surface and then allowing antibodies to covalently bind to the terminal reactive group extends the 
antibody away from the surface (Figure 5.2; Kusnezow et al. 2003). This helps to reduce steric 
hindrance but does not orientate the antibody as any primary amine can react with the epoxide.  
A thorough comparison of surface chemistries was conducted by  Seurynck-Servoss, S. L. et al. 
(2007). Focusing on the lower limit of detection, this work showed that there was little difference in 
sensitivity of the ELISA assay between covalent and non-covalent adsorption (Seurynck-Servoss et 
al., 2007). This was corroborated by another study by Kusnezow et al. (2003) on the surface chemistry 
of protein microarrays. They showed that whilst antibodies immobilised by their amine groups have 
an overall higher signal intensity, simple adsorption onto poly-L-lysine slides had lower background 
and comparable lower limits of detection. In addition, they reported femtomolar sensitivity with 
covalent immobilisation with either the primary amine with GPTS, or by the thiol groups with MPTS 
attached to a carbon chain linker (Kusnezow et al., 2003). A caveat of immobilisation via adsorption 
is that the antibody can exchange with the incubated solution, being only held in place by hydrogen 
bonding, hydrophobic and ionic interactions (Seurynck-Servoss et al., 2007). 
Bailey et al. (2007) developed a strategy circumventing the direct immobilisation of antibodies to 
the surface. Instead they conjugated the antibodies to a DNA nucleotide sequence and printed the 
complementary sequence. By flowing through the antibody complex, the antibody then hybridises 
 75 
to the printed DNA sequence. This technique was tried in our lab but was found that the prepartion 
resulted in huge loss of antibody, and thus was not very practical for our setup. 
Assay sensitivity depends on the amount of pull down antibody effectively available. Therefore, 
antibody immobilisation is a careful balance between density and functionality. In this thesis 
immobilisation with protein G and adsorption to the glass surface was tested.  
 
Figure 5.2. Illustrates functionalising the glass surface with GPTS. The silicon glass surface contains 
numerous hydroxyl groups, cleaning the surface with reducing agents liberates the hyrdrogen ion, leaving the 
reactive oxygen to form a covalent bond the GPTS. This epoxide contains a highly reactive oxygen which will 
covalently bond with amines, aiding the immobilisation of proteins. Diagram taken from Kim et al. 2007.  
?????? ????????????????????
One way to help increase the lower limit of detection is to decrease the background noise. The 
standard method of surface passivation is to block the surface with a non-specific protein. In ELISA 
assays, this is often BSA and was therefore used in this assay. BSA coats the glass surface by 
adsorption, sticking to the glass by a combination of van der waals, ionic and hydrophobic 
interactions (Boenisch et al., 2001). Other methods of blocking are used in other immunostaining 
techniques; semi-skimmed milk proteins and FBS are commonly used in Western blot and 
immunofluorescent staining. Coating the surface with polyethylene glycol (PEG) is another method 
commonly used to reduce background binding.  PEG is an amphiphilic molecule which gives it 
solubility in water whilst retaining its hydrophobic properties. It is this latter property blocks non-
specific protein adsorption after attaching it to the glass surface. 
? ????????
?????? ?????????????????????
Direct and indirect antibody labelling methods were compared. Antibodies were labelled either 
using covalent bonding to the primary amines with alexafluor-488 or indirectly with fluorescently 
conjugated Fab fragments (Apex and Zenon antibody labelling kits, Invitrogen) according to the 
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manufacturer’s instructions. Both kits permit labelling of miniscule quantities of antibody, and are 
therefore particularly suitable for this assay where antibodies are supplied in small amounts.  
5.2.2 Surface passivation with PEG 
Glass coverslips were cleaned with potassium hydroxide for 30 minutes with sonication. After rinsing 
with water, slides were irradiated in a plasma oven for 1 minute. Plasma treated slides were then 
incubated in 2.5% aminosilane solution, containing ethanol and 5% acetic acid, slides then washed 
and incubated with PEG solution in a dark, humidity chamber for up to 2 hours. Slides were 
subsequently washed and dried with nitrogen air. Antibodies were printed onto the PEG coated 
slides and chips were assembled with PDMS microfluidic channels as described in section 6.2.2 . 
5.2.3 Experimental set up 
5.2.3.a Comparison of fluorescent labelling methods 
Fab fragment and primary amine fluorescent labelling were compared by lysing cells directly on 
chip, in 10 µl perfusion chambers.  This was to simulate the cell experiment set-up that the assay is 
intended for. Chambers were loaded with 222 or 111 cells/µl. This was to equate to the theoretical 
single cell concentration of 0.22 cells per nl (or 1 cell per 4.5 nl chamber). Cells were detached using 
trypsin EDTA 0.05% and kept on ice in L15 medium with 10%FBS. L15 medium is designed for cells 
kept out of the incubator for long periods of time. Cells were spun down and diluted to appropriate 
cell number in L15 medium containing 10% FBS, 4% BSA, protease inhibitors and secondary antibody 
diluted to the appropriate concentration. Both antibodies were diluted to the optimised 
concentration of 250 ng/ml. Binding of fluorescently labelled antibodies was compared to printed 
Gata-4 antibody and the respective IgG isotype control. 
5.2.3.b Antibody immobilisation with Protein G 
To assess antibody immobilisation Protein G was printed as a series of 10-fold dilutions between 0.5 
and 500 µg/ml. The slide was then incubated with anti-Gata4 pull down antibody at 0.2 mg/ml. 
Excess antibody was washed away and the sample was incubated with either detection antibody 
alone or with detection antibody plus Hep G2 lysate. Detection antibody was diluted to 250 ng/ml, 
as optimised in section 5.1.1, and the HepG2 lysate to 0.75 mg/ml. Signal was analysed after 30 
minutes. 
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???????? ??????????????????????????????????
To compare surface passivation methods, two independent experiments were performed in the 
microfluidic chip either treated with PEG or with BSA. These 5 channel chips were then incubated 
with varying dilutions of cardiac progenitor cell lysate, ranging from 7.5 pg/nl to 112.5 pg/nl. This 
range of concentrations theoretically spans that of single cell sensitivity. 
? ????????
?????? ????????????????????????????????????
Here, the concentration of detection antibody to use in the assay was optimised. It is important as 
too high a concentration interferes with the TIRF signal; from preliminary experiments this upper 
limit was determined to be 2.5 μg/ml, at which the field of view is distorted, giving spurious image 
acquisitions (data not shown).  
 
Figure 5.3. Optimisation of the detection antibody concentration. Two independent experiments with 
antibodies diluted to 25 ng/ml (left) or 250 ng/ml (right) and incubated with printed protein, Gata-4 and p10. 
There was almost a 10 fold difference in signal between the two concentrations and the signal-to-background 
ratios were 9.2 and 13.6 for 25 ng/ml and 250 ng/ml respectively. Binding to the Gata-4 protein was significantly 
higher than to P10 protein with both concentrations of detection antibody. 
In these experiments, two different purified proteins were printed onto glass: Gata4 protein and p10 
protein, a negative control. They were incubated with fluorescently conjugated anti-Gata-4 at either 
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25 or 250 ng/ml. These concentrations were determined based on the number of molecules per nl, 
which correspond to 1x105 and 1x106 molecules/nl, respectively. 
As expected, binding to the Gata-4 protein was significantly higher than to the negative control 
protein, p10, at both concentrations of antibody. There was a significant difference in binding 
between the two concentrations, with 10 fold higher binding to Gata-4 protein at 250 ng/ml of 
detection antibody than at 25 ng/ml (Figure 5.3). This coincided with a slight increase in non-specific 
binding to P10 protein at 250 ng/ml of antibody. However, the signal to background ratio also 
increased from 9.2 to 13.6 for antibody concentrations 25 and 250 ng/ml, respectively.  
5.3.2 Comparison of direct and indirect antibody labelling methods 
Two labelling methods were compared, Fab fragments and primary amine conjugation. The counter 
antibody was then printed along with the respective isotype controls. Cell solutions were added and 
lysed directly on chip.  
 
 
Figure 5.4. Comparing total single molecule count with two separate antibody labelling strategies, 
Fab indirect labelling and amine direct labelling. Cells were lysed directly on chip and consisted of either 
111 cells per µl (A) or  222 cells per µl  (B). These dilutions are equivalent to having 1 or 0.5 cells in a chamber of 
a microfluidic chip. Overall a significantly higher signal is achieved with Zenon labelled detection antibodies 
than Apex, at both cell concentrations. It is worth noting that the overall non-specific binding to IgG control 
is higher for the Zenon than Apex labelled antibodies, and remains constant despite the different cell 
concentrations. Error bars are SEM and represent 5 antibody spots of both Gata4 and IgG, replicated 3 times 
(n=15). 
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Figure 5.5. Comparison of the signal to noise ratio of the two labelling strategies. SBR for both 
methods are similar at 111 cells/µl but amine labelling has a significantly higher SBR of 65 compared to 18of 
Fab labelling at the higher cell concentration (A). The SBR analysed at time 0 (B), before addition of cells 
shows high initial binding of Fab labelling. SBR was compared for ratio of antibody binding to Gata4 and 
control antibody (G4:IgG) , and Gata4 and background binding to plain glass (G4:bg). Both amine and Fab 
labelling had similar SBR when comparing non-specific binding to antibodies. However, the Fab labelled 
antibodies had an extremely high SBR when comparing antibody to non-specific binding on plain glass. Error 
bars are SEM and represent 5 antibody spots of both Gata4 and IgG, replicated 3 times (n=15). 
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Fluorescent labelling with Fab fragments produced signal far superior to labelling via the primary 
amines (figure 5.4). However, the non-specific binding to IgG was higher with the Fab labelled 
antibodies. Non-specific binding did not scale with cell concentration, with each labelling technique 
having the same amount at both cell dilutions. The amine labelled antibodies had lower signal to 
both the Gata-4 antibody and negative IgG control, with a significant difference between the two. 
Signal to background ratio was also evaluated by comparing the signal at time 0 (before cell lysis) of 
Gata-4 antibody to that of background on glass. Figure 5.2B, compares this with the SBR attained 
from comparing Gata-4 antibody to IgG isotype control. The amine labelled antibodies gave similar, 
low SBR in both situations. However, the SBR for Fab labelling is remarkably different when 
comparing Gata-4 signal to that of background on glass or to the IgG control. This is a demonstration 
of antibody-antibody cross reactivity, with SBR of Gata-4 to IgG antibody being very low at 1.25, and 
very high SBR of 92 for Gata-4 to background on plain glass.  
5.3.3 Antibody immobilisation with Protein G 
The method of immobilising antibody onto a glass surface is important for antibody function. Here, 
immobilisation with Protein G was tried as it has high affinity for antibodies, being commonly used 
in affinity purification of antibodies. It has the added benefit of not requiring any antibody 
modification and so reduces any antibody loss through antibody functionalisation.  
 
Figure 5.6. Comparison of Gata-4 binding versus detection antibody alone to pull down antibody 
immobilised by protein G. There is a significant difference between binding of complex and that of detection 
antibody alone at 50 and 500 µg/ml of protein G. There is no significant difference at 0.5 and 5 µg/ml of protein 
G. Signal on protein G complexes of 500 and 50 µg/ml is significantly higher than at 5 and 0.5 µg/ml of protein 
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G. The problem lies in the amount of unwanted binding of detection antibody to protein G which may be 
enough to mask the signal of Gata4 at the single cell level. Starred points (*) indicates P<0.01. 
Preliminary experiments suggested that protein G bound the free detection antibody despite being 
saturated with the detection antibody. Here, I set out to test whether decreasing the protein G 
concentration reduced the binding of secondary antibody (Figure 5.6).  
Negligible binding of Gatat-4 is observed at 0.5 and 5 µg/ml of Protein G, with no significant 
difference between the Gata-4-antibody complex and when the pull down antibody is incubated 
with detection antibody only (Figure 5.6). At higher concentrations of Protein G, 50 and 500 µg/ml, 
strong signal is observed.  Whilst there is a significant difference between the Gata-4 binding and 
that of antibody only, the cross reactivity remains quite high (Figure 5.6). At the highest 
concentration of Protein G the detection antibody binding makes up over 25% of the signal, at 50 
µg/ml of protein G antibody background binding of detection antibody formed almost 12% of the 
total signal.  
5.3.4 Results of PEG surface passivation 
Surface passivation with PEG was assessed for Gata-4 capture with varying concentrations of cardiac 
progenitor cell lysate (Figure 5.7). In general, the PEG surface had higher signal to background ratio 
than with BSA alone (see Chapter 6, Figure 6.7) but with huge error (Figure 5.8). Despite the high 
SBR with PEG, the Gata4 single molecule count is much lower than for BSA, although the 
background counts are also very low (Figure 5.7). Furthermore, with PEG the signal decreases after 
75pg/nl. 
 
Figure 5.7. Total single molecule count from cardiac progenitor lysate incubated with printed 
antibody on PEG passivated surface. Clear distinction between binding to Gata-4 antibody and IgG1 control 
at concentrations above 37.5 pg/nl.  At 7.5 pg/nl, that equivalent to a single cell, there is no observable 
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difference. Furthermore, the total counts are far lower than that normally observed on BSA passivated glass 
(see figure 5.8). 
 
Figure 5.8. Comparison of signal-to-background ratio of PEG passivated surface and that of BSA. 
Printed antibody was incubated with cardiac progenitor cell lysate at varying concentrations and the SBR was 
produced from the signal from the Gata4 antibody with that of the IgG control. PEG surfaces produce a higher 
SBR at both the lower and higher concentrations of lysate. However, there was huge error at higher 
concentrations than with the BSA passivated surface. 
? ?????????????
?????? ??????????????????????????????????????????????????
It is necessary to determine the optimum concentration of detection antibody, taking into account 
the background binding of the antibody. If the concentration of detection antibody is too low, then 
there is the risk of undercounting the true value of protein molecules. Conversely, high antibody 
concentration leads to increased background; therefore, a compromised needs to be reached 
between the too. 
Two concentrations of detection antibody were compared against printed Gata-4 and a non-related 
protein, P10 protein. A higher single molecule count was achieved at 250 ng/ml of detection 
antibody. The proteins, Gata-4 and P10, were printed at 0.15 mg/ml. Assuming that the print volume 
is 200 pl, then approximately 2x108 Gata-4 molecules were deposited. Clearly, the detection antibody 
has not saturated this, detecting only 25% of what was theoretically deposited. This could be for a 
number of reasons: for instance the print volume could be smaller, the protein could be denatured 
due to drying and surface immobilisation. Additionally, the epitopes could be masked and 
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unavailable for binding. Higher concentrations were not trialled here; however, as mentioned 
earlier, at 2.5 ng/ml the image acquisition is disrupted. 
Whilst the increased antibody concentration also increased the non-specific binding to P10, there 
was also a slight increase in signal-to-background ratio. This indicates 250 ng/ml is more suitable 
than the lower concentration of 25 ng/ml. It is important that the free Gata-4 antigen in the sandwich 
assay is saturated; therefore the higher concentration was used in all subsequent experiments. 
5.4.2 Comparing fluorescent antibody labelling by Fab fragments 
and conjugation by the primary amines  
The Fab fragments are specifically targeted to the antibody isotype. In this manner, the barriers 
presented by the antibody stabilising agents such as BSA and glycerol can be overcome. 
Traditionally, one would have to remove the stabilising agents by dialysis; however this strategy 
avoids this, circumventing antibody loss. In addition, one can label small quantities of antibody, µg 
instead of the mg that is usually needed.  
Initially, the Fab labelled antibodies presented very promising results with extremely high molecule 
counts. The downside of this kit is the high degree of non-specific binding to the antibodies, which 
reduces the signal to background ratio at higher cell concentrations. Further still, the SBR at time 0 
is extremely high, indicating that there is a high degree of antibody-antibody cross reactivity. In 
contrast, the SBR at time 0 for amine labelled antibodies is very low, both when compared to the 
isotype control and background on plain glass, showing that there is little antibody cross-reactivity.  
During the labelling process with the Fab fragment, unbound Fab fragments are not removed but 
quenched by addition of IgG isotype antibody. This might be the cause of the high non-specific 
signal: either free Fab fragments binding to the printed antibody or the Fab-bound-IgG binding to 
the printed antibody. It should be noted that the printed antibody is of a different isotype to that of 
the detection; therefore, the free Fab fragments should not bind.    
The cell concentration of 222 cells per µl is equivalent to the concentration of a single cell in a 
microfluidic chip. The fact that the amine labelled antibodies have a higher SBR at this concentration 
suggests it might be better to use in the long run. 
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5.4.3 Immobilising antibody with protein G 
The aim of immobilising antibody via protein G was to increase the antibody functionality. This 
system also requires the sensitivity to detect low levels of Gata4 protein above background.  
The concentration of detection antibody is set at 250 ng/ml. Any background signal from this will 
therefore always be constant. In contrast, the binding of Gata4 protein is proportional to its 
concentration. Hence, at low concentrations as would be seen at the single cell level, the Gata4 signal 
would be swamped by the background binding of the detection antibody to protein G. 
Other immobilisation strategies would not necessarily improve the sensitivity of the assay. 
Although, there have been many thorough reviews of surface immobilisation (Angenendt et al., 
2003; Kusnezow et al., 2003; Seurynck-Servoss et al., 2007; Vijayendran & Leckband, 2001), it appears 
that whilst these strategies increase the maximal signal and produce high signal to noise ratios they 
also increase the background noise, without much improvement in the lower limit of detection. In 
addition, these surface chemistries are not necessarily suitable for all antibodies. Surface chemistry 
would have to be optimised for each antibody, something to be avoided if you wish to multiplex.  
5.4.4 Surface passivation with PEG 
Surface passivation with PEG initially seemed very promising with incredibly low background and 
high signal to noise ratio. However, the total signal intensity is very low in comparison to BSA 
passivation alone (see chapter  for graphs).  
PEG coating seemed to inhibit high density antibody immobilisation. Though this may not be 
surprising, it is reported the PEG is only resistant to non-specific binding  of up to 100 nM (Jain et 
al., 2012). Other immobilisation strategies can be employed alongside PEG such as biotin-
streptavidin. Alternatively, a species specific antibody conjugated to biotin can be used to 
immobilise pull down antibody (Jain et al., 2012).  There are a few caveats to this: firstly this assay 
requires a dense spot of antibodies which might not be achieved with diffuse biotin availability in 
PEG. Secondly, this introduces an extra binding partner which complicates the stability of the 
protein-antibody complex. In fact preliminary experiments using this assay in the converse, with a 
tertiary detection antibody, indicated this was not an effective method of detection. In this method 
a high level of blinking was observed, indicating a fast off rate.  
Whilst the PEG surface does have a high signal to background ratio, the error in the single molecule 
counts is quite large in comparison to the signal. This might indicate that the PEG surface is not 
stable for antibody printing and cannot give reproducible single molecule count, particularly at the 
higher lysate concentration. 
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A technical caveat that should be mentioned is the leakiness of PEG microfluidic devices. PEG being 
a non-stick surface means that often microfluidic devices will fail. In order to circumvent this high 
device failure rate and in favour of increasing over all signal output, I chose to use glass surfaces 
passivated with BSA. Whilst these surfaces have higher backgrounds, this scales with the lysate 
concentration and is adequately low at low lysate concentrations. In addition, at the theoretical 
single cell level of 7.5 pg/nl, there was no difference between PEG and BSA passivated surfaces as 
neither distinguished signal between the Gata-4 antibody and the IgG isotype control. At the 
opposite end of the scale, the PEG surface seems to saturate at higher concentrations of lysate (Figure 
5.7), suggesting that inadequate amounts of antibody is immobilised on the surface. In addition, the 
single cell experiments had unrivalled low background counts, as will be discussed in chapter 7. 
? ????????
?? Bountiful options available for both antibody immobilisation and fluorescent conjugation 
?? Here we chose non-specific adsorption as the method of immobilisation, producing high 
density spots 
?? For fluorescently labelling antibodies, amine conjugation was the protocol of choice  though 
giving a lower overall signal, it produced good signal-to-background ratio, with lower non-
specific binding 
?? BSA incubations was chosen for surface passivation, permitting high antibody 
immobilisation 
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Chapter 6 
??? Determining assay sensitivity 
? ?????????
The premise of this chapter is to assess the parameters which define the suitability of the TIRF assay 
for single cell protein analysis. These parameters included antibody affinity, assay sensitivity and 
limit of detection and were assessed by constructing Gata4 purified protein calibration curves. 
Finally, applying the assay to cell lysate gives an indication of the assay sensitivity, but also protein 
copy numbers to be expected from individual cells. 
?????? ??????????????????????????????
Affinity represents the strength of interaction between two binding partners (Wild 2001). In the case 
of antibody interaction, affinity is determined by the measurement of the on and off-rates of antigen 
from its binding partner. The affinity of an antibody for its antigen is the main factor which defines 
the sensitivity of the assay, although other factors can be improved to increase overall binding.  
Avidity is a very similar concept to affinity, but refers to the strength of the reaction between 
multivalent antigens and multivalent antibodies. In this thesis the antibody subtype IgG was used 
which contains two identical binding domains (Figure 6.1A). Despite this multivalency, it is standard 
practise to measure affinity assuming only one binding domain (Goodrich & Kugel 2007).  
A further complication to measuring affinity in this assay is the use of two antibodies: one for antigen 
pull down and another for detection. Measuring affinity in a system with trimolecular binding is 
difficult, and was simplified by applying the detection antibody in saturating concentrations (Figure 
6.1B). Consequently, the complex formed by the antigen and detection antibody is treated as a single 
entity (Goodrich & Kugel 2007). 
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Figure 6.1. Illustrates antibody multivalency, depicting the two identical binding sites found on the 
IgG antibody subtype (A). The assay is a trimolecular system, containing two antibodies and an 
antigen; the detection antibody (Y) is applied at a concentration in which the antigen will be 
saturated, allowing the antigen-detection antibody complex to be treated as single entity (B).  
There are several techniques available to measure antibody affinity, including chromatography, 
isothermal titration calorimetry and surface plasmon resonance. Here I used the existing TIRF 
technique in place of the alternative label-free methods.  
The experimental protocol is similar in all techniques. Essentially, this is to measure the binding of 
the antigen to the antibody at equilibrium, varying the concentration of antigen whilst keeping the 
antibody concentration constant.  Ideally, the antigen concentration should be varied across four 
orders of magnitude and should span across the dissociation constant, Kd.  
Another consideration is the concentration of pull down antibody which must be lower than the Kd. 
This ensures that the assay is in the ambient analyte regime, which is when the antigen bound has a 
negligible effect on the concentration of total free antigen. This simplifies measuring the Kd by 
avoiding the need to measure the concentration of unbound antigen as it can be treated as the 
original, total concentration. Thus, only the bound antigen needs to be measured. This only occurs 
when the concentration of printed antibody is lower than that of the Kd (Goodrich & Kugel 2007).The 
dissociation constant is the ratio of reactants to the product at equlibrium: 
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Equation 1   𝐾𝑑 =
𝐴.𝐵
𝐴𝐵
 
Where A is free antigen, B is antibody and AB is the portion of antigen bound to antibody. The Kd 
can be determined by plotting the fraction bound versus the input antigen concentration, where half 
maximal binding is the Kd.  
The time to equilibrium is determined in part by the off rate. If the antibody has a slow off rate, then 
equilibrium will take longer to establish. Time to equilibrium is not only defined by the kinetics, but 
in large volumes it is also limited by mass transport. This is where the rate of antigen diffusion 
directly impacts the antibody-antigen binding kinetics (Kusnezow, Syagailo, Rüffer, et al. 2006; 
Nygren & Stenberg 1989). Depletion of antigen at the antigen-antibody interface means that the 
reaction is limited by the diffusion of new antigen into the vicinity, and thus depends on the diffusion 
coefficient of the antigen molecule which in turn is determined by the protein size and the fluid 
viscosity. In large volumes the limitation of mass transport necessitates long incubation times, 
sometimes up to days (Kusnezow, Syagailo, Rüffer, et al. 2006). It is imperative that the 
measurements are taken at equilibrium, this time can be determined with preliminary experiments 
or by calculating the diffusion time of the molecules in the proposed volume.  
The benefit of using microfluidics means that you can minimise assay volumes. In our setup, we use 
4.5 nl volumes for the cell experiments and 10 nl volumes for the calibration experiments.  The low 
volumes means that the reaction is no longer mass transport limited as the diffusion times are 
reduced, and equilibrium is reached rapidly (Burgin et al. 2014).  Simulations of time to equilibrium 
made by our group indicate that this occurs within 10-20 minutes in the microfluidic chambers 
(Salehi-reyhani 2011). 
6.1.2 Sensitivity and limit of detection 
In general terms, the sensitivity of an assay is the ability to detect small concentrations of target 
antigen. This can be broken down into a few different components: the errors in measurement when 
no analyte is presence, the minimum signal that can be detected and the responsiveness of the assay 
to increases in antigen. 
In reality, the assay sensitivity is less dependent on the antibody kinetics and more dependent on 
the level and precision of non-specific binding in the system as well as the error in signal 
measurement. For example, if you were to apply high concentrations of antibody such that all 
antigen binding sites were occupied, sensitivity would be improved. However it would be limited by 
the increased  non-specific binding which increases concomitantly with increasing antibody 
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concentration (Wild 2001).  Thus, the equilibrium constant is not the limiting factor whilst there is 
significant measurement errors and non-specific binding. (Wild 2001). 
In this study, sensitivity is defined as the slope of the calibration curve, essentially how responsive 
the detection is to the protein put in, or minimum change detectable. The limit of detection (LOD) 
is the minimum amount detectable above background. This minimum signal must be 3 standard 
deviations above the background signal, giving a 99.7% confidence that the observed signal is real. 
The LOD hence defines the minimum signal detectable from single cells.  
Whereas affinity is measured in the ambient analyte regime; the sensitivity and LOD is measured in 
the mass sensing regime. To improve protein capture efficiency we use nanolitre volumes; this 
pushes the binding from ambient analyte to the mass sensing regime. This occurs because the 
concentration of printed antibody exceeds the Kd in these small volumes. Therefore, it is essential to 
measure the assay sensitivity in the same regime, giving a true reflection of what is occurring in the 
MAC chip experiments.  
?????? ???? ???????????????????????????????????
To estimate the approximate number of Gata4 proteins per cell, and assess the assay sensitivity to 
cellular protein, a calibration assay with SP3 cardiac progenitor cell lysate was performed.  The 
difficult nature of single cell protein analysis has meant protein copy number per cell is relatively 
unknown. By conducting a calibration with lysate, the cells were assessed to see if they expressed 
enough protein to be detected in the single cell assay; a priori to doing experiments on single cells. 
The protein concentration in a cell is dependent on cell type and cell volume and is hard to quantify 
absolutely. The volume of mammalian cells can vary between 1-100 pl (Williams et al. 2012) and the 
cellular protein concentration can range between 50-200 pg/pl (Finka & Goloubinoff 2013). The 
cardiac progenitor clones are small cells, with an estimated volume of 0.2-3.3 pL. We took a 
conservative estimate of 75 pg per cells as an average quantity of protein in each cell. Therefore to 
replicate one cell per chamber, lysate was diluted to 7.5 pg/nl, giving 75 pg in a 10nl chamber. 
? ????????
General information on how lysates and protein were made is detailed in the Methods chapter. 
Below is a description of experimental setup for the assay calibrations discussed in this chapter. 
 ?
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6.2.1 Gata4 calibration curve in large volume chambers 
The calibration curve was conducted in a large volume of 10µl and incubated with a serial dilution 
of purified Gata4 protein. Chambers were sealed and incubated at 4oC overnight before imaging with 
TIRF, as a long incubation period is required to establish equilibrium. 
6.2.2 Gata4 calibration in microfluidic chips 
Using the microfluidic chip (Figure 6.2), five different concentrations of Gata4 protein were 
incubated with the printed antibody, in solution containing 250 ng/ml detection antibody. Samples 
were incubated overnight at 4oC before imaging. 
 
 
 
 
 
 
 
 
Figure 6.2. Layout of microfluidic chip used for lysate experiments. It contains 5 independent lines, 
each with 10 chambers of 10 nl each. Each chamber can contain 1 printed antibody spot of 
approximately 100uM in diameter.  
6.2.3 Calibration with cardiac progenitor cell lysate 
To assess the sensitivity of the assay in small volumes microfluidic chips were used. These were 
designed to allow lysate to flow through 10 nl chambers. Chips contained 5 individual lines, allowing 
5 test subjects each with 10 chambers (see Figure 6.2). Each chamber could contain 1 printed antibody 
spot. Cardiac progenitor cell lysate was incubated in each line at different concentrations. The 
effective cell concentration was between 1 and 15 cells per chamber. The microfluidic design was 
based on work by members of our group (Salehi-reyhani 2011), this thesis used a revised design which 
was modified by Dr. Natalia Goehring (SCP group, Imperial College London, UK). 
 
2mm 
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? ????????
?????? ?????????????????????????????????????????????????????? ??
The Gata4 protein calibration was conducted in the ambient analyte regime. This was illustrated by 
plotting the fraction of Gata-4 bound against the total input Gata-4 (Figure 6.3). The fraction bound 
at each concentration averaged at 4x10-7, a miniscule portion of the input protein and well beneath 
Ekins’ maximum 1% cut-off limit (Ekins 1998; Saviranta et al. 2004; Wild 2001). 
 
Figure 6.3. Comparison of the total input Gata4 protein with the number of molecules counted. The 
ratio of input to output is similar at all Gata4 concentrations. The fraction bound 7 orders of 
magnitude lower than the input protein indicating that the bound fraction would have a negligible 
effect on the concentration of free analyte. The tail off observed is similar to that seen in Figure 6.4 
and is due to the prozone effect. 
?????? ???????????????????????????????????????????
The Gata4 calibration curve (Figure 6.4) follows sigmoidal binding curve as expected for a semi-log 
plot. A curve was fitted using software (Prism), the half maximal binding of Gata4 is taken as the 
affinity and is given as 6 nM ±2.2 nM. There is a noticeable dip in binding after the plateau, this is 
known as the prozone phenomenon or hook effect. It is seen commonly in ELISAs and can be 
misleading, with high concentrations of antigen producing low readouts.  
? ? ?? ??? ? ?? ? ??? ? ? ???? ?? ? ? ? ?? ? ?? ? ?? ?? ?? ? ?
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The prozone effect occurs due to high antigen concentrations saturating the binding sites of both 
liquid and solid phase antibodies. This means that the printed and detection antibody cannot bind 
the same antigen at the same time, and thus the sandwich assay is inhibited (Wild 2001; Bodor et al. 
1989; Haller et al. 1992). 
The saturation point of the printed antibodies is about 70,000 molecules (Figure 6.4). Given that the 
approximate printing volume is 200 pl and the antibody concentration is 0.25 mg/ml, there are 
approximately 2x108 antibody molecules in a printed spot. Therefore, the fraction of these that are 
active is less than 0.03%. The saturation point in the nanolitre volumes is much increased, attaining 
290,000 molecules, giving antibody activity of 0.14% (Figure 6.5).  
 
Figure 6.4. A calibration curve with Gata4 purified protein in large volume chambers (10 ul). The 
lowest concentration tested was 5.2 ng/ml and saturation occurs at approximately 1000 ng/ml. After 
this, binding to the antibody is inhibited. 
6.3.3 Fraction of Gata4 bound in the microfluidic chips 
As mentioned earlier, reducing the reaction volume pushes the system out of the ambient analyte 
regime and into the mass sensing regime. With the 10 nl volume microfluidic chips, the antibodies 
can capture up to 9% of the total Gata4 protein present (Figure 6.5). This reduces to 0.1% as the 
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concentration of Gata4 antigen increase, reducing even further once the assay enters the prozone 
region.  
 
Figure 6.5. Reducing the volume can increase the capture by pushing the system out of the ambient 
analyte regime. In the 10 nl volume chambers, the volume is still not small enough to push the system 
towards 100% capture. Instead the antibody sandwich system captures between 0.1 and 9%, 
depending on the antigen concentration. 
6.3.4 Determining the sensitivity of Gata4 sandwich assay in 
nanolitre volumes 
The sensitivity of the assay can be determined by the region of the calibration curve that the assay 
falls into. For this, a calibration was conducted in nanolitre volumes in the microfluidic chip; the 
resulting calibration curve can be seen in Figure 6.6. The assay was tested across 5 orders of 
magnitude with respect to the number of Gata4 protein molecules, and produced a sigmoidal 
binding curve in a semi-log plot, as expected. The most responsive region, the linear region, is 
between 20,000 – 250,000 single molecule counts, corresponding to 2.7x105- x108 input molecules.  
The protein count at the single cell level is approximately between 3-4000 for Gata4, these increases 
to ~60,000 up to about 15 cells (Table 6.1). This means that the cell experiments fall into the sub-
linear region of the calibration curve  (Figure 6.6.).  
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The limit of detection is determined in the presence of antibody only, essentially measuring the cross 
reactivity. The limit is defined as the signal above background for which you can be 99.7% sure is 
true signal (3 standard deviations). In the microfluidic set-up, the LOD is 1810 single molecules, and 
is calculated with incubation with antibody only (i.e. no cells; Figure 6.7).  
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Figure 6.6. To determine the assay sensitivity, total input of Gata4 protein molecules is compared to 
the output single molecule count. This gives a sigmoidal curve with the linear region between 
20,000- 251,000 molecule counts which corresponds to an input of 2x105-x107 molecules per chamber. 
According to Figure 6.7 and Table 6.1, the number of molecules from a single cell would fall into the 
sub-linear region. 
6.3.5 Application of the assay to cell lysate: Gata4 copy number 
and single cell sensitivity 
Five lines of the MAC chip were incubated with different concentrations of lysate, including no lysate 
containing just antibody. Lysate was tested between 1-15 cells per chamber; this was calculated based 
on the average protein concentration per cell. This produced a linear response to the in-put lysate 
concentration and the number of molecules counted (Figure 6.7).  
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Printed IgG1 was used as the negative control and which plateaus at about 14-15000 single molecule 
counts. This is significantly below binding to the Gata4 antibody at lysate concentrations between 
37-112.5 pg/nl. However, there is no significant difference between the control and Gata4 antibody 
at the lowest lysate concentration of 7.5pg/nl.  
 
 
Figure 6.7. Calibration curve was conducted with SP3 cell lysate and diluted between 0 – 112.5 pg/nl. 
These dilutions equated to 0, 1, 5, 10 and 15 cells per chamber. Cell concentration is estimated at 75 
pg/nl. The assay is not single cell sensitive here. The limit of detection lies between 7.5-37.5 pg/nl (1 
and 5 cells per chamber). 
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Total single 
molecule count  
Test 
conc. 
(Pg/nl)  
Molecule per 
cell (75pg)  
3867 7.5 3867 
25054 37.5 5010 
38338 75 3834 
62461 112.5 4164 
Table 6.1 Estimates the number of Gata4 proteins per cell based on the lysate calibration curve. One 
cell is considered to contain 75 pg or protein. This data indicates there is roughly 3500-5000 Gata4 
molecules per cell. 
Gata-4 copy number per cell was calculated based on the assumption that a cell contains 75pg of 
protein (Table 6.1). From the lysate calibration curve (Figure 6.7), Gata4 is measured in the narrow 
range between 3800-5000 protein molecules per cell. It is interesting to note that at 7.5 pg/nl of 
lysate, the lowest concentration tested, the Gata4 count per cell is similar to that calculated from 
other concentrations. Even despite this data point not being significantly different to the IgG control. 
? ????????????
?????? ??????????????????????????????????????????????????????
Avidity of the assay was measured as 6 nM ±2.2 nM. We required antibodies with nanomolar affinity 
to gain the sensitivity to detect protein from single cells. Whilst we didn’t measure the affinity for 
each antibody, the avidity represents the strength of interaction across the three interacting 
molecules, and suggests that the assay has the potential sensitivity for single cell protein analysis.  
?????? ???????????????????????????
Operating in the mass sensing regime has the benefit of capturing more protein, particularly at lower 
protein concentrations. Ideally, we would like to bind all the protein expressed in cells and count 
the absolute protein expression. However, in the current format this assay only captures a maximum 
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of 9% of the expressed protein (Figure 6.5), decreasing as the protein concentration increases.  This 
because the concentration of antibody relative to antigen is constant, and whilst there is a 
proportional increase in binding with increased antigen concentration the number of antibody 
binding sites are limited. 
Improvement in mass sensing is not greatly increased by better affinity antibodies as with high 
affinity antibodies most the sites are already occupied (Wild 2001). Therefore, one has to increase 
the number of active printed molecules. Based on the analysis of input and output Gata-4 protein 
(Figure 6.6), only 0.14% of the printed antibody is active. Whilst this might seem low, this is plausible 
given the steric hindrance, denaturation and orientation affects that can occur with immobilisation 
on to a solid surface (Saviranta et al. 2004; Wild 2001). There are many strategies devised to improve 
this (reviewed in Chapter 5, section 0); however, improvements in activity is generally quite limited 
with full length antibodies although increased activity has been shown with Fab fragments 
(Saviranta et al. 2004). 
An estimate of Gata4 copy number per cell was attained by testing different concentrations of SP3 
lysate. This gave copy number per cell between the range of 3500-5000. Since at lower Gata-4 protein 
concentrations, the total capture is approximately 9% of the input, the actual copy number per cell 
should be in the region of 38-56,000 per cell.    
This is a crude estimate of the copy number per cell, and was measured to give an approximation of 
what to expect from single cell analysis. This estimate also indicates whether the assay is likely to be 
sensitive enough to detect protein from single cells. Whilst the lysate calibration curve (Figure 6.7) 
suggests the assay could possibly be at its limit with respect to single cell analysis, reductions in 
background might improve the limit if detection and thereby improve sensitivity.  
6.4.3 Sensitivity and limit of detection 
One important constraint to the overall sensitivity of the assay is the limit of detection. Here the 
LOD was taken as the signal above the antibody-antibody cross-reactivity, for which it can be 99.7% 
confident that the single molecule count is due to Gata4 binding.  
The LOD in this assay is approximately 1810 molecules; this means that the assay should be capable 
of detecting Gata4 from single cells. A calibration from cell lysate indicates that there are between 
3500-5000 detectable Gata4 protein molecules per cell, which is approximately 2 times the LOD. 
The LOD was not assessed in the presence of negative control lysate. The latter control would have 
been particularly instructive given that the observed binding to IgG isotype control in the presence 
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of lysate was much higher than the LOD measured in the absence of lysate (Figure 6.7). Therefore, 
this additional background binding observed might be a feature of adding lysate. 
This may indicate that the limit of detection is higher than 1800 molecules counts. However, data 
from cells lysed directly on chip show that background binding in the presence of Gata4 negative 
lysate is much lower (Chapter 7, Figure 7.7). This implies that pre-made lysate is inherently sticky, 
which could be due to various reasons including; inefficient clearing, degradation or even buffer 
choice which can effect protein charge and thus protein-protein interactions. 
Whilst the antibody-antibody cross-reactivity cannot be directly reduced, other factors can be 
reviewed to improve LOD. The effect of background binding in the presence of sticky lysate 
significantly increases the LOD. Whilst this might not be an issue with real cell experiments, it might 
be worth reviewing different blocking reagents, or surface passivation chemistries, such as PEG 
(Chapter 5, section 0). Another useful tool would be to analyse the LOD in the presence of a control 
purified protein, this would give a good indication as whether the increased background is an 
artefact of the lysate. In addition, preliminary experiments support this as the Gata-4 antibody 
negligibly binds to a printed control protein, P10 (appendix, figure B), indicating the antibody is 
specific to its target, Gata4. 
Ideally the sensitivity would lie in the linear, most responsive, region. However, due to the low 
concentrations being detected the sensitivity lies in the sub linear region. Essentially this impacts 
the responsiveness of detection to the concentration of input protein. From the lysate calibration 
curve (Figure 6.7), the assay appears responsive at low concentrations of cell lysate, with single 
molecule count linearly increasing with lysate concentration. This implies that the assay is sensitive 
enough to distinguish protein concentration with small numbers of cells and that the overall 
sensitivity pends on the LOD as previously discussed. 
Increased responsiveness could be achieved by increasing the quantity of capture antibody and its 
activity. Antibody activity could be improved by different surface immobilisation strategies, e.g. 
orientation by specific coupling in the Fc region. However, this has other drawbacks including loss 
of antibody during the preparation steps. Hence, there is perhaps increased activity but overall the 
antibody concentration is reduced.  
Another solution could be to simply print a higher concentration of pull down antibody. This could 
be increased until its maximum packing density; reports from the literature suggest that effective 
printed concentration is antibody dependent, demonstrating maximum signal anywhere between 
0.5-1 mg/ml (Kusnezow, Syagailo, Goychuk, et al. 2006). A caveat to this is that excess antibody will 
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just be washed away or, in the case of the closed chambers, will just be freely floating in solution 
binding antigen. A final solution could be to reduce the chamber volume, but this is discussed later 
(Chapter 7, section 7.4.5). 
? ?? ?????????
?????? ?????????????????????????????????????????????????
Printing with a micro-contact printer enables antibodies to be printed at high density, maximising 
the number of capture sites and is therefore clearly beneficial to this assay. However, the exact 
printing volume cannot be controlled and is therefore an unknown variable. Further to this, antibody 
immobilisation can impinge on the antibody function, reducing their activity (section 0). The 
combination of these two factors means that we do not know exactly how much pull down antibody 
is immobilised.  
According to the manufacturer the delivery volume is estimated to be around 200 pl (Arrayit 
Corporation, USA). If this is true then the effective concentration of printed antibody in a 10μl 
volume will be approximately 56 pM. Given that immobilised antibody usually has very low activity, 
maximum 1%, the effective antibody concentration is likely to be much lower than this. The average 
monoclonal antibody is estimated to have nM affinity for its target protein. Therefore, in this setup 
the effective pull down antibody concentration will be at least 100-fold less than the Kd, and should 
be suitable for conducting the assay in the ambient analyte regime (Goodrich & Kugel 2007). 
This also impacts the concentration in the microfluidic chips, with maximum concentration of 
56nM. This concentration could in fact be much lower due to limited antibody activity. This impacts 
the mass sensing regime, which requires high printed antibody concentration in order to increase 
the percentage of antigen captured. 
?????? ????????????????????????? ?????
Although the affinity of the two antibodies was not measure individually, the affinity obtained is a 
good representation of the assay strength as a whole. It is possible to attain affinities of the individual 
antibodies, and label free techniques that are commonly used include  chromatography, isothermal 
titration calorimetry, and surface plasma resonance (Hearty et al. 2012). The limitation of the first 
two techniques is that they require large amounts or protein and antibodies (mg amounts) and were 
not suitable here.      
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Surface plasmon resonance is a powerful, label free technique which can measure effectively 
antibody- antigen affinity in a bimolecular system. It uses small volumes and flow to assess the 
binding at equilibrium whilst avoiding the limitations of mass transport (Hearty et al. 2012). In 
addition, measurements in real time mean that it can even give kinetic data (Hearty et al. 2012). It 
wasn’t pursued in this study due lack of access to a Biacore facility and cost. In effect, the TIRF 
system can perform a similar experiment with the only limitation of fluorescently labelling for 
detection purposes. 
The TIRF set up could be arranged so that it measures the affinity in a bimolecular system, either by 
printing the antigen and detecting with a fluorescently labelled antibody or alternatively by 
immobilising the antibody and detecting with a fluorescently labelled antigen. This would require 
fluorescently tagging the antigen which could adversely affect antigen-antibody binding. 
Additionally, printing Gata4 directly onto a glass surface may give spurious affinity readings as the 
binding epitopes are often obscured.  
6.5.3 Limited data input 
A big draw back with assessing the sensitivity and LOD is the number of data points. Because the 
microfluidic chips only contained 5 independent lines, only 5 different concentrations could be 
tested at any one time. It would be ideal to have more data points to populate the standard curve. 
6.5.4 Cardiac progenitor clones are small cells 
The Gata4 copy number provides only an estimate of the true copy number you would expect in a 
single cell.  The cardiac progenitor cells are quite small, having a radius of between 4-9μM. Therefore 
the volume approximates to between 0.2-3.3 pL. Reported values of protein content per cell volume 
is approximately 0.2g/ml (Albe et al. 1990), giving a range of 40-660 pg per SP3 cell. It is hard to 
estimate the true single cell protein concentration, but in the absence of concrete Gata4 copy 
number, the calibration does provide a good indicator. 
6.5.5 Gata-4 protein purity 
The purity and quality of the protein sample used will affect the affinity read out. This was assessed 
using silver staining (see appendix, figure A), which showed that the sample was fairly pure but may 
have slight contamination. The amount of contamination was not determined. In addition lower 
bands suggest slight protein degradation. Both these factors will have an impact on the affinity 
reading.  
  
101 
 
? ????????
?? The Gata-4 detection assay has nanomolar affinity and should therefore be capable of 
detecting protein from single cells 
?? Calibration with cardiac progenitor cell lysate estimates the detectable Gata-4 copy number 
to be between 3-5000 per cell 
?? The limit of detection is below the estimated Gata-4 copy number per cell 
?? Single cell sensitivity is not obtained in the calibration with cell lysate; however, cell lysate 
is inherently sticky and increases the background binding 
?? Assay sensitivity could be increased by reducing background noise
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Chapter 7 
??? Analysis of Gata-4 expression in cells with TIRF 
microscopy 
? ?????????
Single cell proteomics is inherently difficult for many reasons and to date only a few research groups 
have succeeded in achieving this (Shi et al. 2012; Bendall et al. 2011). The prominent limitations to 
single cell proteomics are; the lack of amplification that is readily available for RNA and sensitive 
enough technology that can detect few proteins. Whilst TIRFM is a highly sensitive technique, it in 
turn is restricted by the availability of good antibodies. These need to be both specific and have high 
affinity and is further compounded by the challenges encountered with antibody immobilisation. 
Despite over two decades of development, miniaturised proteomics still remains one of the greatest 
challenges in current molecular biology 
Moving toward single cell proteomics, this chapter builds on the lysate and protein calibrations 
covered in the previous chapters, progressing to experiments with live cells. A few parameters make 
this possible; precise cell handling, nanolitre chamber volumes and the sensitivity of TIRFM. The 
latter of which detects fluorescent signal with high resolution and thereby permits detection of 
proteins from individual cells. This chapter presents several cell experiments where cells are lysed 
directly on-chip. Unfortunately, this did not result in single cell sensitivity but does show a logical 
progression, working to overcome the obstacles to single cell protein detection. 
?????? ???????????????????????????????????????????????
The development of soft lithography in the late 90’s made fabrication of devices with nanoscale 
features easily and readily available. The technique involves creating a mask on silicon wafers and 
using that to mould the elastomer, polydimethylsiloxane (PDMS). Development of microfluidic 
devices for RNA sequencing and single cell PCR is well underway in the field of single cell biology 
(Buganim et al. 2012; White et al. 2011). Microfluidic devices offers small volumes, facilitated cell 
handling and limits reagent dilution; thereby reducing sample loss which consequently facilitates 
the detection of target molecules. 
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The underlying idea of using microfluidic devices in this study is to minimise the diffusion distance 
of the proteins and thereby establish equilibrium quickly. In addition, a smaller volume drives the 
binding reaction toward the bound state as it increases the relative concentration of printed 
antibody to antigen. This in turn, means it is able to capture more protein and thereby increase assay 
sensitivity (see chapter 6 for more detail). With respect to cells, these chips facilitate cell handling 
and restrict the effect of dilution on the lysed cells.  
The single cell microfluidic chip in this study consisted of a main channel, through which to flow 
cells, with 30 cell chambers branching off (Figure 7.1). The chamber dimensions are 300 μm2 by 50 
μm depth, giving a volume of 4.5 nl. This is a reduction from the 10 nl volume of the original lysate 
chips. At the time of study, this was the smallest physical dimensions for the cell chip that could 
accommodate the antibody spots. The small volume reduces the total diffusion time, allowing 
equilibrium to be established within 10-20 minutes (Salehi-Reyhani et al. 2013; Salehi-reyhani 2011), 
together with nanomolar affinity antibodies, the total capture percentage will be further increased 
beyond that of the lysate chips. 
? ????????
?????? ??????????????????????????????????????????????????
The design of the microfluidic devices for the cell experiments differs from that of the lysate 
experiments and was developed by other members of the group (Salehi-Reyhani et al. 2013). Instead, 
they have a large central channel through which to flow cells. Branching off of this are 30 chambers, 
in which cells are lysed (Salehi-reyhani et al. 2011). These have the dimensions of 300 μm2 by 50 μm 
in height giving a volume of 4.5 nl each (Figure 7.1). These chambers are separated by a small access 
channel, this separation is to reduce diffusion into and out of the cell chamber, minimising 
contamination from the bulk cell solution and loss of sample out of the chamber. 
Optical trapping was used to confine cells in to separate chambers of the microfluidic device. Cells 
were then lysed and protein pull-down subsequently occurred in these defined, small volume 
chambers, using the antibody sandwich systems for pull down and detection. The benefit of this 
setup is that the solution containing cell debris remains separate and does not come into contact 
with the printed antibody. Thus, this reduces the possibility of contamination from free Gata-4 
protein in the cell suspension.  
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Figure 7.1. Diagram of the microfluidic design used for single cell experiments. (A) is the design of the 
whole chip, which consists 30 square chambers branching off of the central channel, through which the 
cells are flown. (B) is a close up of the 300 μm2 cell chamber which, when cast in PDMS, has a volume of 
4.5 nl. The white arrow marks the input channel, where cells are introduced into the chamber. Cells are 
placed in the small square outcrop (*), ready for laser lysis. There is an extra reserve channel (**) for 
retaining air bubbles that are not desiccated out of the device.  
7.2.2 Cell handling 
Cells were cultured as described in the methods in Chapter 2. Cells were detached using trypsin 
EDTA 0.05% and kept on ice in L15 medium with 10%FBS. L15 medium is designed for cells kept out 
of the incubator for long periods of time. Cells were spun down and diluted to appropriate cell 
number in L15 medium containing 10% FBS, 4% BSA, protease inhibitors and secondary antibody 
diluted to the appropriate concentration. 
7.2.3 On-chip cell lysis methods 
Two lysis methods were used in the development of this single cell proteomic assay; laser lysis and 
chemical lysis. Laser lysis had the benefit of being a precise and quick method for lysing single cells. 
It works by using a pulsed laser to produce a cavitation bubble near the cell, the force of which causes 
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the cell to rupture. Whilst this hypothetically also disrupts the nuclear envelope, the degree of this 
is unclear (Salehi-reyhani 2011). 
The method of chemical lysis employs non-ionising surfactants to disrupt the cell integrity. With 
the current design (Figure 7.1) this solution can only be introduced by diffusion which takes about 
50 minutes (appendix, figure C). Despite this limitation, this method is of benefit when there are 
many cells in one chamber. In this scenario laser lysis is very challenging as the force of the cavitation 
bubble causes the cells to move around. This means that one has to chase the cells in x, y and z 
directions in order to lyse them with the laser, which is very time consuming. 
?????? ???????????????????????? ?????
Coverslips were printed as previously described (see Chapter 2, section 0 ). Coverslips were then 
aligned with perfusion chambers (Sigma Aldrich) of 8 μl in volume. Cells were loaded at either 1778, 
889, 178 or 89 cells per chamber. The loading volume was 4 μl, with an addition of 4 μl of 1x lysis 
solution (Cell signaling, #9803) to lyse the cells. The chambers were then sealed with film to prevent 
dehydration. Antibody spots were imaged before cell lysis and for 90 minutes afterwards. 
The number of cells loaded in the 8 μl chambers was determined based on the volume of the MAC 
chip chamber. In the MAC chip set-up, if the assay had single cell sensitivity then we would be able 
to detect 1 cell per 4.5 nl volume, or 0.22 cells/μl. Scaling this up to the large volume format of 8 μl 
would equate to 1778 cells per chamber. Therefore, the large volume format is equivalent to testing 
cells in the range of 1 cell to 0.1 cell per MAC chip chamber. 
? ????????????
?????? ?????????????????? ???????????????????????????????????????
??????
In order to test the efficacy of this assay at the single cell level HeLa cells transiently transfected with 
a GFP tagged Gata-4 expression vector were used. This permits Gata-4 binding to the printed 
antibody to be directly detected due to its fluorescent tag. Whilst it does omit the secondary 
antibody, it does give an indication of whether the assay can detect protein at the single cell level in 
the microfluidic chip, illustrated in Figure 7.1.  
HeLa cells were harvested 36 hours after transfection and cell chambers were loaded with either 1, 
2, 3, 5 or 0 cells. Successfully transfected cells were identified by their fluorescence using 
epifluorescence microscopy and loaded into cell chambers using an optical trap. Cells were lysed on 
chip by diffusion of lysis solution.  
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In the raw data, very distinct binding to the Gata-4 antibody was observed in comparison to the 
isotype or no cell control. However, after processing there was little significance between binding to 
the Gata-4 antibody and the controls in chambers loaded with 0, 2 or 3 cells ( 
Figure 7.2). There was only significant binding of Gata-4 protein above background with 1 cell and 5 
cells per chamber ( 
Figure 7.2). 
 
Figure 7.2. Titration of cells transiently transfected with GFP tagged Gata-4 expression vector. Graph 
shows the binding observed after 140 minutes after cell loading, or 90 minutes after effective cell 
lysis with lysis solution (*, p < 0.05; **, P < 0.01). 
7.3.2 Single cell analysis of cardiac progenitor clone, SP3 
Initial experiments with lysate and with Gata-4 purified protein (see section 6.3.4) indicated that 
this assay has the potential to detect protein at the single cell level. In order to test this with real 
cells, the microfluidic device illustrated in Figure 7.1 was used, loading cells into the chambers using 
an optical trap and then lysing them on chip with a laser pulse. Five chambers containing either 
printed IgG1 or anti-Gata-4 antibody were loaded with 1 cell, 2 cells or no cells.  
Two conditions were tested, first laser lysis (Figure 7.3) and chemical lysis (Figure 7.4); lysed cells 
were subsequently incubated on chip over 1.5 hour period. In the first experiment with laser lysis 
(Figure 7.3) an overall increase in signal was observed with 2 cells per chamber and was significantly 
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higher than with 1 cell or no cell per chamber. However; there was no distinguishable difference in 
binding to the Gata-4 antibodies over the isotype control (Figure 7.3). 
 
Figure 7.3. Analysis of Gata-4 protein expression after laser lysis of cardiac progenitor clones. Cells 
were loaded into chambers containing either printed IgG1 or Gata-4 antibody, at 1, 2 or 0 cells and binding 
measured 1.5hours after cell lysis. No significant difference was observed. 
 
Figure 7.4. Chemical lysis of cardiac progenitors in microfluidic chips. Lysis solution was diffused into 
cell chambers containing either printed IgG1 or Gata-4 antibody and loaded with 1, 2 or 0 cells. Binding 
was measured 1.5 hours after cell lysis, where a statistical difference was observed between IgG1 and Gata-
4 antibody chambers containing either 1 or 2 cells. 
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From the raw data, it could be seen that the fluorescence remained localised in the vicinity in which 
cells were lysed (Figure 7.5.) and did not diffuse across the chamber to the antibody spot as expected. 
This can be seen from the tile scan images in Figure 7.5, a sequence of images taken across the cell 
chamber and stitched together. This set of images compares the control chamber containing printed 
IgG1 with that of anti-Gata-4 each containing either 1, 2 or 0 lysed cells.  
Subsequently, chemical cell lysis was tried in place of laser lysis (Figure 7.4). The cell experiment 
was carried out as previous, but allowing diffusion of lysis buffer from the main channel to the cell 
chamber to lyse the cells (Figure 7.4). Overall, the single molecule count for all antibody spots was 
low, both Gata-4 antibody and isotype control. No statistical significance was observed between 
isotype control and the Gata-4 antibody with 0 cells per chamber. There was larger binding to the 
isotype control in both 1 cell and 2 cells per chamber.  
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Figure 7.5. Tile scan images of single cell chambers 2 hours after laser lysis. Printed antibody spots 
(BD) are located in the central image tile. Typically cells are loaded and lysed in the cell loading chamber 
(semi-circle outcrop on right hand side of chamber). Images show that fluorescence does not accumulate 
on antibody spot but rather remains in the area where cells were lysed and does not diffuse throughout 
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the chamber after 2 hours of incubation. Here, the cardiac progenitor cells, clone 3 was used and the 
fluorescently labelled Gata-4 antibody (MAB) was used. 
7.3.3 Limit of detection in large volume chambers 
Since the experiments with cells in the microfluidic chips were not successful, I turned to the large 
volume assays to try to determine the problem. The possible issues were either: inefficient cell lysis, 
limit of antibody sensitivity, or the antibodies were no longer active. To begin the assessment, I 
decided to repeat the experiment on a large scale format, lysing cells directly on chip by pipetting 
on lysis solution. 
 
Figure 7.6. A) Direct cell lysis of cardiac progenitor cells, SP3, in microlitre volume chambers. Cells 
were loaded into 8 µl chambers with both printed anti-Gata-4 antibody (black) and IgG1 control (grey). 
Binding can be detected with as few as 111 cells/µl, which is equivalent to 0.5 cells in a microfluidic chip 
chamber. There is no significant difference between anti-Gata-4 and the IgG1 control at 22 or 11 cells per 
µl. Error bars represent standard error of the mean of three replicates, each containing 4 capture spots of 
each antibody. B) Cells were stained with propidium iodide and imaged post lysis. Images show presence 
of cells in chambers containing different concentrations of cells. Data are presented as means of 3 
independent experiments using the same cell line ± SEM. 
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The assay was conducted in 8 µl chambers, with two of the cardiac progenitor clones: SP3 which 
expresses Gata-4 protein and SP16 which does not express Gata-4. Cells were diluted to either 1778, 
889, 178 and 89 cells per chamber. This equated to between 1 to 0.1 cell of the MAC chip chamber.  
 
Figure 7.7. A) Lysis of control cardiac progenitor cells, which do not express Gata-4 protein, in 
microlitre chambers. The graph shows negligible binding of Gata-4 from SP16 negative control cells  to 
either Gata-4 (  black ) or IgG1 (grey ) control. B) Cells were stained with propidium iodide and imaged 
post lysis. Images show presence of cells in chambers containing different concentrations of cells. Data 
are presented as means of 3 independent experiments using the same cell line ± SEM. 
According to this data set, the assay can detect Gata-4 protein at a level equivalent to the single cell 
sensitivity in the microfluidic chip (Figure 7.6). The lowest limit of detection tested here was 11 cells 
per microliter. There is good linearity between the number of cells loaded and the signal produced, 
with the R2 value of 0.743. 
Testing the assay with a negative control cell line, SP16, showed that there was little detectable Gata-
4 in these cells (Figure 7.7). This agrees with PCR data which shows SP16 does not express Gata-4 
(see figure 4.5). 
  
 112 
 
7.3.4 Limit of detection in the microfluidic antibody chip 
Since experiments with single cells or two cells per chamber yielded no result, we set out to find the 
limit of detection of this single cell set-up.  The lysate calibrations previously conducted (chapter 5), 
along with cell experiments in larger volumes (section 7.3.3 ), suggested that this antibody sandwich 
system could detect Gata-4 protein at the single cell level. However, this did not correlate with 
experiments with real single cells. Hence, we set out to find the true limit of detection for this assay 
in the microfluidic volumes. 
To investigate this, 3 chambers of the single cell chip, containing either printed anti-Gata-4 or IgG1 
antibody, were loaded with 3, 5, 10, 15 or 0 cells. Cells were then lysed by diffusion of 10x lysis solution 
into the cell chambers. Diffusion from the main channel to the cell chambers takes approximately 
60-90 minutes and the binding plateau is reached at approximately 150 minutes (see Appendix, 
Figure C). 
After 4 hours incubation on chip, observed binding to the Gata-4 antibody is higher than to control 
antibody (Figure 7.8). However, it is only significantly higher with 15 cells per chamber and is not 
significantly different for chambers containing 0, 3, 5 or 10 cells. 
 
Figure 7.8. Titration of cardiac progenitor cells in microfluidic chambers and chemically lysed. 
Chambers were loaded with either 3 cells, 5 cells, 10 cells, 15 cells or no cells. A significant increase in 
binding to Gata-4 antibody (black) above the IgG control (grey) was only observed at 15 cells per chamber.   
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? ????????????????? ?????????
?????? ???????????????????????????????????????????????????
??????????????????
There were a few caveats with this experiment, the first being that transfection can stress the cells 
as it forces cells into overproduction of protein. Cell viability was calculated from trypan blue, and 
the addition of propidium iodide helped to exclude selection of dying cells on-chip. The second 
limitation is that the amount of protein produced per cell cannot be controlled. Whilst fluorescent 
intensity might give a good indication of protein content, it can also be misleading as GFP takes time 
to mature (Evdokimov et al. 2006), and may not be functional or simply misfolded. In addition, the 
intensity can be affected by cell size and cellular location, though in this instance, fluorescence was 
nuclear. 
Whilst in ( 
Figure 7.2) there is a clear difference between isotype control and the Gata-4 antibody, the lack of 
significance could be an artefact of processing. Some of the fluorescent cells could be seen in the 
field of view, giving a high fluorescent background. This in turn would increase the single molecule 
count due to the increased fluorescent intensity in the images. It is challenging task to process out 
these artefacts without losing real single molecules. 
In general, there was a large variation in the single molecule count for the Gata-4 antibody; whereas 
there was a very small variation for the isotype control. This possibly reflects the different Gata-4 
expression levels in the transfected cells. However, this experiment was limited to 3 samples per 
antibody, per cell number; thus sample size would have to be increased in order to see the true 
variation. 
Another factor to consider is the degree of cell lysis and the lack of mixing in the chambers. Further 
still, the PDMS is inherently sticky and despite passivation with BSA, protein may be adhered to the 
chamber walls and hence not able to bind to the antibody.  
Despite these caveats, this data suggests that this assay, at least in part, is capable of detecting 
protein at the single cell level. Albeit, this is testing an over expressing cell line and not endogenous 
expression. 
 ?
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7.4.2 Challenges with single cell proteomics with cardiac 
progenitor clones 
Lysing CPCs in the microfluidic chip (Figure 7.3 and Figure 7.4) yielded no signal at either 1 or 2 cells 
per chamber. Two different lysis methods were tried but this made no improvements. In the first 
experiment, a generalised increase in signal was seen with 2 cells per chamber, and was significantly 
higher than 1 or no cells per chamber. However, the isotype control produced an equivalent signal. 
It is possible that this is due to the location of the cells, being closer to the antibody spot (see Figure 
7.5.). With laser lysis, minimal diffusion of the Gata-4 protein away from the cells was observed. 
Thus, the cells being present near the antibody spots can increase the overall intensity in the field 
of view and thereby increasing the single molecule count.  
In contrast to chambers containing 2 cells, the signal in the 1 cell chambers is constrained to one 
image (one field of view) and does not interfere much with the central field of view, where the 
printed antibody spot in located (Figure 7.5). This might contribute to the reduced signal in the 1 
cell chambers, which would consequently have much reduced fluorescent intensity. 
Whilst there was more binding to the isotype control with chemical lysis (Figure 7.4), this was 
generally quite low, especially when considering the lysate calibrations (Chapter 6). The signal 
produced was similar to background levels expected, and is most likely due to non-specific binding.  
Although one might be cautionary with the use of lysis solution in a protein assay, preliminary data 
with lysate showed that lysis solution did not hinder the assay (see Appendix, Figure D).  However, 
from the results obtained here chemical lysis produced meager binding when compared to the laser 
lysis technique. Although the laser technique seemed to release more protein, the signal remained 
in the location of cell lysis and perhaps requires on chip mixing. 
7.4.3 Directly lysing cells in large volumes indicates single cell 
sensitivity 
Initially, this experiment was conducted to see if there was a problem with the chemical lysis 
solution. To help replicate the conditions on chip, it was necessary to minimise any mixing; loading 
cells into chambers and directly lysing on chip by careful addition of lysis solution, avoiding any 
adverse mixing.  
The cells were diluted so that the cells per volume were equivalent to that found in the microfluidic 
chips. A linear correlation was observed between the number of input cells and the single molecule 
count, as would be expected. In essence, this experiment showed that the assay works and 
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demonstrates a propensity for single cell sensitivity. However, this doesn’t correlate with the single 
cell experiments conducted in the microfluidic chips. 
One possible reason for this is that the lack of mixing might create a high concentration of protein 
local to the printed antibody spot. Since the cells settle at the bottom of the chamber due to gravity, 
any cell lysis will occur in this area. Without adequate mixing, the proteins released will be at a 
higher concentration in this region, relying on diffusion to equilibrate the solution. Since the printed 
antibodies are also in this region, the very high local concentration of Gata-4 would favour increased 
Gata-4-antibody binding (illustrated by Figure 7.9). 
 
Figure 7.9. Illustration of high local concentration of Gata-4 protein in region of printed antibody. 
Increased Gata-4 signal observed due to higher concentration of the protein (shaded blue area) in lower 
part of chamber. Cells (small circles) loaded into the chambers sink to the bottom. Upon addition of lysis 
solution, cells are not mixed and are lysed in the vicinity of the printed antibody spots. On release of 
intracellular proteins, diffusion occurs within the local area. Time to reach homogenous concentration 
throughout the 8µl volume is much longer than the 1.5 hour incubation time.  
This experiment does not give information on the number of Gata-4 molecules per cell. The 
percentage capture in this large 8µl volume is miniscule in comparison to the microfluidic chips (see 
calibrations in Chapter 6). According to the Gata-4 calibration curves, the percentage capture is as 
low as 4x10-7 % in the large volume chambers (Chapter 6). In this large volume experiment, the 
printed antibody patches detect on average 20 Gata-4 molecules per cell. Based on the theoretical 
copy number of Gata-4 per cell calculated in Chapter 6, the capture in these experiments is on the 
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order of 10-4 %. This is still in the ambient analyte regime but the capture is 3 orders of magnitude 
higher than that experimentally determined in Chapter 6. This could possibly be explained by the 
theory of high local Gata-4 concentration, as this would favour more Gata-4-antibody binding. 
Whilst there was limited mixing in this large scale experiment, there is still potentially more mixing 
than occurs in the microfluidic chips. This extra agitation, however slight, might contribute to the 
positive signal seen in the 8 µl chambers. Thus, it is conceivable that the cells in the microfluidic 
chips are not adequately agitated in order to release nuclear protein.  
Another factor to notice about this experiment is the control conducted with the Gata-4 negative 
cells, SP16 (Figure 7.7). These gave virtually no non-specific binding, with non-specific binding 
between 30-60 single molecules. This indicates that on chip these antibodies are truly specific to 
their target protein. Further still, the direct cell lysis produces low non-specific binding and thus the 
limit of detection might be lower than calculated in Chapter 6.  
7.4.4 Improving the lysis methods on the MAC chip 
There are a couple of limitations with the current microfluidic chip design, and it’s possible that a 
few adjustments may increase the sensitivity. One of the issues not resolved here is that of cell lysis. 
It is not certain that the cell lysis methods, either by using laser or chemical lysis, was effective 
enough to release the nuclear localised transcription factor, Gata-4. Whilst work in the group has 
shown that laser lysis is efficient at releasing the transcription factor P53 (Salehi-reyhani et al. 2011), 
it did not work with Gata-4. In contrast to P53, Gata-4 is constrained to the nucleus and may not be 
as abundant. It might require high salt buffers in order to elute the nuclear proteins and DNase to 
break down the DNA. Although the salt concentration of 150mM seemed effective in the large 
volume experiments, this could be increased to release proteins on chip. 
Normally, when making lysate in bulk, one uses a combination of mechanical force with detergents 
to release nuclear proteins. In the case of on-chip cell lysis, no mechanical force is used. It is possible 
that the application of on-chip mixing would release more nuclear proteins, freeing them to bind to 
the antibodies.  
With chemical lysis, the nucleus of cells in the microfluidic chips remains intact (Figure 7.6 and 7.7). 
This is seen by incubating the cells with propidium iodide (data not shown). Whilst the nuclei may 
be chemically perforated, there is no mechanical force to disrupt the membrane physically. 
In contrast laser lysis does physically disrupt the cell nucleus. However, without the use of detergent 
it is foreseeable that the Gata-4 protein remains attached to the DNA. One solution could be to used 
laser lysis in combination with chemical lysis; lysing cells first with a cavitation bubble and then 
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diffusing in the lysis solution. The draw back here is that diffusion of the lysis solution takes 
approximately 1 hour. 
This raises another drawback to the current system of chemical lysis: the diffusion time. It takes 
approximately 1 hour for lysis solution to diffuse from the main channel to the cell chambers (see 
Appendix, Figure C). During this time cells can begin to undergo apoptosis, thereby destroying 
proteins and reducing the amount of Gata-4 available to be detected. However, all solutions do 
contain protease inhibitors, although this will not inhibit intracellular protein degradation prior to 
cell lysis. 
It would be better to introduce the lysis solution so that cells were lysed instantaneously. This could 
be done by using a two layer microfluidic device, but this was beyond the scope of this project. 
Another option would be a “flip chip” design, which has been trialed by members of our group. This 
entails having a grid of chambers on which you pipette a cell solution, diluted so that there is 
approximately 1 cell per chamber. A cell lysis solution would then be applied on top and the grid 
sealed. This would save a huge amount of time in both cell loading and cell lysis; thereby reducing 
cell stress and degradation. The two main disadvantages are that of cell loading and antibody-chip 
alignment.   
In this flip-chip system there is no control over how many cells are loaded per chamber. However, 
this could be sidestepped by using bright field imaging to count the number of cells in each chamber. 
The second is the problem of aligning the chip on to a printed coverslip. The problem of alignment 
arises due to the delicate nature of the grid. It would be open topped and have a maximum height 
of 50 µM, in order to retain small chamber volumes. Thus, the thinness of the grid would make it 
challenging to manipulate, unlike the current PDMS microfluidics.  
7.4.5 Reducing the cell chamber volume 
The volume of the chambers in the microfluidic chips is 4.5 nl. Diffusion time across the chamber is 
reported to be within 30 minutes (Salehi-reyhani 2011; Salehi-reyhani et al. 2011).  Hence, diffusion 
time is not the limiting factor at this volume. Instead, the assay is limited by the binding kinetics, 
LOD and sensitivity. The volume of 4.5 nl is large enough that antibodies are in sampling mode, as 
defined by Ekins’ microspot theory (Ekins 1998), detecting only a small proportion of the proteins 
present. Reducing this volume would push the proteins more towards the bound state, thereby 
increasing sensitivity. Simulations from our group indicates that this is true (Salehi-reyhani 2011). 
However, there are technical caveats with reducing the chamber volume even further. The first is 
that the chambers need to be sufficiently deep to manipulate and load the cells. Another issue is that 
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of alignment. Presently we align the printed slides and microfluidic devices using a hand-operated 
jig. This can be very challenging, even at the present chamber sizes. Reducing the cell chamber sizes 
would require a more precise, perhaps automated, alignment jig. Without this the device, output 
would be significantly reduced.  
? ????????
?? The experimental limit of sensitivity achieved here was 15 cells, a very small population of 
cells. 
?? Experiments with cells transfected with GFP-tagged Gata-4 suggests that this assay has 
single cell sensitivity. 
?? In addition, large volume cell experiments indicates the assay has single cell sensitivity. 
?? The assay might be limited by lysis methods, antibody kinetics or chamber dimensions. 
?? The data presented here shows the TIRFM assay is a promising technique for single cell 
proteomics, although working with transcription factors proves challenging. 
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Chapter 8 
??? DNA Capture of Gata-4 protein as an alternative 
to antibodies 
? ???????????????????????????????????????????????
Whereas DNA microarrays have excelled in recent years, application of protein arrays is vastly 
limited particularly in the area of single cell studies. One of the bottle necks in protein array 
technology is that of the antibodies themselves; limited by their kinetics, sensitivity, specificity and 
stability. 
Manufacturing good antibodies is also a constraint: it is costly, time consuming and the inherent 
inconsistency leads to batch-to-batch variability, requiring functional assessment of each batch. 
Research into alternative capture agents has led to the development of aptamers, affibodies, peptide 
binders and molecular imprinted polymers (MIPs) (Even-Desrumeaux et al. 2010; Germer et al. 2013; 
Gunneriusson et al., 1999; Jing et al. 2011; McKeague et al. 2012; Patel et al., 1997; K.-M. Song et al.  
2012; Vasapollo et al., 2011). 
Improvements in antibody technology itself has seen the rise of Fab fragments, ScFv, as well as  
different antibody species such as chamelid antibodies (Nelson, 2010). The benefit of these is that 
the in vitro manufacturing yields more control, reducing costs and giving more flexibility for 
modifications. However, like antibodies they are still relatively thermally unstable, being generally 
less stable than the full length antibodies (Nelson, 2010). Recent exploration of Chamelid antibodies 
offers an interesting alternative, though not yet commercially available. These antibodies contain no 
light chain, consisting of a single chain these are thus easier to produce in vitro. Coupled with the 
streptavidin biotin immobilisation, they become very sensitive protein detection tools, with a 
subnanomolar limit of detection (Even-Desrumeaux et al., 2010). 
Antibody development has taken a few different avenues in the past few decades, with many having 
great success and applicability in the clinic. The simplest was the modification of monoclonal 
antibodies into Fab fragments, essentially cleaving off the Fc region leaving only the binding region, 
the Fab fragement (Nelson, 2010) . A derivative of this is the short chain variable domain fragment 
(scFv), where the variable regions of both the light and heavy chain are manufactured by 
prokaryotes, and fused together by a linker peptide (Nelson, 2010). The advantage of these is that 
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the lack of Fc region reduces nonspecific binding from this region, although this is more relevant in 
direct cell staining than immunoassays. The major benefit of scFv is that manufacturing can be less 
time consuming and less costly. 
Application of phage display technology to antibody production offers an automated production 
system, accelerating the synthesis of high affinity, high specificity antibodies. Libraries containing 
all the variable (V) genes of antibodies permits in vitro selection by incubating with the antigen of 
interest (Schirrmann et al. 2011; Winter et al. 1994). To attain the antibody fragment of interest the 
phage libraries are subjected to several rounds of selection, amplification and mutation (Wild, 2001). 
This process of increasing the affinity by mutation has had varying degrees of success with one study 
achieving picomolar affinity for fibronectin (Pini et al., 1998) and others claiming up to a 4 fold 
increase (Winter et al., 1994).  The winning phage can then be sequenced and V genes used to make 
Fab, scFv fragments or even full length antibodies (Cai et al. 2013; Schirrmann et al., 2011).  
8.1.1 Alternatives to antibodies 
RNA has many functions in the cell, from transcription and translation to expression regulation. 
One of their inconspicuous roles is their protein binding capabilities. First identified in the 1980s 
from research in HIV, viral RNA was shown to bind  proteins with high specificity and affinity (K.-
M. Song et al., 2012). Single stranded RNA molecules can form intricate tertiary structures that allow 
protein binding. In addition, these molecules are thermally stable, reforming after heating, and are 
stable at a range of pH (K.-M. Song et al., 2012). 
The use of single stranded DNA or RNA molecules, termed aptamers, have been in development 
since the 1990s when two research groups (Ellington et al. 1990; Tuerk et al. 1990) simultaneously 
developed a selection process that specifically identified protein binders. This involved using a 
library of aptamers and selecting the most specific to the protein of interest. This process, termed 
Systematic Evolution of Ligands by EXponential enrichment (SELEX), involves several cycles of 
aptamer-protein binding, followed by washing away of unbound aptamer, eluting the protein and 
amplifying the aptamers of interest by PCR. The products then go through several repeat rounds to 
produce the aptamer with highest specificity (Germer et al.  2013; K.-M. Song et al., 2012; Tombelli 
et al. 2005). There has even been some clinical success with RNA aptamers with the first RNA-
binding drug, Pegaptanib, being approve for Macular Degenerative Disorder in 2004 (Jing et al. 2011).  
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Figure 8.1. Generation of RNA aptamers by the technique of Systematic Evolution of Ligands by 
EXponential enrichment (SELEX). A library containing random nucleotide sequences is synthesised 
and then incubated with target antigen. This is then washed to remove unbound RNA, and the 
bound RNA is eluted and amplified. The amplified library is then subjected to further rounds of 
selection in order to identify the most specific protein binders. Adapted from Tombelli et al. 2005; 
Song et al. 2012. 
Whilst there are many strategies to produce high affinity, high specificity protein binders, 
development and validation is very time consuming and was outside the scope of this project. 
Instead, I decided to use Gata-4’s quality as a transcription factor and used double stranded DNA 
containing the consensus sequence as a method of protein capture. 
Double stranded DNA hasn’t been conventionally developed for protein capture on microarrays. 
However,  protein-binding DNA microarrays have been used to determine transcription factors 
sequence specificity (Berger et al., 2006; Bulyk et al., 2001; Mukherjee et al., 2004). These studies 
suggested that the DNA binding quality of transcription factors can be harnessed for protein capture, 
more specifically using double stranded DNA as the bait to capture Gata-4. 
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8.1.1.a Gata-4 binding specificity for DNA 
The original premise of using DNA as a capture agent is that it is cheap, has high affinity (Merika et 
al. 1993) and is easy to manipulate on glass surface with high level of activity. In addition, it is 
anticipated that the DNA will provide a more natural binding conformation that would also allow 
detection of protein-protein interactions. Finally, zinc finger transcription factors have a good 
reputation for conferring specificity and picomolar affinity (Moore et al. 2001). By substituting only 
a few amino acids in the DNA binding domain and adding more zinc fingers in modular fashion, the 
class I zinc fingers have been harnessed for targeting specific genes (Moore et al., 2001). 
There are 6 members to the Gata family, each having varying yet sometimes overlapping roles. Gata1 
and Gata2 are both found in the developing haematopoietic system; including erythrocytes, mast 
cells and megakaryocytes. Gata3 is more restricted to T lymphocytes and brain cells (Merika et al. 
1993). Gata-4 specifically is involved in the developing endoderm and heart, having overlapping 
expression with Gata5 and 6 (Holtzinger, Rosenfeld et al. 2010; J D Molkentin, 2000; Singh et al., 
2010; van Berlo et al., 2010; Zhao et al., 2008). 
Members of the Gata family each contain two zinc fingers which belong to the class IV structure 
(Gronenborn, 2005). The DNA binding core consists of two antiparallel beta sheets and an alpha 
helix, stabilised by four cysteine’s that coordinate with central zinc atom (Omichinski et al., 1993). 
These Gata zinc fingers typically recognise 8 nucleotide bases (Omichinski et al., 1993) for which  the 
consensus sequence is A/T GATA A/G (Merika et al. 1993).  The Gata enhancer that is found in the 
promoter regions of target genes varies considerably from the consensus sequence. A study by 
Merika and Orka (1993) showed that Gata1 and 2 have quite lax binding specificity, whereas Gata3 is 
more restricted.  It’s postulated that the differential recognition of similar but not identical Gata 
binding sequences might convey the differential gene activation of the Gata factors (Merika et al. 
1993). This is important considering they are often co-expressed in the same cell.  
In general the Gata factors have demonstrated high affinity for their binding sequences (Merika et 
al. 1993). Specifically, a binding study of Gata-4 and Gata-6 showed that these both bound the ANF 
promoter with nanomolar affinity (Charron et al., 1999). However, the Kd of the two Gata members 
differed depending on whether they bound the distal or proximal enhancer. This differential affinity 
presents a possible method of discriminating binding from unwanted Gata family members. 
Development of DNA aptamers began by looking at a database of Gata-4 consensus sequences, 
selecting those which are more specific for Gata-4. 
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? ????????
The methods used are as described in Chapter 6. The 10 nl lysate chips were used, with lysate from 
either endogenous Gata-4 expressing cells or transient transfected cells (see Chapter 6). Lysates were 
incubated at 7.5 pg/nl or 75 pg/nl, equivalent to 1 or 10 cells per chamber. This was calculated on the 
basis of cells containing on average 75 pg of protein (Chapter 6 for more detail). 
?????? ????????????????????????????????????
Information on Gata 4 binding elements was collected from the Transfac database, which provides 
reference material of published binding sequences. Sequences were chosen on the basis of how many 
of the Gata family members bound the sequence, preferring only Gata-4. At the time, longer 
sequences were selected as oppose to length similar to 6 base consensus sequence, hoping that it 
would confer higher specificity.  
 
Table 8.1. List of DNA sequences used as protein capture agents. Forward and reverse strands listed 
in the direction 5’ to 3’. Bold sequences identify the binding sequence; otherwise the sequence is the 
spacer used to lift the DNA off of the glass surface. The reverse sequence was conjugated at the 5’ 
end with and amino linker (*).  
The sequences used are listed in Table 8.1. The DNA oligos included an extension sequence (Bulyk 
et al., 2001), whose aim was to lift the DNA off of the glass surface to prevent steric hindrance 
(Shchepinov et al. 1997). To attach the DNA to the glass surface, the 5 prime sequence of the forward 
was modified to contain an amine group separated from the DNA by a 6 carbon spacer. This single 
amine group thus permits orientation of the double stranded DNA. 
 ?
DNA oligo Forward sequence Reverse sequence
Gata4 TATATGATAGCAGTGATATATAT
AAGTCAATCGGTCC
*GGACCGATTGACTTATATATATC
ACTGCTATCATATA
ANF
 
TATAGATCTCCCAGGAAGATA
ACCAAGGACTCGTATATATAAGT
CAATCGGTCC
*GGACCGATTGACTTATATATACG
AGTCCTTGGTTATCTTCCTGG
GAGATCTATA
Mutant
 
TATAGATCTCCCAGGAACCTAA
CCAAGGACTCGTATATATAAGTC
AATCGGTCC
*GGACCGATTGACTTATATATACG
AGTCCTTGGTTAGGTTCCTGG
GAGATCTATA
 124 
8.2.2 Surface modification for printing 
Glass coverslips were functionalised with GPTS solution for amine attachment of the modified DNA. 
GPTS forms a neutral surface coating (Carré, Birch, et al. 2007; Guiseppi-Elie et al. 2005) which is 
good for reducing unwanted protein-surface interactions. The epoxide is very reactive due to the 
strained nature of the three atom cyclic ring  et al. 2005). Nucleophilic attack by a primary amine, 
opens the ring allowing the now charged oxygen molecule to bind its nearest hydrogen and the free 
nitrogen to covalently bond the carbon molecule (Figure 8.2; Guiseppi-Elie et al. 2005).  Coverslips 
are prepared by cleaning in ethanol with sonication, followed by sodium hydroxide, rinsed in water 
and then air dried and with a final activation of the hydroxide groups by plasma treating for 1 minute. 
The siOH activated slides are immediately incubated in 2.5% GPTS solution in Ethanol and 5% acetic 
acid.  
 
Figure 8.2. Immobilisation of DNA onto GPTS functionalised glass surface. DNA is modified with an 
amine linker, such that it contains one binding site per double stranded DNA molecule. This amine 
group is then able to react with cyclic carboxyl ring on the epoxysilane, forming a covalent bond. 
Adapted from Guiseppi-Elie & Lingerfelt 2005 
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? ????????
?????? ???? ?????????????????????????????
DNA microarrays is a well-established field, having been in development since the 1980’s and 90’s. 
Here the printing buffer of 3x SSC with 1.5M betane was used to prevent spot drying and give optimal 
signal (Diehl et al., 2001). In addition spacer sequences were included to reduce steric hindrance 
which arises due to the interaction of DNA with the electrostatic charges on the glass surface 
(Peterson, 2001; Shchepinov et al., 1997).  Protein-DNA microarrays are not a common technique 
and whilst some studies suggest the use of between 10-20 μM of DNA (Bulyk et al., 2001) the effect 
of DNA density on protein binding is not well studied.  Too little DNA will result in reduced signal, 
too much can result in inhibition of binding, as has been seen in traditional DNA microarrays 
(Peterson, 2001). Here, I optimised the concentration of printed DNA for protein binding. 
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Figure 8.3. Titration of printed Gata-4 DNA oligo concentration. DNA capture agent incubated with 
5 μg/ml Gata-4 purified protein for 30 minutes on an open chip assay. P <0.01 
DNA was diluted from 50 μM  to 50 nM and incubated with purified Gata-4 protein. Minimal binding 
mas observed between 0 to 1 μM of printed DNA, with no significant difference observed (Figure 
8.3). Gata-4 protein bound significantly higher to DNA at 10 μM and 50 μM, than at any other 
concentration. The concentration of 50 μM was significantly higher than 10μm. Thus DNA was 
printed at 50μM in all subsequent experiments.  
*
*
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8.3.2 DNA probe development 
Gata-4 binds many enhancer sequences, here I used the distal ANF enhancer which is known to have 
nanomolar affinity for Gata-4 and yet has a 3 fold lower affinity for Gata-6 (Charron et al., 1999). The 
ANF oligo was compared with the Gata-4 consensus sequence and a mutated ANF sequence. DNA 
oligos were incubated with either HEK Gata-4 transfected or HEK untransfected cell lysate. Figure 
8.4 shows that whilst there is significantly higher binding to the ANF oligo compared to the other 
two oligos, there is also significantly higher non-specific binding of the untransfected lysate. There 
is significant signal with the HEK-Gata-4 lysate with both the Gata-4 consensus sequence and the 
mutated sequence in comparison to incubation with untransfected lysate. 
 
Figure 8.4. Compares Gata-4 binding to three different oligonucleotides, the Gata-4 ANF enhancer 
(ANF), Gata-4 consensus sequence (Gata-4) and the mutated ANF sequence (Mutant). 
Oligonucleotides were incubated with either HEK Gata-4 transfected lysate (HEK G4) or HEK 
untransfected lysate (HEK UT).  The ANF oligo bound both the transfected and untransfected lysate 
to high degrees. Whilst no significant differences were observed between the mutant oligo and the 
Gata-4 oligo, neither oligo bound protein from the untransfected lysate control. The ensuing 
experiments were pursued with the Gata-4 consensus oligo. 
8.3.3 Gata-4 protein pull down with printed oligonucleotides 
Ability of DNA oligos to capture Gata-4 protein was assessed in a microfluidic chip with HEK  lysate 
transfected with Gata-4. Lysate was diluted to either 7.5 pg/nl or 75 pg/nl, which equated to 1 cell 
per 10 nl assay chamber and 10 cells per chamber respectively.  The untransfected lysate acted as an 
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additional control to the mutant oligo. There was significantly higher binding to the Gata-4 oligo 
with the HEK Gata-4 transfected lysate than the untransfected control lysate. In addition there was 
a significant difference between the Gata-4 oligo and mutant oligo at 7.5 ng/nl of lysate. However, 
this was not the case at the higher lysate concentration of 75 ng/nl. 
 
Figure 8.5. Testing the DNA capture sensitivity, incubating with lysate at either 7.5 or 75 ng/nl; this 
equates to 1 cell and 10 cells per chamber respectively. DNA oligos were incubated with either HEK 
Gata-4 transfected lysate (HEK Gata-4) or untransfected lysate (HEK control). There was 
significantly higher binding to Gata-4 oligos incubated with Gata-4 transfected lysate than 
untransfected lysate control lysate. However at 75 ng/nl no difference was observed between the 
Gata-4 and mutant oligo when incubated with transfected lysate. A difference in binding between 
mutant and Gata-4 oligos was observed at 7.5 ng/nl for both lysates. Students t-test, p<0.01 
? ???????????
?????? ???? ????????????????????????????
A range of printing concentrations were tested using purified protein. The research groups that had 
developed the protein-binding DNA arrays had suggested between 10-20 μM of DNA (Bulyk et al., 
2001; Linnell et al., 2004). This data certainly shows that any less than this is ineffective at pulling 
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down protein. Concentrations higher than 50 µM of DNA were not tested here, as the starting 
concentration was 100 µM and the printing solution required 1:1 mixing. 
8.4.2 DNA oligonucleotides for Gata-4 pull down 
Three different oligos were tested for Gata-4 pull down (Figure 8.4); the ANF enhancer, the Gata-4 
consensus sequence and the mutated ANF sequence. The ANF oligo had the highest level of Gata-4 
binding. Whilst there was a significant difference between the positive and negative control lysate 
for ANF, the level of binding from the untransfected control was high. This level of binding, at just 
below 3000 single molecule counts, would be enough to mask any signal from single cell. This signal 
seen with ANF negative control could be endogenous Gata-4 from the untransfected cell lysate.  
However, HEK untransfected lysate was negative for Gata-4 in Western blot analysis (Chapter 4). 
The Gata-4 and the mutant oligo generated similar signals from the HEK transfected lysate.  This 
was unexpected as the mutant oligo had a mutated sequence that should inhibit Gata-4 binding.  
However, in contrast to the ANF oligo, the Gata-4 and mutant oligo had much less signal from the 
untransfected control. This indicates that the Gata-4 and mutant oligo are binding Gata-4 protein 
specifically, but suggests that the mutant oligo is not a suitable negative control.  
The Gata-4 consensus oligo was used for further investigations.  Whilst it had reduced signal in 
comparison to ANF, it had minimal binding from the HEK control lysate, indicating it is more 
specific than the ANF probe. 
8.4.3 Does DNA capture provide single cell sensitivity 
At first sight the DNA capture agents appear unsuccessful, with Gata-4 binding to both the positive 
and negative control oligo (Figure 8.4 and Figure 8.5). This is deceptive as testing this against a 
negative control cell lysate shows that there is no binding in the absence of Gata-4 protein (Figure 
8.4 and Figure 8.5).  
Given this data, it is likely that the mutant oligo (Mt) is in fact pulling down Gata-4 protein rather 
than non-specific protein and that all the specificity is conferred by the Gata-4 antibody. An 
alternative to this is that the mutant oligo is picking up protein interactions, with the Gata-4 protein 
binding other proteins in the lysate which subsequently bind to the oligo. However, the level of 
binding is similar to that for the Gata-4 oligo and further still,  experiments with other negative 
control oligos shows that these also bind Gata-4 (see Appendix, figures F-H ). 
As noted in Chapter 5, the non-specific binding increases upon addition of lysate. Here the LOD 
when incubated with negative control lysate was negligible at, 3.7 and 9.2 single molecule counts for 
lysate concentration of 7.5 ng/nl and 75 ng/nl respectively. The single molecule count for Gata-4 
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protein at single cell concentration is approximately 1000 molecules (Figure 8.5). This is well above 
the limit of detection, therefore indicates that the DNA capture has single cell sensitivity. 
Whilst the DNA capture shows an impressive limit of detection with very limited antibody-DNA 
cross talk, the dose-responsiveness of the assay still remains to be tested. This DNA assay was not 
pursued further due to the major limitation with negative control oligos, which bind Gata-4 protein.   
8.4.4 Transcription factors inherently bind nonspecific DNA 
The fact that we see Gata-4 binding to supposedly non-specific DNA may be no surprise. Since the 
80s much research has gone into how transcription factors find their specific binding sites. There 
are four main mechanisms proposed (see Figure 8.6); 3D diffusion, 1D sliding along DNA, 
intersegmental transfer and sliding with intrasegmental ‘hopping’ (Givaty et al., 2009; Halford et al. 
2004; von Hippel et al. 1989). 
The action of 3D diffusion, means that the process of a protein finding its binding site is random, 
fuelled simply by Brownian motion. This passive process places an upper limit on the rate of 
association of 108 Ms-1 (Halford et al. 2004). In many instances, protein DNA binding has been 
experimentally determined to exceed this. So what are the driving forces behind this increased 
association? 
 
 
Figure 8.6. Illustration of transcription factors searching for DNA binding sequence. This is achieved 
either through sliding along the DNA (1); through 3D diffusion within the nucleus (2); 
intersegmental transfer whereby protein simultaneously binds to two distant DNA sequences (3); or 
by hopping between various local DNA sites. The degree of non-specific binding may depend on 
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which mechanism is prominent, although it is currently thought a combination of these mechanisms 
are used. Adapted from Givaty & Levy 2009. 
An alternative mechanism is the theory of facilitated diffusion. This is where transcription factors 
bind DNA non-specifically and search for their specific targets by a process of one dimension 
diffusion along the DNA (Halford et al. 2004; von Hippel et al. 1989). This is measured to be three 
orders of magnitude quicker than the passive process of 3D diffusion, (Gao et al. 2009). 
A few factors increase the likelihood of the non-specific binding; the first is the inherent stickiness 
that occurs when two macromolecules collide, the collision not being as elastic as micromolecules 
(von Hippel et al. 1989).  The second is the electrostatic forces between the two molecules. Salt 
concentration is the final factor with low concentration favouring binding and high concentration, 
as occurs in vivo, impeding binding by masking the local charges on the protein (Halford et al. 2004). 
Together, this indicates that transcription factors do indeed bind DNA non-specifically. Reportedly 
they have a low affinity of anywhere between 103-106 M (Jen-jacobson, 1997; Jolman et al. 2011) and 
when considering the mechanisms at play searching for target sites, there is probably high rate of 
association and dissociation. 
Further to this, a specific study on Gata binding specificities showed that the members of this family 
do bind sequences unrelated to the core A/T GATA A/G consensus sequence (Merika et al. 1993). 
Whilst this study was not specifically on Gata-4, it did show that Gata-1 and 2 are more flexible in 
terms of their binding sequence, whereas Gata3 was more restricted (Merika et al. 1993). Whether 
Gata-4 is as liberal as Gata-1 and 2 is still unanswered, and if this is the case it may be difficult to find 
a suitable negative control. 
As mentioned earlier, salt concentration is a crucial factor to protein-DNA binding; too low and the 
protein remains tightly bound, whereas too high a concentration impedes associations (Givaty et al. 
2009). Standard PBS buffers were used in these experiments, giving a salt concentration of 137 mM. 
According to a computational study by Givaty et al. (2009) this would favour 3D diffusion over the 
1D sliding. Perhaps this could be manipulated to further decrease binding, but this might cause 
knock on effects with antibody-protein binding and other protein-protein interactions. 
8.4.5 Further development of negative controls is required 
Whilst many studies have used a mutated binding sequences to show specificity (Charron et al., 
1999; Hautala et al., 2001; Ip et al., 1997) these sequences do not necessarily fully abrogate binding. 
In this chapter, a mutated ANF sequence (Charron et al., 1999) was used as a control but the 
mutation did not appear to completely block Gata-4 binding. This could be due to the ability of 
transcription factors to bind DNA non-specifically, or it could be that the sequence requires further 
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mutation. The DNA oligos present an alternative to antibody capture, and are limited by the lack of 
a negative control in this study. Further development of the controls should be considered, using 
either a non-related enhancer sequence, random non-specific sequence, or by adjusting the buffer 
compositions to weaken non-specific interactions. Despite the problem of control oligonucleotides, 
the DNA capture agents provide binding with high affinity and this could be applied to other 
proteins when there is limited availability good antibodies. ?
? ????????
?? In the absence of a good antibody pair, DNA capture agents offer an alternative for capture 
of transcription factors 
?? Coupled with antibody detection, DNA oligonucleotides are able to pull down Gata-4 
protein 
?? The antibody confers good specificity in this instance, as seen by the negative control lysate 
?? Negative control DNA oligonucleotides appear to be the limiting factor 
?? Confers advantage of low non-specific binding, giving a superb limit of detection, as defined 
by background binding of negative control lysate 
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Chapter 9 
??? Discussion and conclusion 
Here, a sensitive assay was developed that can detect Gata-4 protein from a small population of 
fifteen cells. Many challenges have been faced in developing this immunoassay; these include 
identifying suitable antibodies, followed by their subsequent immobilisation and labelling for use in 
this immunoassay. Limitations to the sensitivity of the assay is highly dependent not only the 
antibody affinity, but the limit of detection as defined by non-specific background and also the 
physical dimensions of the assay. This chapter discusses the main findings and challenges to single 
cell proteomics using this assay, and closes with the future work resulting from this study.  
? ???????????????????????????? ????????
The primary limitation of any antibody sandwich assay is the availability of antibodies. They need to 
be specific, have good affinity for their targets and each antibody in the pair needs the ability to 
recognise different epitopes. In this thesis 6 monoclonal antibodies were tested by Western blot for 
suitability in this assay. Of these, three proved to be specific, antibodies MAB2606 (R&D systems), 
Sc (Santa Cruz Biotechnology) and BD (BD Biosciences; Figure 4.2), with the rest having intermittent 
results.  
The Gata family has 6 members, of which Gata-5 and Gata-6 are the most similar to Gata-4, sharing 
45% and 33% identity respectively (as determined by NCBI BLAST analysis). To ensure specificity to 
the protein of interest, the antibodies, BD and MAB2606, were tested against HeLA cells transfected 
with either of the three closest members of the Gata family, Gata-4, Gata-5 or Gata-6. 
Immunofluorescent staining showed that these antibodies were specific to the protein of interest 
(figure 4.6).  
This together with the clean profile shown by western blotting suggested that these antibodies have 
the specificity required for the TIRF assay. In addition these antibodies recognised different epitopes, 
MAB2606 in the N-terminus and the BD antibody in the C-terminus (Figure 4.1) suggesting that they 
are suitable for use in a sandwich assay format. Whilst the antibodies have shown promising results 
with regard to specificity, it is worth noting that the success of the antibodies in the microfluidic 
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immuno assay is also highly dependent on the affinity of the antibodies for their target and must be 
at least 1 nM for the assay to work (Salehi-Reyhani et al. 2013).  
A third antibody, Sc, may also have been a good candidate for the TIRF assay (figure 4.2), however, 
this was not rigorously explored. Whilst preliminary TIRF experiments with this antibody suggested 
this was not a suitable (data not shown), this may have been confounded by the long difficulties 
faced with protein stability, and thus led to this antibody being overlooked. Protein stability in 
general maybe a shortcoming of the assay. Indeed, it is known that printed antibodies remain largely 
non-functional (Kusnezow et al. 2003a) and conducting experiments at room temperature to aid 
kinetics (Goodrich et al. 2007) may be detrimental to protein stability. Whilst steps were taken to 
mitigate the latter factor, such as protease inhibitors and keeping all reagents on ice prior to the 
experiment, this assay was marred by problems with protein stability. Great effort was put into 
determining the cause of the problems experienced, this included changing printing buffers, testing 
fresh reagents, different labelling techniques and different antibody combinations. Ultimately, the 
issue of protein stability in combination with other factors, such as the physical failure rate 
experienced with the microfluidic chips, severely hindered development of this assay. 
 
9.1.1 Antibody immobilisation directly affects their activity 
Inherent to the success of all immunoassays, is the antibody immobilisation technique, which 
directly impacts the antibody’s functionality through steric hindrance, denaturation and orientation 
effects. There have been many thorough reviews of surface immobilisation (Seurynck-Servoss et al. 
2007; Angenendt et al. 2003; Kusnezow et al. 2003; Vijayendran & Leckband 2001), and whilst these 
strategies increase the maximal signal and produce high signal to noise ratios, they also increase the 
background noise, without much improvement in the lower detection limit. In addition, these 
surface chemistries are not applicable to all antibodies and would need to be optimised specifically 
for each antibody.  
An interesting approach that avoids antibody-specific surface chemistries is the antibody-DNA 
barcode strategy. By conjugating antibodies to a single stranded DNA oligonucleotide, they can be 
immobilised by annealing to the printed complementary strand. This therefore maximises antibody 
functionality as they are lifted off of the glass surface. The Heath group (California Institute of 
Technology, USA), who developed the technique, subsequently showed single cell sensitivity using 
an epifluorescent scanner for detection (Shin et al. 2010; Wei et al. 2013; Shi et al. 2012). The caveat 
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to this method is that the preparation of DNA-antibody conjugates results in antibody loss. This 
method was therefore not pursued in this thesis.   
In this thesis, immobilisation using protein G was trialled due to the minimal loss of antibody and 
its effectiveness at pulling down antibody. However, the printed protein G was not sufficiently 
saturated with pull-down antibody, despite the range of concentrations trialled (Figure 5.6). This 
resulted in unwanted binding of the fluorescently conjugated antibody to the protein G. This 
background binding was as high as 4600 molecules which is too high for this application, as it would 
mask any signal from a single cell. 
Buffer evapouration is another stressful factor for printed antibodies. This has the effect of rapidly 
increasing the spot concentration, the ionic strength and changes the pH, all of which can cause 
protein denaturation. Additives can be included in the printing buffer to help resolve this. Some 
improvements have been seen with trehalose (Kusnezow et al. 2003), PVA (Wu & Grainger 2006) 
and glycerol, the latter of which completely inhibits evaporation (MacBeath & Schreiber 2000).  
9.1.2 Antibody conjugation 
This assay uses detection with fluorescently conjugated antibodies, thereby avoiding genetic 
modifications to the proteins of interest. Whilst antibody conjugation can reduce antibody activity 
there are a few different methods available to help circumvent this.  The most common method 
labels the antibody at the primary amines or at the cysteine residues in the disulfide bridge, located 
in the hinge region. Labelling the cysteine residues is a more targeted approach than labelling the 
primary amines which can be located anywhere in the antibody, including the antigen binding 
region. However, cysteine labelling involves breaking the disulfide bridges which can make the 
antibody less stable.  
Labelling via Fab fragments was also tested in this thesis; however, this approach yielded high levels 
of background binding (Figure 5.4 and 5.5). Thus, labelling via primary amines was used as the 
conjugation method of choice. Although there was a lack of control over the location of the antibody 
labelling, the degree of labelling could be controlled, and the antibodies were finally assessed, by 
measuring the concentration of fluorescence. 
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? ???????????????????????????????
?????? ??????????????????????????????????????????????????????
The avidity of the assay was measured as 6 nM ±2.2 nM (Figure 6.4). This assay required the use of 
antibodies with nanomolar affinity, in order to achieve single cell sensitivity. Whilst the affinity for 
each antibody was not determined, the measured avidity represents the strength of interaction 
across the three interacting molecules and suggested that the assay had the sensitivity for single cell 
protein analysis. 
The benefit of microfluidics is that they offer nanolitre assay volumes. This means this assay operates 
in the mass sensing regime. This has the benefit of capturing more protein, which is particularly 
useful for low protein concentrations. Ideally, we would like to bind all the protein expressed in cells 
and count the absolute protein expression. However, in the current format, this assay can only 
capture a maximum of 9% of the expressed protein, a percentage which decreased as the protein 
concentration increased (Figure 6.5).  
Improvement in mass sensing is not greatly increased by better affinity antibodies. This is because 
with high affinity antibodies most sites are already occupied (Wild 2001). Therefore, one has to 
increase the number of active antibody molecules printed on the surface. Currently, it is estimated 
that only 0.14% of the printed antibody is active. Whilst this number might seem low, it could be 
explained by the steric hindrance, denaturation and the orientation effects that can occur with 
immobilisation onto a solid surface (Saviranta et al. 2004; Wild 2001). Many studies have assessed 
surface chemistries to improve the reduced antibody functionality seen with immobilisation (see 
section 5). However, improvements in activity are generally quite limited and often coincide with a 
decrease in the amount of antibody deposited due to the antibody loss that occurs during 
modifications. 
Other factors affecting the antibody affinity include: denaturation due to extreme buffer pH, the 
buffer ionic strength which impacts the binding reaction, and the incubation temperature. The latter 
is important to the binding stability with low temperatures stabilising binding by reducing the 
energy of water (Reverberi & Reverberi 2007). 
?????? ?????????????????? ????????????????
The limit of detection (LOD) is the signal above the non-specific binding, for which it can be 99.7% 
confident that the single molecule count is due to Gata-4 binding. The LOD in this assay is 
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approximately 1810 molecules. A calibration from cell lysate indicates that there are between 3500 
and 5000 detectable Gata-4 protein molecules per cell (Figure 6.7 and Table 6.1), which corresponds 
to approximately two times the LOD. These numbers indicate that the assay should be capable of 
detecting Gata-4 from single cells. 
However, the addition of lysate seems to have a higher non-specific binding than the antibody alone 
(Figure 6.7Figure 6.7, time zero represents antibody alone). At single cell concentrations there is not 
a significant difference between the test antibody and the control, suggesting that the assay is at its 
limit with respect to single cell analysis.  
This high non-specific binding seems to be specific to lysate, as cells lysed directly on-chip has much 
lower levels of non-specific binding. This could be due to the lysate preparation conditions. The 
chemical lysis buffer used in the cell experiments was commercial, and was similar to the non-
denaturing lysis buffer used to make the lysate, with both containing 1% Triton X-100. The non-
specific background is likely due to ionic and electrostatic interactions between non-specific 
proteins in the lysate and the antibodies. The overall charge on any given protein is determined by 
its isoelectric point (pI). The pI of antibodies can range between 5.8 and 8.5 and so at physiological 
pH, antibodies can be positive, negative or neutral. Therefore they are attracted to negatively 
charged, positively charged or hydrophobic proteins respectively.  
Although blocking with BSA can minimise these non-specific interactions, non-specific binding 
from both antibody-antibody cross-reactivity and non-specific interactions with lysate were 
observed in the TIRF assay. Other blocking reagents could be used, such as casein, which was 
reported to be particularly efficient at blocking hydrophobic interactions (Boenisch et al. 2001). 
However, it was not tested here. Other passivation methods include using detergent such as tween-
20, adjusting the buffers pH or ionic strength, or coating with the copolymer poly ethylene glycol 
(PEG) (Boenisch et al. 2001). The properties of PEG make it particularly attractive for surface 
passivation; its amphiphilic quality gives it solubility in water whilst retaining its hydrophobic 
properties which blocks non-specific protein adsorption (Jonkheijm et al. 2008).  
PEG passivation was tested in this thesis. Whilst it produced a high signal to noise ratio, there was 
a large variation in positive single in comparison to the BSA passivated surface (Figure 5.7 and Figure 
5.8). This suggested that the PEG surface is not stable for antibody printing and cannot give 
reproducible single molecule counts, particularly at the higher lysate concentration. PEG can be 
combined with biotin-streptavidin to aid antibody immobilisation. However, highly concentrated 
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antibody spots are required in this assay and printing biotin-conjugated antibodies on a layer of 
diffuse biotin-streptavidin might not yield the concentration required. 
A technical caveat that should be mentioned is the leakiness of PEG microfluidic devices. PEG being 
a non-stick surface means that often microfluidic devices will fail. In order to circumvent a 
detrimental device failure rate, and in favour of increasing over all signal output, BSA passivation 
was chosen. Whilst these surfaces have high backgrounds, this scales with the lysate concentration 
and is adequately low at low lysate concentrations. In addition, at the theoretical single cell level of 
7.5 pg/nl, there was no difference between PEG and BSA passivated surfaces as neither distinguished 
signal between the Gata-4 antibody and the IgG isotype control. At the opposite end of the scale, the 
PEG surface seems to saturate at higher concentrations of lysate, suggesting that inadequate 
amounts of antibody is immobilised on the surface. 
A final point to raise on passivation is the inherent stickiness of PDMS (Huang et al. 2005). In the 
experiments conducted in this thesis, PDMS was passivated by BSA and the issue of non-specific 
binding was not explored any further. It is possible that protein is depleted by adsorption to the 
PDMS, and one study has suggested that n-dodecyl-beta-D-maltoside can reduce this (Huang et al. 
2005). This would need to be considered in the future in order to improve assay sensitivity. 
9.2.3 Sensitivity 
Sensitivity is defined by the responsiveness of the assay to the increasing concentration of protein. 
Ideally the sensitivity of the assay would lie in the linear, most responsive, region. However, 
detecting such low concentrations means the assay is working in the sublinear region, as defined by 
the Gata-4 calibration curve in Chapter 6 (Figure 6.4).  Despite this, data showing a linear increase 
in single molecule count with lysate concentrations indicates the assay is sufficiently responsive at 
low concentrations (Figure 6.7). This implies the assay is sensitive with small numbers of cells and 
that the overall sensitivity is limited by the LOD as previously discussed. 
Nonetheless, pushing the assay sensitivity into the linear range would be beneficial. This could be 
achieved by increasing the quantity of capture antibody and its activity. As mentioned earlier 
(Section 5) antibody activity is directly impacted by immobilisation. Various chemistries have been 
tested to help improve this. However, the antibody preparation steps required in order to achieve 
this often results in antibody loss. Whilst the activity may be increased, the overall antibody 
concentration is reduced.  
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Another solution could be to simply print higher concentration of pull down antibody. A study of 
microarray production parameters showed that a maximum signal can be achieved with up to 1 
mg/ml of antibody printing solution, but higher concentrations adversely affects the signal 
(Kusnezow et al. 2003). A caveat to this is that excess antibody will be washed away. In the case of 
the closed chambers, excess antibody will freely float in solution and consequently bind antigen, 
thereby reducing overall signal. A final solution could be to reduce the chamber volume, which is 
discussed in section 0. 
9.2.4 Variable expression of Gata-4 in GFP tagged Gata-4 
transfected cells 
In order to determine the sensitivity of the assay, cells were transfected with GFP-tagged Gata-4 
expression vector, and protein pull down was conducted on cells lysed in situ. The results from this 
study were promising, as a significant difference was observed for one and five cells per chamber. 
However no difference was observed for two or three cells per chamber (Figure 7.2). One possible 
explanation for observing a significant difference at one cell and not two or three cells is the variable 
expression of protein between cells. It is possible that the one cell had higher expression than the 
others. Another possibility may be that the signal variation between chambers with two and three 
cells was too large for the statistics to determine a statistical difference.  
In general, there is large variation in the single molecule count for the Gata-4 antibody; whereas 
there is very small variation for the isotype control. This is likely a reflection in the different Gata-4 
expression levels in the transfected cells. However, there are only 3 samples per antibody, per cell 
number; n would have to be increased to see the true variation. 
Despite these caveats, this data suggests that this assay is capable of detecting protein at the single 
cell level. Albeit, this is testing an over expressing cell line and not endogenous expression. 
9.2.5 Single cell sensitivity indicated by on-chip cell lysis in 
microlitre volumes  
Cells were serially diluted and lysed directly in large volume chambers. Initially, this experiment was 
conducted to investigate the usability of the chemical lysis solution. However, the results suggested 
that the assay had single cell sensitivity, in addition to exceptionally low background binding with 
the fresh cells (Figure 7.6 and Figure 7.7). 
  
 139 
 
The cells were diluted so that their concentration would be equivalent to that found in the 
microfluidic chips. A linear correlation was observed between the number of input cells and the 
single molecule count, and thus demonstrated single cell sensitivity. However, this did not translate 
to the single cell experiments conducted in the microfluidic chips (Figure 7.3, Figure 7.4 and Figure 
7.8). 
Contributing to this observation might be the lack of mixing in the large volume chambers. To 
replicate conditions in the microfluidic chips, the large volume chambers were deliberately not 
mixed. Since the cells settle to the bottom due to gravity, lysis without mixing would likely create a 
high concentration of protein local to the printed antibody spot. Increased local protein 
concentration would therefore favour increased Gata-4-antibody binding (Figure 7.10).  
Another noticeable factor in this experiment is the control conducted with the Gata-4 negative cells, 
SP16. These gave negligible non-specific binding, with a low single molecule count of between 30 
and 60 (Figure 7.7). This indicates that on chip these antibodies are truly specific to their target 
protein. 
?????? ????????????????????????????????????????????????????
??????????????????
The cardiac progenitor clone, SP3, which is known to express Gata-4, was tested in the single cell 
experiment set up. However, testing at both one and two cells per chamber yielded no signal. Two 
different lysis methods were tested but this made no improvement (Figure 7.3 and Figure 7.4). In the 
first experiment, a generalised increase in signal was seen with two cells per chamber, above one or 
no cells per chamber. However, an equivalent signal was observed with the isotype control. Looking 
at a tilescan of the raw data in Chapter 7 (Figure 7.5), negligible on-spot binding is observed; instead 
the fluorescence seemed more diffuse. Consequently, a different lysis method was tested. 
The concern of using chemical lysis in an antibody assay was addressed in preliminary experiments, 
where no detrimental impacts were seen on the outcome. However, chemical lysis showed no 
improvement in the assays ability to detect protein from cells.  
? ????????????????? ???????????
?????? ????????????????????????????????????????????
There are a couple of limitations with the current microfluidic chip design, and it is possible that a 
few adjustments could increase the sensitivity. One of the challenges which were not resolved here 
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is that related to the cell lysis. It is not certain that cell lysis, either laser or chemical, was effective 
enough to release the nuclear localised transcription factor Gata-4. Whilst work in the group has 
shown that laser lysis is efficient at releasing the transcription factor P53 (Salehi-reyhani et al. 2011), 
it was not found to be as successful here with Gata-4. In contrast to P53, Gata-4 is constrained to the 
nucleus and may not be as abundant as P53 is in the cytoplasm. Therefore, it might require high salt 
buffers in order to elute nuclear proteins and DNase to break down the DNA.  
Further to this, nuclear staining of cells in the MAC chip indicated that the nucleus remains intact 
after chemical lysis. Whilst the nuclei may be chemically perforated, there is no mechanical force to 
disrupt the membrane physically. 
In contrast, laser lysis physically disrupts the cell nucleus. However, without the use of detergent it 
is possible that the Gata-4 protein remains attached to the DNA. One possible solution could be to 
use laser lysis in combination with chemical lysis. This process would first lyse cells with a cavitation 
bubble and then diffuse in the lysis solution. 
The diffusion time is a current limitation of using chemical lysis alone. It takes approximately 1 hour 
for lysis solution to diffuse from the main channel to the cell chambers. During this time cells can 
start apoptosis, thereby destroying proteins and reducing the amount of Gata-4 available to be 
detected. 
It would be better to introduce the lysis solution so that cells were lysed instantaneously. This could 
be done by using a two layer microfluidic device. Or by using a “flip chip” design, which has been 
trialled by members of our group. This design entails having a grid of chambers onto which a diluted 
cell solution is applied, so that there is approximately 1 cell per chamber. A cell lysis solution would 
then be applied on top and the grid sealed. This would be much more time efficient with regards to 
both cell loading and cell lysis, and therefore also reduce cell stress. The two main disadvantages are 
that firstly, there is no control over how many cells are in each grid. Although, this could be 
sidestepped by using bright field imaging to count the number of cells in each chamber. The second 
is the challenge of aligning the chip onto a printed coverslip. The grid would be open topped and in 
order to retain small volumes the height would be restricted to 50 µM. Therefore, the device would 
be inherently flimsy and challenging to align.  
Normally, when making lysate in bulk, one uses a combination of mechanical force with detergents 
to release nuclear proteins. In the case of on-chip lysis, no mechanical force is used. It is possible 
that with the use of on-chip mixing, more nuclear proteins would be released and able to bind the 
antibodies .   
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Another advantage of mixing is that the system becomes less restricted by mass transport. Mass 
transport arises due to depletion of analyte in the reaction zone, and insufficient mixing  means 
binding is gradient driven (Cretich et al. 2014). Making the solution homogeneous would make the 
reaction kinetically driven (Cretich et al. 2014). However, chamber size helps to overcome the limit 
of mass transport as small volumes reduce the time to establish equilibrium. 
9.3.2 Reducing the cell chamber volume 
The volume of a MAC chip chamber is 4.5nl. The diffusion time across the chamber is reported to 
be 30 minutes (Salehi-reyhani 2011). Hence, the diffusion time is not the limiting factor at this 
volume. Instead, the assay is limited by the binding kinetics. The volume of 4.5nl is large enough 
that antibodies are in sampling mode, as defined by Ekins’ microspot theory, and is only detecting a 
small proportion of the proteins present. Reducing this volume would push the proteins towards the 
bound state, thereby increasing sensitivity (Salehi-Reyhani et al. 2013).  
However, there are some technical caveats with reducing the chamber volume even further. The first 
is that the chambers need to be sufficiently deep to manipulate and load the cells. Another challenge 
is that of alignment; presently we align the printed slides and microfluidic devices using a hand-
operated jig. This can be very cumbersome, even at the current chamber sizes. Reducing the cell 
chamber sizes would make alignment more difficult and reduce the output of what has already a 
limited throughput.  
9.3.3 Development of alternative capture agents 
Gata-4 can bind its DNA enhancers with nanomolar affinity (Charron et al. 1999), and this makes 
DNA-protein capture an attractive proposition for the TIRF assay in development here. At first sight 
the DNA capture agents appeared unsuccessful, with Gata-4 binding to both the positive and 
negative control DNA oligo (Figure 8.4). However, testing this against a negative control cell lysate 
shows that there is no binding in the absence of Gata-4 protein (Figure 8.5).  
Given this data, it is likely that the mutant oligo (Mt) is pulling down Gata-4 protein rather than 
non-specific protein and that all the specificity is conferred by the Gata-4 antibody. A potential 
alternative process is that the mutant oligo is picking up protein interactions. Gata-4 protein could 
be binding other proteins in the lysate and that this complex is then binding to the oligo. However, 
the level of binding observed is similar to that for the Gata-4 oligo (Figure 8.4 and Figure 8.5), and 
experiments with other negative control oligos show that it binds these also (Appendix, figure F-H). 
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An important benefit of the DNA capture system is that the limit of detection for this set up is very 
low at less than 10 single molecules. This is much lower than with the antibody sandwich assay which 
as a LOD of 1800. Since the signal for single cell is estimated to be at least two orders of magnitude 
higher than the LOD, the DNA capture assay might be more suitable for single cell studies.  
?????? ???????????????????????????????????????????????????????
Transcription factors have affinity for non-specific DNA sequences, although this might be very low 
in comparison to specific sequences. This a consequence of the searching mechanisms which 
include; 3D diffusion, 1D sliding as well and intra- and inter-segmental hopping ’ (Halford & Marko 
2004; von Hippel & Berg 1989; Givaty & Levy 2009).  
Other factors that increase the likelihood of the non-specific binding include macromolecule inertia, 
electrostatic forces and buffer compositions (von Hippel & Berg 1989; Halford & Marko 2004). 
Further to this, other Gata members are known to be less stringent in their binding specificities 
(Merika & Orkin 1993).  Whilst in this thesis Gata-4 was observed to bind non-specific DNA 
sequences, the exact stringency of Gata-4 remains unknown. 
Despite the problem of control oligonucleotides, the DNA capture agents provided a promising 
solution for single cell protein analysis. This is particularly advantageous where suitable antibodies 
are in short supply.  Development of DNA controls could be explored further, starting with the buffer 
conditions which are known to affect the molecular interactions. Additionally, other non-related 
DNA sequences should be tested in order to find a suitable negative control.  
? ?? ?????????
?????? ?????????????????????????????????????????????????
One particular limitation with this system is that the exact amount of pull down antibody which is 
immobilised remains unknown. Printing with a micro-contact printer enables antibodies to be 
printed at high density, maximising the number of capture sites, which is therefore beneficial to this 
assay. However, the actual volume of printed antibody is not defined.  
In measuring the affinity, the assay must be conducted in the ambient analyte regime and the 
concentration of the pull down antibody must be lower than the expected affinity. According to the 
manufacturer, the delivery volume is estimated to be around 200 pl. Based on this information, the 
effective concentration of printed antibody in a 10 μl volume would be approximately 56 pM. Given 
that immobilised antibody usually has very low activity of around 1%, the effective antibody 
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concentration is likely to be much lower than this. The average monoclonal antibody is estimated to 
have nM affinity for its target protein. Therefore, in this setup the effective pull down antibody 
concentration will be about 100-fold less than the Kd, and should be suitable for measuring affinity 
(Goodrich & Kugel 2007). 
In the microfluidic chips, the pull down antibody should be at a high enough concentration to push 
the assay into the mass sensing regime. With the current assumption of printing 200 pl, the 
maximum concentration of antibody would be 56 nM, although the effective concentration could be 
much lower due to limited antibody activity.  
9.4.2 Antibody affinity is estimated 
Although the affinity of the two antibodies was not measured individually, the affinity obtained is a 
good representation of the assay strength as a whole. Uncertainties lie in the unknown amount of 
pull down antibody deposited, the antibody functionality, and the efficacy of saturating the antigen 
with the secondary antibody.   
It is possible to attain affinities of the individual antibodies using label free techniques such as 
chromatography, isothermal titration calorimetry and surface plasmon resonance (Hearty et al. 
2012). The limitation of the first two techniques is that they require large quantities of protein and 
antibodies (milligrams) and would therefore not be suitable here.      
Surface plasmon resonance is a powerful, label-free technique which can measure effectively 
antibody-antigen affinity in a bimolecular system. It uses small volumes and flow to assess the 
binding at equilibrium whilst avoiding the limitations of mass transport. In addition, measurements 
in real time mean that it can even provide kinetic data (Hearty et al. 2012). This technique was not 
pursued in this study due to the lack of access to a Biacore facility and its related cost. In effect, the 
TIRF system can perform a similar experiment with the only limitation of fluorescently labelling for 
detection purposes. 
The TIRF setup can be arranged so that it measures the affinity in a bimolecular system, either by 
printing the antigen and detecting with a fluorescently labelled antibody or alternatively by 
immobilising the antibody and detecting with a fluorescently labelled antigen. The latter method 
would require fluorescently tagging the antigen which could adversely affect antigen-antibody 
binding. Additionally, printing Gata-4 directly onto a glass surface may give spurious affinity 
readings as the binding epitopes might be obscured.  
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???????? ?????????????????????????????????????
Ligand activity may also pose a limit; activity of purified protein was not assessed prior to 
experiments. The actual activity may be much lower than its concentration. Therefore the affinity 
constant attained provides an upper limit.  
As a transcription factor, the activity of Gata-4 is defined by how well it binds to DNA. In theory this 
can be assessed by using an electromobility shift assay to determine how much of the Gata-4 is 
unbound under saturating conditions (Goodrich & Kugel 2007). Unfortunately, it is hard to 
determine this without labelling the protein and it requires high sensitivity that only radio-labelling 
can provide. 
?????? ?? ?????????????????
A big draw back with assessing the sensitivity and LOD is the number of data points. Because the 
microfluidic chips only contained five independent lines, only five different concentrations could be 
tested at any one time. It would be ideal to have more data points to populate the standard curve. 
?????? ???? ?????????????????????????????????????????????????????
In order to assess the capability of this assay, cell lysates were tested at various concentrations. 
However, estimating true cellular protein concentration depends on the cell activity and the cell 
size. The SP3 cells are quite small, having a radius between 4 and 9μM. Therefore the volume 
approximates to between 0.2-3.3 pL. Reported values of protein content per cell volume is 
approximately 0.2g/ml (Albe et al. 1990), giving a range of 40-660 pg per SP3 cell. A lower estimate 
of 75pg per cell was used, as it is better to under-estimate the assay capability. In addition, this 
calibration suggested an estimated number of Gata-4 proteins per cell, although how much this 
affects the true number is limited by the true value of protein concentration in these cells. 
? ??????????????????????????????????????????????????????????
?????????????????
Single molecule counting using TIRFM offers a multitude of possibilities in cell biology. Ideally, this 
system would support a panel of antibodies, to observe protein expression across the board in cardiac 
progenitor cells. This panel would include the core cardiac transcription factors; Tbx5, Mef2c, 
Nkx2.5, SRF and NFATc, as well as the chromatin regulators such as Baf60c, the class II HDACs and 
the HAT, p300 as well as cardiac structural genes. However, this relies on the availability of 
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antibodies that are highly specific and have high affinity for their targets and requires two antibodies 
that bind to different epitopes with high affinity.   
Another issue with multiplexing is the antibody-antibody cross-reactivity. Whilst other studies have 
reported use of up to 11 proteins at a single time (Shi et al. 2011), in this thesis we have seen antibody 
cross talk with only two or three antibodies used.  
One interesting approach would be to study the protein-protein interactions from single cells. Co-
immunoprecipitation is the standard method for detecting protein-protein interactions. Typically, 
these studies are conducted in bulk and not at the single cell level. Another caveat with this method 
is that it can only detect strong protein interactions. Using the sensitive system of TIRFM, 
interactions could be visualised in real time and it is possible that the weaker interactions could be 
detected. In addition, this would only require one antibody per protein. 
Other protein interaction studies use techniques such as FRET. The close proximity of proteins 
labelled with a fluorophore confers an energy transfer between the donor and acceptor fluorophores. 
Whilst this implies an interaction it is not entirely reliable and can give no information about the 
affinity of the interaction. Furthermore, it relies on genetic modification of the proteins of interest 
which can produce other artefacts.   
Another facet would be to investigate the distribution of expression within a population of single 
cells. In recent years, there has been a lot of interest in the role of stochastic expression in stem cell 
differentiation.  (Enver et al. 2009; Wang et al. 2011; Raj & van Oudenaarden 2009) 
Compelling work by Paulkin and Vallier has shown that stem cell differentiation is also highly 
dependent on the stage of the cell cycle and not only on gene expression (Pauklin & Vallier 2013).  
They showed that endoderm and mesoderm formation was preferentially formed by cells in early G1 
phase, and neurectoderm by those in late G1. This highlighted a method by which many stem cell 
lineage choices could be controlled. With regard to cardiac progenitor cells it could be interesting 
to look at the cell cycle phase in correspondence to cardiac gene expression. 
In order to determine if cardiac gene expression was dependent on cell cycle, TIRFM could be 
applied to measure the cardiac protein expression. This could have implications in how best to 
differentiate the SP cells from an arrested state to the cardiac cell fate.  
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? ???????????
This thesis shows the steady progression toward single cell proteomics in cardiac progenitors. Whilst 
single cell sensitivity was not achieved here, the complexity of the setup means there are many 
avenues for improvement. These include modifications to microfluidic chip design, reducing the 
chamber volumes, different passivation compounds, more effective cell lysis methods and 
alternative capture agents.  
An increasing number of studies are demonstrating single cell sensitivity (Shin et al. 2010; Shi et al. 
2011), showing that the immunoassay is an effective tool for single cell proteomics. However, these 
have not achieved absolute quantification to date. Further still, many of the proteins in these studies 
are involved in oncogenic signalling pathways and are highly studied proteins, having a huge 
repertoire of antibodies available. Ideally, a panel of antibodies would need to be validated in order 
to conduct insightful studies on the cardiac progenitor cells. However, this is severely limited by the 
availability of suitable antibodies.  
The development of novel protein capture agents could be a viable alternative to antibodies. They 
offer the benefits of high affinity, although from this study the stringency of the specificity is not yet 
fully understood. The results here suggest that Gata-4 inherently binds to non-specific DNA and the 
challenge of developing good quality negative controls still remains. Despite this, discrimination of 
non-specific binding could be achieved with the combination of DNA capture with a highly specific 
antibody for detection. 
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Appendix 
 
 
 
Figure A. Polyacrylamide gel electrophoresis of Gata-4 purified protein 
under denaturing conditions. The most prominent band is at the height 
expected for Gata-4 protein. Lower bands are faint and indicate slight 
protein degradation. There are a few faint bands at a higher height, these 
are unlikely to be Gata-4 aggregates due to the denaturing conditions 
used. These thus indicate a small amount of contaminant protein in the  
Gata-4 protein sample. 
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Figure B. Binding of Gata-4 antibody to printed purified protein, Gata-4 and P10, over a period of 40 
minutes. Binding to Gata-4 protein increases over time whilst binding to P10 control protein remains 
low, demonstrating the high specificity the antibody has for its target. 
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Figure C. is a cell experiment, where chambers are loaded with 3, 5, 10, 15 or 0 cells. Binding of Gata4 
protein to either the isotype control (left) of the Gata4 antbody (right) is observed over 4 hours of 
incubation. At time zero, cells are loaded into chambers and not lysed. Lysis solution is added before 
the next time point of 10 minutes. Diffusion of the lysis solution from the main channel to the cell 
chambers appears to take approximately 60-90 minutes. This is indicated by the steady increase in 
signal from 60 minutes incubation onward. 
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Figure D. As a priori to conducting cell experiments with lysis solution, the assay was tested by 
comparing lysate in BSA only with Lysate in 1x lysis solution. This was in order to see if lysis solution 
degraded the assay. The two solutions were compared with both HeLa Gata-4 (G4) transfected lysate 
with untransfected lysate (UT) as the negative control.  No signal was observed with the HeLa 
untransfected cells. With the transfected lysate a slight improvement was seen with the lysis solution 
in comparison to BSA solution. 
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Figure E. DNA-protein binding assay with cell lysated that endogenously expressed Gata4. The 0ne 
cell concentration gives a similar single molecule reading to that of the SP3 lysate in the antibody-
antibody sandwich assay. This might suggest that the two assays are equally powerful in detecting 
Gata4 protein from single cells. 
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Figure F. Open chip comparison of different DNA oligonucleotides to capture Gata4 protein, 
incubation with either HEK Gata4 transfected or untransfected cell lysate. ANF represents a putative 
Gata4 binding sequence found in the promoter for the atrial natriuretic peptide. Gata4 A1 and A2 
are similar sequences known to bind Gata4, the only difference being in the spacer sequence. Mt is 
the mutated ANF sequence and Bg is simply background binding to plain glass. ANF shows 
exceptional binding of Gata4 however, the binding of the negative cell lysate control is also quite 
high. Despite there being significant difference between them, this background binding will be two 
high for single cell sensitivity. G4 A1 and A2 display similar binding and are both significantly higher 
than the negative lysate control. Although there is no significant difference between Mt with positive 
and negative cell lysate, this is also not different to the Gata4 oligos A1 and A2 when incubated with 
HEK lysate expressing Gata4.  
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Figure G. Comparison of of binding to two different DNA oligos, the Gata4 binding sequence (Gata4) 
and the retinoic acid receptor respose sequence (RAR). Higher binding is observed to the Gata4 oligo 
but still significant binding to the RAR oligo, which gives a signal well above the LOD 194 and 101 for 
Gata4 and RAR oligo respectively. 
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Figure H. Here Gata binding was compared between a Gata4 oligo and that of the oestrogen receptor 
(ER).  The oligos were incubated with Hep G2 lysate that endogenously expresses Gata4, equivalent 
binding was observed to both oligos suggesting ER is not a suitable negative control 
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Technology Detection method 
Number of different 
proteins detected 
Operating 
volume (l) 
Sensitivity Materials Refs 
TIRF Antibodies- fluorescence 3 5.00E-05 
LOD of 600zM, 
Linear range 
800zM-37aM 
TNF alph purifed 
protien and clinical 
saliva sample 
Lee et al. 2009 
TIRF 
Antibodies  and YFP 
+mCherry tagged proteins  
6 1.00E-04 10 cells Cell lysate Jain et al. 2011 
Single cell mas 
cytometry 
Antibodies- conjugated to 
metal tag 
22 5.00E-03 
Single cell, semi 
quantitative 
leukaemia cell lines and 
clinical samples 
Bandura et al. 
2009 
Single cell mas 
cytometry 
Antibodies- conjugated to 
metal tag 
31 1.00E-03 
Single cell, relative 
expression 
human haematopoietic 
cells 
Bendall et al. 
2011 
Fluorescent 
scanner 
Antibodies immobilised 
with DNA bar code, 
detection via fluorescent 
antibodies 
12 3.00E-09 
Lower limit of 100-
1000 (protein 
dependent) to 10e6 
molecules/chamber 
Secreted cytokines from 
single cells 
Ma et al. 2011 
Fluorescent 
scanner 
Antibodies immobilised 
with DNA bar code, 
detection via fluorescent 
antibodies 
10 2.00E-09 
Single cell 
sensitivity, relative 
expression 
Single cancer cells, lysed 
on chip 
Shin et al. 
2010, Shi et al. 
2011 
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Epifluorescent 
microscopy with 
separation by 
electorphoresis 
Fluorescent labelled 
antibodies 
1 1.00E-12 
Single cell, detect 
between 2000-
60,000 proteins per 
cell 
Single cells transduced 
with B2AR 
Huang et al. 
2007 
Epi fluorescence 
FISH and YFP tagged 
proteins 
1 NA 
as low as 10 proteins 
per cell 
YFP tagged protein 
library in bacteria 
Taniguchi et 
al. 2010 
Epi fluorescence 
with flow 
Fluorescent antibodies 1 1.00E-04 LOD 10-100pg/l 
Plasma proteins: 
cytokines or biomarkers 
Todd et al. 
2007 
MS in microfluidics No labelling 3 peptides 1.00E-04 
2 peptide released 
from single cell, 2 
peptides from 5 
cells 
Secreted peptides from 
single neurons 
Jo et al. 2007 
Mass spectrometry  No labelling 5 peptides 1.00E-04 
attomolar 
sensitivity 
Vesicles, 1uM in 
diameter 
Rubakhin et 
al. 2000 
Mass spectrometry 
with  capillary 
electrophoresis 
No labelling 
100 chemical 
molecules 
1.00E-04 low nanomolar Single neurons 
Lapainis et al. 
2009 
Table A: summary single cell techniques and their limits of detection 
